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Abstract  
 
Chronic obstructive pulmonary disease (COPD) is increasingly recognised to be 
heterogeneous and complex, with several extra-pulmonary manifestations, necessitating 
categorisation of patients in order to better tailor treatments towards distinct phenotypes. 
Cardiovascular disease and peripheral skeletal muscle dysfunction are amongst the most 
important comorbidities in COPD, with systemic inflammation proposed as a potential 
mechanistic link. Therefore, there is considerable interest in novel anti-inflammatory drugs, 
as well as understanding underlying mechanisms. 
 
An observational study of 729 COPD subjects confirms that cardiovascular co-morbidity and 
quadriceps weakness affect 46.3% and 43.6% of the study population respectively. 
However, these comorbidities are present as distinct manifestations, and do not overlap to 
present as a combined phenotype more often than expected. Markers of systemic 
inflammation (fibrinogen, white cell count and C-reactive protein), relate neither to arterial 
stiffness, quadriceps weakness nor to diaphragm weakness as measured via sniff nasal 
inspiratory pressure (SnIP).  
 
Consistent with the above findings, Losmapimod, a novel anti-inflammatory p38-MAPK 
inhibitor, did not improve cardiovascular or muscle performance, measured as arterial 
stiffness, SnIP and 6-minute walk distance, in a double-blind, randomized control study of 67 
COPD subjects.  
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Definitive evidence of whether inflammatory and/or atrophy pathways are up-regulated in 
human quadriceps is currently lacking, possibly due to the use of whole muscle samples 
failing to account for altered fibre type composition amongst COPD subjects. Quadriceps 
biopsy specimens from 12 COPD and 6 healthy subjects were used to separate type I and 
type II muscle fibres via laser capture microdissection (LCM). In this pilot study, there was 
evidence of lower MURF-1 and Atrogin-1 expression in type II fibres of COPD versus control 
subjects, a difference that was not apparent in whole muscle samples. Therefore LCM can 
potentially provide a more sensitive, novel method to identify therapeutic targets for 
skeletal muscle dysfunction. 
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1.1 Overview of COPD 
 
1.1.1  Definition, epidemiology and pathophysiology 
 
Chronic Obstructive Pulmonary Disease (COPD) is “a common preventable and 
treatable disease, characterized by airflow limitation that is usually progressive and 
associated with an enhanced chronic inflammatory response in the airways and the 
lung to noxious particles or gases. Exacerbations and comorbidities contribute to the 
overall severity in individual patients" (1). The recent update in the Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) definition of COPD reflects the 
increasing recognition that COPD is heterogeneous, with its complexity not explained 
by the presence of airway obstruction alone. Fletcher et al  proposed that COPD is 
characterized by an accelerated decline in forced expiratory volume (FEV1) in 1977 
(2), but recent and larger longitudinal studies have suggested that FEV1 decline both 
in terms of rate and volume in COPD is highly variable, and that subgroups of 
patients do not display any decline for several years (3). The degree of variability in 
chest symptoms and the presence or absence of extra-pulmonary manifestations has 
led to growing interest in determining phenotypes or clusters of comorbidities within 
COPD, as it is becoming increasingly clear that treatment needs to be stratified 
according to patient subtypes in order to improve disease related morbidity and 
mortality. 
 
The diagnosis of COPD has traditionally been a clinical one, and is made in patients 
with respiratory symptoms such as breathlessness, cough or wheeze, and the 
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presence of airflow obstruction on post-bronchodilator spirometry (Forced 
expiratory volume in 1 second (FEV1)/ Forced vital capacity (FVC) ratio of <0.7), and 
often, at least in the developed world, a history of smoking. The GOLD criteria have 
been used to categorise the severity of the airflow obstruction, with GOLD stage I 
(FEV1 >80% predicted) representing mild disease, GOLD stage II (FEV1 50 – 80% 
predicted) representing moderate disease, and GOLD stages III (FEV1 30 – 49%) and 
IV (FEV1 <30% predicted) representing the most severe stages of disease (4). 
 
Being the third leading cause of mortality worldwide, COPD remains an important 
public health concern (5). In the UK alone, there are an estimated 1.96 million 
people with COPD, with exacerbations of COPD utilising 1 million hospital bed days 
in England and being the second most common reason for emergency presentation 
to Accident and Emergency in the UK (6).  
 
Tobacco smoke is most commonly implicated as a risk factor for developing COPD 
(7), but indoor pollution from cooking with biomass fuels, outdoor pollution, 
occupational exposure to dusts and genetic predisposition constitute other risk 
factors (8).  
 
1.1.2 Treatment  
 
The parenchymal damage in the lung in COPD is currently irreversible. 
Bronchodilator therapies and pulmonary rehabilitation remain the mainstay of 
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treatment, conferring symptomatic relief. Other therapies for selected patients with 
COPD include long-term oxygen therapy (LTOT), lung transplant and lung volume 
reduction but are only suitable for a select group of patients (9) .  
 
Novel therapies to improve mortality and morbidity in COPD are urgently needed. 
Given the heterogeneity of COPD, it is likely that targeting extra-pulmonary 
manifestations may be a prudent way of reducing both morbidity and mortality, 
especially when considering that cardiovascular causes form one third of COPD 
deaths and that pulmonary rehabilitation, which targets skeletal muscle weakness, is 
currently the most effective therapy for COPD. 
 
1.2 Phenotypes within COPD 
 
The combined effect of gene expression and environmental modulation on 
observable characteristics in an organism has traditionally been termed phenotype, 
but, with respect to COPD, Han and colleagues define phenotype as: “a single or 
combination of disease attributes that describes differences between individuals 
with COPD as they relate to clinically meaningful outcomes ….symptoms, 
exacerbations, response to therapy, rate of disease progression, or death”(10). The 
purpose of defining phenotypes as such in COPD is to improve predictive value, as 
well as to help identify underlying pathophysiological mechanisms or endotypes. 
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The concept of phenotypes in COPD is not new; chronic bronchitis and emphysema 
existed as distinct entities until combined under a new umbrella term “COPD” in the 
1960s, and immediately afterwards, heterogeneous subtypes of COPD were 
categorised into type A or type B (“the pink puffers” or “blue bloaters”) (11).  
 
Chronic conditions often coexist, and COPD is no different in this respect from other 
chronic conditions, with several recognised co-morbidities or extra-pulmonary 
manifestations including systemic inflammation, cardiovascular disease, skeletal 
muscle dysfunction, cachexia, osteoporosis, depression and impaired glucose 
tolerance or metabolic syndrome (12). Whether or not these features are extra-
pulmonary manifestations of COPD or simply co-morbidities is harder to determine 
since several of these, such as cardiovascular disease and osteoporosis, share 
common risk factors with COPD. Smoking, for example, is known to increase risk for 
both cardiovascular disease and COPD, however the risk of developing 
cardiovascular disease is higher in COPD even when traditional risk factors such as 
smoking are accounted for (13, 14).  
 
Co-morbidities within COPD are recognised to increase symptom burden, risk of 
hospitalisation and mortality (15). Frequencies of co-morbidities have been 
described across several cohorts, with cardiovascular disease emerging as the 
commonest co-morbidity, although the definition can vary, ranging from self-
reported “heart trouble” to ECG evaluation or measuring atherosclerosis. Mullerova 
et al found that cardiovascular co-morbidity affect between 28% to 70% of people 
with COPD across different studies(14).  
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Contrary to expectations, the severity of airflow obstruction does not necessarily 
relate to the number of comorbidities or health status. The ECLIPSE study noted that 
COPD exacerbation frequency correlated with a lower FEV1, yet a significant portion 
of patients with severe airflow obstruction remained free of exacerbation. Although 
this study did not report the prevalence of muscle mass depletion, it noted a high 
presence of cardiac disease (54%) in COPD subjects versus 20% in healthy smokers. 
Osteoporosis, which often coexists with cachexia in COPD, was present in 14% of 
patients with COPD as compared with 5% of healthy smokers. Prevalence of these 
conditions did not vary across different GOLD stages. Since ECLIPSE is not a 
population study, there may be sampling bias in this trial population, however this is 
a large cohort of over 2000 COPD subjects, and is multi-centered therefore selection 
bias should be minimised; additionally, it has the advantage of well characterized 
subjects in terms of confirmation of clinically diagnosed COPD with post 
bronchodilator spirometry, and objectively defined comorbidities, whereas 
population studies can lack this level of detail (16).  
 
A descriptive analysis of co-morbidities amongst newly diagnosed COPD patients 
from GP databases identified cardiovascular disease or angina as the most frequently 
occurring co-morbidity (17). Since this study only followed new events to define co-
morbidity in patients 1 year after initial diagnosis, this may explain why the incidence 
of angina was only 8%, much lower than prevalence estimates in other studies. A 
further limitation of this analysis is the acquisition of patients from GP databases, 
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without confirmatory post bronchodilator spirometry to confirm COPD diagnosis, 
and therefore many of these patients could represent asthma cases. 
 
Divo et al (18) conducted a study of over 1600 outpatients with COPD to map out the 
frequency of co-morbidities as determined by medical and prescription history, and 
followed these patients over a period of 12 years. Figure 1.1 illustrates their mapping 
of the variety and frequency of different co-morbidities found in their patients, 
noting that cardiovascular (including hypertension and hyperlipidaemia) co-
morbidity is most prevalent in COPD, followed by degenerative joint disease, 
although skeletal muscle weakness was not specifically assessed. They also 
developed the COTE index, which relates the number of co-morbidities to increased 
risk of mortality, and noted that cardiovascular causes, diabetes, peptic ulcer 
disease, cancer and anxiety were amongst the comorbidities that were most 
associated with mortality.  Their findings are not fully applicable to the general COPD 
population however since several important groups of patients were excluded: those 
with severe life-limiting disease, a recent history of myocardial infarction and 
patients unable to perform spirometry or other study procedures. A further 
weakness of the study was the inclusion of subjects with other respiratory diseases 
such as lung fibrosis, which are traditionally excluded from studies, however the 
mixed lung pathology can make interpretation of results in the context of COPD 
difficult. Importantly, co-morbidities were not confirmed or quantified objectively 
using further testing as part of the study. 
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Figure 1.1 The “comorbidome” is a graphic expression of comorbidities with more than 10% 
prevalence in the entire cohort, and those comorbidities with the strongest association with 
mortality (hazard ratio [HR], >1; 95% confidence interval, >1; P ≤ 0.05). The area of the circle relates 
to the prevalence of the disease. The proximity to the center (mortality) expresses the strength of 
the association between the disease and risk of death. This was scaled from the inverse of the HR 
(1/HR). All bubbles associated with a statistically significant increase in mortality are fully inside the 
dotted orbit (1/HR <1). Bubble colors represent organ systems or disease clusters (cardiovascular = 
red, female-specific comorbidities = pink, pulmonary = green, psychiatric = blue, others = brown and 
orange). A. fibrillation = atrial fibrillation/flutter; BPH = benign prostatic hypertrophy; CAD = 
coronary artery disease; CHF = congestive heart failure; CRF = chronic renal failure; CVA = 
cerebrovascular accident; DJD = degenerative joint disease; GERD = gastroesophageal reflux disease; 
OSA = obstructive sleep apnea; PAD = peripheral artery disease; pulmonary HTN+RHF = pulmonary 
hypertension and right heart failure. Reprinted with permission of the American Thoracic Society. 
Copyright © 2016 American Thoracic Society. Divo et al (2012).  Comorbidities and risk of 
mortality in patients with chronic obstructive pulmonary disease. Divo M, Cote C, de Torres JP, 
Casanova C, Marin JM, Pinto-Plata V, Zulueta J, Cabrera C, Zagaceta J, Hunninghake G, Celli B, and for 
the BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic 
obstructive pulmonary disease. American journal of respiratory and critical care medicine. 
2012;186(2):155-61. The American Journal of Respiratory and Critical Care Medicine is an official 
journal of the American Thoracic Society 
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Cardiovascular and muscle comorbidities appear to be the most frequent 
comorbidities even in pre-clinical COPD, present in current smokers but not never-
smoker controls, with smoking and physical activity levels predicting the presence of 
two or more comorbidities (19). The frequency of these comorbidities is similar to 
that found in ECLIPSE, and is much lower in pre-clinical COPD than reported in 
patients with COPD however suggesting that COPD is an independent risk factor in 
their development.  
 
Most studies in the literature so far have examined co-morbidities separately, or rely 
on databases that were not initially set up for the purpose, whereas it is likely that 
individual patients may exhibit one or more co-morbidity together and that clusters 
of certain co-morbidities exist. Cluster analyses to identify sub-groups of patients 
with COPD have been carried out by only a few groups. 
 
Garcia-Aymerich et al (20) identified 3 distinct clusters (severe respiratory 
phenotype, moderate respiratory phenotype and systemic respiratory phenotype) 
with different mortality risks in a cohort very well characterized for respiratory 
features. Their study examined relatively few co-morbidities, excluding for example 
osteoporosis, and studied only patients admitted to hospital with an exacerbation, a 
population that is likely to behave quite differently and is at higher risk of mortality 
than a stable outpatient or community COPD population.  
 
Burgel et al (21) also identified 3 distinct phenotypes in COPD, out of which 2 (young 
patients with severe respiratory disease and older patients with milder respiratory 
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disease but with more co-morbidities such as cardiovascular disease) were 
associated with a higher risk of mortality. The study included a wider range of co-
morbidities, but used two separate study populations that did not have identical 
measurements, and importantly one population was being screened for inclusion in 
a lung cancer screening study, therefore likely to contain selection bias. The criteria 
used to define co-morbidities also likely overestimates prevalence of comorbidities 
in some cases, for example skeletal muscle weakness is defined as <80% predicted, 
unlike other studies using COPD-specific derivative equations that include a lower 
cut-off (22).  
 
Van Fleteren and colleagues (23) have tried to group together self-mapping clusters 
in a single-centre cohort of just over 200 patients attending an in-patient pulmonary 
rehabilitation facility. Their study examined 13 co-morbidities and identified 5 self-
mapping, distinct clusters (less co-morbidity, cardiovascular, cachectic, metabolic 
and psychological), being the first study to map clusters against frequencies of co-
morbidities that they contained. Cardiovascular diseases were again most prevalent, 
followed closely by the cachectic cluster, with each cluster accounting for 
approximately a quarter of the cohort. Muscle wasting affected 28% of subjects, 
comparable to the prevalence of muscle weakness in previous work from Seymour et 
al (22), with atherosclerosis affecting 53% of patients, and 9% of patients having ECG 
evidence of previous myocardial infarction, comparable to existing studies (17).  
Importantly, the cachectic cluster consisted of younger patients with the worst 
indicators for mortality, including a higher BODE score and lower TLCO than other 
groups.  
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A particular strength of the Van Fleteren study was the use of international 
definitions of co-morbidities that were confirmed by direct measurement, instead of 
self-reported comorbidities. One important omission was the lack of a measure of 
skeletal muscle strength, with cachexia being used as a substitute. This is an 
important methodological issue since although quadriceps weakness and cachexia 
are related, quadriceps weakness typically precedes the development of cachexia 
(24). Additionally the study was carried out in patients being referred for pulmonary 
rehabilitation, and therefore contains intrinsic bias towards patients with moderate 
or severely symptomatic COPD and/or patients with frequent exacerbations.  The 
single-centre nature of the study also means that the generalizability is limited, 
however it is interesting to note that the hazard risk ratios for mortality for Spanish 
and American populations in the study by Divo et al were almost identical at 1.12 
and 1.13 respectively. 
 
The use of cluster analyses is important in future studies of multiple comorbidities in 
COPD (25), as it allows the mapping of heterogeneous variables and organizing them 
into a homogenous group, therefore allowing identification of phenotype. In 
contrast, previous studies using multivariable analysis can miss the presence of 
complex phenotypes. Cluster analysis can be carried out via k-analysis or self-
organizing maps. Limitations of k-analysis include the need to determine the number 
of clusters prior to the analysis, and since this analysis favours clusters of roughly 
equal sizes, it can ignore important small but important phenotypes. Self-organising 
maps, as used by Van Fleteren et al, avoid this issue of pre-determining cluster 
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numbers but relies on selection of clinically important variables to determine 
clusters, which in turn means this method can only be used in large, well 
characterized cohorts.  
 
Although systemic inflammation (defined as a rise in circulatory inflammatory 
markers or cytokines) is proposed as a phenotype in its own right (26), it has also 
been proposed as a potential contributor towards several of the other extra-
pulmonary manifestations, including cardiovascular disease (27) and skeletal muscle 
dysfunction (28). Ageing could be an alternative or additive contributor towards both 
progression of lung disease and co-morbidities. For the purposes of the thesis, I will 
be looking only at skeletal muscle weakness and cardiovascular parameters, with 
systemic inflammation as an independent variable, since these are two of the most 
important and prevalent co-morbidities in COPD. 
 
1.3 Systemic Inflammation in COPD 
1.3.1 Source of systemic inflammation in COPD 
 
In COPD, smoking results in increased numbers of neutrophils, macrophages and 
lymphocytes, which form the inflammatory infiltrate in the small airways. 
Importantly, airway wall inflammation persists in COPD subjects who have stopped 
smoking. The lung appears to be a source of increased circulatory cytokines in COPD, 
with “overspill” of inflammatory cytokines from the lung into the systemic circulation 
(29); in addition to airway inflammation, increased work of breathing, induced 
experimentally by resistive breathing, has been shown to cause the respiratory 
31 
 
muscles to produce inflammatory cytokines (30) and respiratory muscle work is 
known to be elevated in patients with severe COPD. 
 
 
1.3.2 Markers of systemic inflammation 
 
There appears to be an imbalance between pro- and anti- inflammatory cytokines in 
COPD. IL-10 and TGF-β have anti-inflammatory effects, and there appear to be lower 
IL-10 levels in COPD (31), with underlying genetic polymorphisms for a low IL-10 
allele as a contributory factor in COPD (32). TGF-β signalling is also known to be 
impaired in patients with COPD (33), whereas pro-inflammatory cytokines have been 
found to be elevated in the serum compartments of COPD subjects in several studies 
(34, 35). Serum markers of inflammation are raised in all groups of stable COPD 
patients, even in those with early disease, in comparison to healthy age-matched 
subjects (34).  
 
High sensitivity C-reactive protein (hsCRP), fibrinogen and leucocyte or white cell 
count (WCC) are amongst the most studied inflammatory markers in COPD, partly 
due to the ease of measurement and wide availability of assays in clinical use, 
therefore I focus on studies of these markers in Table 1.1, which contains a summary 
review of key findings (36).  Previous studies have also suggested that circulating 
TNF-α is raised in COPD, with more recent studies suggesting that this is not the 
case. This change in finding may be explained by the improved specificity in testing 
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for TNF-α (37), or the composition of the COPD cohort in terms of early versus late 
disease or smoking status. 
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Study Study design Subjects Inflammatory 
markers studied 
Comments 
Man et al 
(38), 2006, 
Thorax 
(Lung Health 
Study) 
Prospective, 
longitudinal, 
observational 
cohort study 
4803 
Subjects with 
mild-
moderate 
COPD  
CRP measured at 
baseline only 
Raised CRP predicts all cause 
mortality, relating to 
cardiovascular and cancer 
deaths but not respiratory 
causes at 1 year. Mild to 
moderate COPD patients 
studied; cross sectional CRP 
data 
Dahl et al  
(39), 2007, 
AJRCCM 
 
(Copenhagen 
Heart Study) 
Prospective, 
longitudinal, 
observational 
cohort study 
1302 
subjects with 
airway 
obstruction 
CRP at baseline 
only 
Baseline CRP (4.3 vs. 2.3 mg/l) 
predicted all-cause mortality 
independently of lung function 
at 8 years; cross-sectional CRP 
data 
Thomsen et 
al  (40), 
2013, 
AJRCCM 
Prospective, 
longitudinal 
observational 
cohort study 
6574 
patients with 
COPD 
Baseline CRP, 
fibrinogen and 
leucocyte count 
at baseline 
Simultaneously raised levels of 
CRP (>3mg/L), fibrinogen 
(>14mumol/L) and leucocyte 
count (>9 x109/L) associated 
with increased risk of 
exacerbations, even in subjects 
without history of exacerbation. 
Cross-sectional data on 
inflammatory markers 
ECLIPSE 
study: 
Celli et al , 
AJRCCM 
2012 (41), 
Miller et al 
(27), Respir 
Med, 2013 
Dickens et al  
(42), Respir 
Res, 2011  
Prospective, 
longitudinal, 
observational 
study carried 
out over 3 
years 
2164 
subjects with 
COPD, 337 
smokers and 
245 non-
smokers 
CRP, WCC, 
fibrinogen, IL-6, 
IL-8, SP-D, CL-18, 
TNF-a, PARC 
amongst panel of 
biomarkers 
measured at 
baseline, 3 
months, 6 
months and at 1 
year 
Celli et al : IL-6, fibrinogen, 
WCC, PARC, CRP, IL-8 and SP-D 
all independently associated 
with mortality at 3 years in 
COPD subjects and addition of 
these panel of biomarkers to 
clinical variables improves 
prediction of all-cause mortality 
Miller et al : High fibrinogen, IL-
6 and IL-8 associated with 
presence of heart disease in 
patients with COPD 
Dickens et al : Subset of only 
201 ex-smoker COPD patients 
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examined. CRP and Fibrinogen 
significantly different between 
COPD and 37 smoker and non-
smoker control subjects; WCC 
not assessed. Fibrinogen was 
biomarker that is most stable 
and repeatable at 3 months in 
COPD patients, with CRP 
showing great variability 
Wanda  et al 
(43) 
AJRCCM, 
2014 
(SPIROMICS) 
Prospective, 
longitudinal, 
observational 
study 
479 COPD 
and 112 
healthy non-
smokers at 1 
year 
CRP, IL-6, TNF-α , 
WCC, fibrinogen, 
IL-8 measured at 
baseline and 1 
year 
Where one marker is elevated 
at baseline, a significant trend 
emerges towards having that 
same marker raised at 1 year, 
supporting ECLIPSE results (26) 
that demonstrated persistence 
of inflammation. Full data 
awaited; subset presented 
Thomsen et 
al  (44), 
2012, 
AJRCCM 
Combined 
data from 2 
prospective, 
observational,  
studies 
8656 
patients with 
COPD 
CRP, fibrinogen, 
leukocyte count 
at baseline 
Increased risk of hospitalisation 
due to comorbidities; 
simultaneously raised 
fibrinogen (>14mumol/L), 
leucocytes 9x109/L) and CRP 
(>3mg/L) associated with two-
fold increase of myocardial 
infarction over a 5 year period 
of follow up. Cross sectional 
data for inflammatory markers 
Gan et al  
(35), Thorax, 
2004 
Systematic 
review/ 
Meta-analysis 
14 studies 
reviewed 
(from 1872 
search 
results); 5 
studies for 
CRP, 4 for 
fibrinogen, 6 
for 
leucocytes, 6 
for TNF-α , 2 
for IL-6 and 2 
for IL-8; 
studies 
included 
COPD and 
CRP, Fibrinogen, 
Leucocytes, TNF-
α , IL-6 and IL-8 
measured at 
baseline 
CRP higher than controls in all 
studies, mean difference 0.53 
units 
Fibrinogen higher in COPD than 
control subjects; mean 
difference 0.47 units 
Leucocytes also higher in COPD 
subjects than controls; 
standardised mean difference 
0.59 
 
Heterogeneity in patient 
populations studied and 
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control 
subjects 
selection criteria for different 
studies; all studies were cross-
sectional in nature 
Ferrari et al  
(45) , Respir 
Res 2013 
Prospective, 
longitudinal, 
observational 
77 stable 
outpatients; 
53 followed 
up 
prospectively 
IL-6, CRP at 
baseline and at 3 
years 
Il-6 increase significantly at 3 
years but not CRP (remains at 
5mg/L); no comparator group. 
Mostly GOLD I/II patients 
Kolsum et al  
(46), Int J 
COPD 
2009 
Prospective, 
longitudinal, 
observational 
58 stable 
COPD 
patients 
followed up 
prospectively 
Serum CRP, IL-6 
and TNF-α  
measured at 
baseline and 1 
year 
CRP, IL-6 and TNF-α  repeatable 
at 1 year. No control subjects. 
High proportion of current 
smokers amongst COPD 
patients. Do not account for 
change in smoking habit. 
De 
Torres(47), 
2008, Chest 
 
Prospective, 
longitudinal 
cohort study 
218 stable 
clinic 
patients with 
COPD 
CRP  CRP levels not related to 
mortality. Study subject to 
sampling bias; moderate to very 
severe patients studied from 
clinics. Additionally, study may 
be underpowered compared to 
larger Danish cohorts 
Table 1.1 Key studies of CRP, fibrinogen and leucocyte count in COPD 
 
Several studies have examined a panel of biomarkers to assess whether any of these 
correlate well with severity of COPD, but few studies have done so prospectively in a 
longitudinal cohort. Instead, most studies of inflammatory markers are cross-
sectional and examine different panels of biomarkers, hence a lack of overall 
consensus about which inflammatory pathways are important in COPD.   
 
Inflammatory markers are raised in other chronic conditions, such as diabetes or 
chronic heart failure, a confounding factor when examining whether inflammation 
contributes to the development of co-morbidity. For this reason, more longitudinal 
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studies in early COPD are required. Importantly, inflammation appears to persist in 
patients who have stopped smoking (48), suggesting that there is an ongoing 
systemic inflammatory process as part of the disease. In contrast, ECLIPSE is one of 
the few longitudinal, prospective studies of biomarkers in COPD, having the 
advantage of a large number of both patients and controls from multiple centres, 
and suggests that only 16% of patients with COPD exhibit persistent evidence of 
inflammation through the course of 1 year (26), as illustrated in figure 1.2.  
 
 
Figure 1.2 Persistent systemic inflammation. Proportion of patients with 0, 1, or 2+ elevated 
inflammatory biomarkers (WBC count, CRP, IL-6 and fibrinogen), at baseline (left bars) and after one 
year follow up (right bars).  An elevated biomarker was defined as a value falling within the 
uppermost quartile for that biomarker in the distribution for subjects with COPD. Reproduced from 
Agusti et al (2012): Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in 
COPD: A Novel Phenotype. PLOS One. DOI: 10.1371/journal.pone.0037483 
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The differences observed could be due to a number of reasons. Firstly, the ECLIPSE 
study defines raised inflammatory markers as >95th centile of each inflammatory 
marker in healthy ex-smokers participating in the study. Consequently, cut-off values 
for fibrinogen were determined at 5.18g/dL, much higher than the widely accepted 
clinical cut-off of 4.5g/dL; conversely a high WCC was defined as 8.6 x109/ml, which 
is well within normal reference ranges. The healthy cohort used as the reference 
population was almost 10 years younger than the COPD population, with a higher 
BMI and proportion of female subjects, both factors known to be determinants of 
fibrinogen. Other studies do not have a healthy cohort of sufficient size to normalize 
their data (full results from the SPIROMICS study are still awaited) and therefore only 
test between group differences or do not have a control group at all, making it 
difficult to know whether inflammatory markers are truly raised, since the 
magnitude of differences between groups is often small and well within clinically 
acceptable ranges. 
 
A further problem with most longitudinal studies prospectively measuring 
biomarkers is the failure to account for a change in smoking habits during the course 
of the study, which could impact inflammatory markers. Furthermore, ECLIPSE only 
reports whether the number of inflammatory markers is raised; it is not clear 
whether the same inflammatory marker is persistently elevated at 1 year. Given the 
high degree of variability and short half-life of markers such as CRP, as well as the 
narrow reference ranges in the study, results on any one given day may not reliably 
diagnose inflammation. The study authors try to overcome this by defining 
persistent inflammation as the elevation of 2 or more inflammatory markers at 
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baseline and 1 year, however it is important to note that 40% of their COPD cohort 
has at least 1 inflammatory marker raised at baseline and at 1 year, therefore 
perhaps the report that 16% of patients have systemic inflammation is an 
underestimate. Only 30% of patients with no inflammation at baseline had evidence 
of no inflammation at 1 year, suggesting inflammation affects much of the COPD 
population at one time or another as well as highlighting the fact that the nature of 
inflammation can vary widely between COPD patients. An interesting aspect of this 
work was that TNF-α was significantly elevated in current smokers without COPD but 
this difference disappears in later disease, suggesting either a switch in inflammatory 
pathways or possible dampening or “burning out” of the inflammatory response in 
later disease.  
 
Inflammatory markers, especially CRP levels, can show great individual variability, 
whereas fibrinogen was the only marker to show repeatability within a three-month 
period in a subset of ECLIPSE patients (42). Importantly, Dickens et al  did not 
compare white cell count results in their study, despite it being measured in patients 
from ECLIPSE, nor did they comment on repeatability at 6 months and 1 year in their 
subset of patients, although blood samples were taken at these intervals.  CRP levels 
have been shown to be repeatable in very small COPD cohorts previously, however 
these studies lacked a control group unlike ECLIPSE. 
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1.3.3  Fibrinogen 
 
Fibrinogen has been linked to cardiovascular disease in the general population, both 
as a marker of mortality from ischaemic heart disease (49, 50) , as well as being 
directly implicated in cardiovascular events via promoting a prothrombotic state 
(51). Similarly, in COPD, elevated fibrinogen during acute exacerbations has been 
proposed as a mechanism for the excess cardiovascular mortality related to COPD 
exacerbations (52). 
 
Population studies have shown that elevated fibrinogen levels relate to mortality, 
worse lung function and more frequent exacerbations in COPD (53). The mechanisms 
leading to the excess mortality and the relationship between fibrinogen and extra-
pulmonary manifestations of COPD require further characterization however. 
Several cross-sectional studies report associations between elevated fibrinogen and 
reduced physical activity (54, 55), and elevated fibrinogen and sedentary lifestyle 
could be both causative factors for, as well as a consequence of, extrapulmonary 
manifestations such as cardiac disease. 
 
Fibrinogen is an acute phase protein that is primarily synthesized in the liver in 
response to the cytokine IL-6, but several studies suggest that it can be synthesized 
directly in the lung (56, 57), with infection as a driving factor for synthesis in some 
disease (58). It is feasible that fibrinogen plays a similar role in COPD, and that 
elevated levels relating to exacerbations are a consequence of increased production 
of fibrinogen by the lung. Levels of fibrinogen rise in relation to exacerbations and 
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remain elevated for up to four weeks before returning to baseline, but elevations do 
not appear to correlate to severity of exacerbations (52).  
 
Despite being an acute phase protein, fibrinogen shows much less variability than 
hsCRP over the course of three months as demonstrated in both observational (42) 
and in placebo arms of randomized-control studies (59, 60) in COPD.  The range for 
fibrinogen values is very narrow however, which limits its utility, and furthermore 
the definition of an elevated fibrinogen level can be quite different between studies, 
ranging from >2.7 g/L (61) to over 5g/L (26), and there is disagreement over what 
level of fibrinogen confers risk or mortality or co-morbidity. The differences between 
studies can be due to the population studied or the assay used since immunoassays 
on frozen samples tend to give higher values for fibrinogen than the more commonly 
used Klauss method in clinical laboratories. 
 
Fibrinogen is therefore emerging as a useful serum biomarker to predict mortality in 
patients with stable COPD (62), and has recently been qualified by the Food and 
Drug Administration (FDA)  as a biomarker for clinical trials of in COPD, where a level 
of >3.5 g/L confers elevated risk of exacerbations or mortality (63).  
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1.3.4 Potential effects of systemic inflammation in COPD 
 
Systemic inflammation has been proposed as a potential contributor towards several 
of the extra-pulmonary manifestations seen in COPD; osteoporosis (64), 
cardiovascular disease (65), skeletal muscle wasting (28), cachexia (66), depression 
(67) and metabolic syndrome (54). Recent work has suggested that elevated TNF-α 
only correlates with metabolic syndrome in COPD, whilst elevated levels of IL-6 are 
seen in cachexia within COPD but that otherwise low-grade inflammation is 
comparable between co-morbidity clusters in COPD (23). Whether inflammation 
plays a causal role in the development of comorbidities in COPD remains equivocal, 
with important limitations being the variety of inflammatory markers used in 
different studies as well as most studies examining comorbidities in isolation, making 
comparisons difficult. 
 
Elevated levels of C-reactive protein and fibrinogen are associated with increased 
likelihood of developing coronary heart disease in the general population (68), with 
suggestions that elevated fibrinogen could be playing a causative role in the 
development of atherosclerotic disease by promoting platelet aggregation and a pro-
thrombotic state. Systemic inflammation could be one explanation for the excess 
cardiovascular morbidity and mortality seen in COPD patients (65), and this is 
discussed in more detail later.  
 
Cytokines can produce a central response, causing patients to feel ill or lethargic and 
therefore leading to inactivity (69). Additionally, acute administration of IL-6 has 
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impaired exercise performance in healthy athletes, suggesting that systemic 
inflammation could reduce exercise performance in the absence of airflow 
obstruction (70). 
 
Additionally, an inflammatory process has been postulated as a contributor towards 
skeletal muscle wasting and dysfunction in patients with COPD, although this is a 
subject of current debate (28). Possible mechanisms linking inflammation and 
skeletal muscle wasting will be discussed in more detail later. 
 
Physical inactivity does appear to relate to higher fibrinogen levels as well as 
quadriceps weakness in COPD patients (55), however associations of fibrinogen with 
muscle strength and performance have not been examined in these patients. 
 
1.4 Cardiovascular morbidity in COPD 
1.4.1 Significance of cardiovascular morbidity in COPD 
 
Lung cancer and cardiovascular disease are the predominant causes of 
hospitalisation and death in patients with mild to moderate COPD. Amongst patients 
with severe COPD, death is more often from non-malignant respiratory causes but 
cardiovascular mortality still forms the second most common cause of death, 
affecting approximately one third of patients with COPD (71). As discussed earlier, 
cardiovascular disease has repeatedly been found to be the most frequent co-
morbidity in COPD, and exists as a separate entity to metabolic syndrome (23), 
although the definition of cardiovascular disease is perhaps too broad in COPD, with 
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studies frequently citing “heart trouble”, “arrhythmia”, “angina” and “heart failure” 
in isolation or combination, despite these conditions having different aetiologies 
potentially. As discussed earlier, angina is the most frequent complaint in patients 
with COPD, suggesting that ischaemic heart disease is key in COPD. 
 
Increased cardiovascular risk and morbidity is not unique to COPD, but seen across 
several other chronic conditions such as chronic kidney disease, cancer and diabetes. 
Whilst age is an important shared risk factor for development of multi-morbidities, it 
is also important to consider the Ben Shlomo “life-course model” where a 
combination of biological and psychosocial pathways are important in influencing 
development. Exposures at a “critical” or “sensitive” period can lead to the 
development of more than one co-morbidity in later life; such exposures can include 
in-utero development or social deprivation in later life (72). Furthermore, 
development of one co-morbidity can lead to a more sedentary lifestyle, therefore 
increasing risk of development of cardiovascular co-morbdity. 
 
COPD appears to be an independent risk factor for developing ischaemic heart 
disease (73), almost doubling the risk of cardiovascular disease even when the 
effects of smoking and other traditional risk factors are taken into account (13), with 
adjusted relative risk ratios ranging from 1.6 to 2.7 for unspecified cardiovascular co-
morbidity in COPD versus matched controls (14). In this systematic review, for 
ischaemic or coronary heart disease, prevalence rates ranged between 4.7% to 60%, 
with adjusted relative risk ratios ranging from 0.7 to 6.8 for subjects with COPD. A 
more recent meta-analysis by Chen et al suggests a 2.5 times increased risk of overall 
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cardiovascular disease in patients with COPD. The authors further note a risk of 
major cardiovascular disease (e.g. ischaemic heart disease, arrhythmias and heart 
failure) of almost 5 to 6 times in COPD, as well as elevated risk of traditional 
cardiovascular risk factors such as hypertension. Notably, cerebrovascular disease, 
obesity and dyslipidaemia risk does not appear to be raised in COPD. Although it is 
the most comprehensive meta-analysis to date, Chen et al were limited by the cross-
sectional nature of the data, which meant that directionality of associations could 
not be examined. Furthermore, the studies included in the analysis had very 
heterogeneous data sets (74), a similar problem to the earlier systematic review by 
Mullerova et al (14). 
 
1.4.2 Mechanisms of cardiovascular morbidity in COPD 
 
Increased cardiovascular morbidity in COPD is likely to result from a combination of 
multiple mechanisms, such as accelerated ageing, changes in vascular wall structure 
and function, changes in atheromatous plaque formation and structure and changes 
in sympathetic tone. Systemic inflammation has been proposed as a contributor 
towards several of these mechanisms.  
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Figure 1.3 The role of inflammatory mediators at different stages of atherosclerosis. 
Reproduced from Fisk et al (2014). Evaluation of losmapimod in patients with chronic 
obstructive pulmonary disease (COPD) with systemic inflammation stratified using 
fibrinogen (‘EVOLUTION’): Rationale and protocol. Artery Research. 
doi:10.1016/j.artres.2013.10.380 
 
Inflammation has been shown to be important for atheromatous plaque initiation, 
development and rupture (75) via increasing cytokine production and expression of 
cell adhesion molecules (e.g. ICAM-1 and VCAM-1), which promote leucocyte 
adherence to endothelial surfaces. Additionally, increased macrophage expression of 
scavenger receptors in an inflammatory environment promotes formation of foam 
cells, triggering a cascade of plaque formation, vessel wall fibrosis and subsequent 
calcification, resulting in eventual production of a fibrous cap surrounding a lipid-rich 
core. 
 
Cytokines such as IL-1, IL-6, and TNF-α can promote the deposition of components of 
atheromatous plaque, and CRP, which is found in atheromatous lesions, may be a 
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causative agent in atherogenesis (76). In vitro and in vivo studies have shown that 
CRP can inhibit endothelial production of nitric oxide (77, 78) as well as inhibit tissue 
plasminogen activator (79), thereby inhibiting fibrinolysis. Interaction between CRP 
and endothelial cells also stimulates production of IL-6 and endothelin-1.  IL-6 drives 
hepatocyte production of fibrinogen and CRP, and circulating CRP can upregulate 
other inflammatory cytokines, activate complement, and increase uptake of low-
density lipoproteins by macrophages. Fibrinogen is also directly implicated in plaque 
formation due to increased procoagulant activity, which further promotes 
inflammation and atherothrombosis in the general population (80). 
 
Atherosclerosis may therefore be partly driven by systemic inflammation in COPD 
(81), although the precise mechanisms underlying cardiovascular risk in COPD 
remain unclear (82, 83). Measurements of subclinical atherogenesis and arterial 
stiffness can reflect atheromatous plaque burden in patients. Subclinical 
atherogenesis, as measured via B-mode ultrasonography of carotid intimal media 
thickness (CIMT), is independently linked with FEV1 within the COPD population (84). 
Additionally, plaque characteristics as studied on magnetic resonance imaging within 
COPD subjects show features that make the atheromatous plaques more likely to 
rupture than in people without COPD (85). 
 
Carotid-femoral pulse wave velocity and aortic augmentation index provide useful 
measures of arterial stiffness. Whilst augmentation index is easier to measure 
technically, carotid-femoral pulse wave velocity is the gold standard measure of 
arterial stiffness, and is an independent pre-clinical predictor of all-cause mortality 
47 
 
and cardiovascular events in the general population (86, 87). Arterial stiffness in 
COPD is increased in comparison to healthy, age-matched subjects (88). The 
mechanism through which arterial stiffness in COPD is increased remains unknown 
but could be linked to connective tissue changes in arterial wall, such as elastin 
degradation which gives rise to calcification (89), as part of the accelerated ageing 
seen in COPD. Arterial stiffness also appears independently linked to emphysema or 
the degree of airflow obstruction in COPD (90).  Whilst earlier work demonstrated 
that raised arterial stiffness was associated with IL-6 (65) and TNF-α, subsequent 
studies have reported no association between inflammation and arterial stiffness 
(90, 91). There is a difference amongst groups in the use of the inflammatory 
markers, and although methodology, sample sizes and inclusion criteria are similar, 
the cohorts examined also differ, with Mills et al using a greater proportion of 
current smokers in their COPD cohort, which is likely to increase levels of acute 
phase proteins. Importantly, Van Fleteren et al  (92) adjusted their pulse wave 
velocity values for age and gender unlike some of the other studies, which could 
explain the differences and would make their results more reliable, however it 
should be noted that while gender is an important determinant of augmentation 
index, it is not for pulse wave velocity (93, 94). 
 
The role of systemic inflammation in driving cardiovascular morbidity in COPD is 
consistent with evidence from retrospective analyses reporting that statin 
prescription is associated with reduced incidence of cardiovascular events in COPD 
subjects (95, 96), and separate studies report an association between statin 
administration and reduced systemic inflammatory markers (97). Moreover a recent 
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randomized control trial of 6 weeks of simvastatin against placebo (98) failed overall 
to show significant improvement in arterial stiffness or inflammatory markers in 
subjects with COPD; however the subset of patients with elevated arterial stiffness 
did have a significant reduction in pulse wave velocity following the course of statin 
therapy, thereby supporting the cause of stratified entry criteria for subjects into 
trials, where subjects are selected on the basis of known risk factors for the 
therapeutic indication.  This study was relatively short in duration however and likely 
underpowered given the wide standard deviations in observed pulse wave velocity 
measurements compared with those used in the power calculation, and furthermore 
the composition of smokers versus ex-smokers was considerably different between 
placebo and treatment groups, which could potentially influence results for 
inflammatory markers.  
 
Physiologic stress from intermittent or persistent hypoxia in COPD can further 
contribute to cardiovascular morbidity. Hypoxic conditions are associated with 
increased systemic inflammation, including raised CRP. Furthermore, hypoxia can 
cause haemodynamic changes, leading to changes in vascular tone. Hypoxia reduces 
renal blood flow, thereby stimulating the renin-angiotensin system, as well as 
causing increased sympathetic tone, resulting in peripheral vasoconstriction, 
increased resting heart rate, heart rate variability and increased blood pressure in 
COPD subjects versus controls (83, 99). 
 
Another proposed mechanism for increased cardiovascular risk in COPD is 
endothelial dysfunction, which results in reduced nitric oxide release and impaired 
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vasodilatation. Barr et al and Eickhoff et al found evidence of endothelial dysfunction 
evidenced as impaired flow mediated dilatation in COPD subjects compared with 
control subjects, and this was linked both to raised inflammatory markers (100) and 
to emphysema (101). However other studies have disputed this finding (88), showing 
no evidence of greater endothelial dysfunction in COPD. Flow mediated dilatation is 
a difficult technique to study endothelial dysfunction however, especially using older 
software that cannot measure dynamic brachial arterial diameter. The technique 
requires subjects to lie perfectly still for 15 minutes and is therefore prone to error, 
especially in breathless subjects, which could explain the conflicting results. 
 
A role for increased vascular inflammation in COPD has been suggested by Positron 
Emission Tomography (PET) studies of the vascular tree in COPD patients, which 
show excessive aortic inflammation in patients with COPD as compared to healthy 
ex-smokers but less inflammation than subjects with metabolic syndrome (102). This 
study was limited by a small sample size (7 patients with COPD), and only measured 
IL-6 as a marker of inflammation, which did not vary significantly between the three 
patient groups. The numbers are too small to draw any conclusions about the 
relation of systemic inflammatory markers with vascular inflammation. 
 
In their study of 942 of subjects that compared COPD patients with smokers and 
non-smokers, Williams et al  describe elevated coronary calcification scores as higher 
than expected in COPD (103). Increased coronary calcification is known to relate to 
increased mortality, and in their study Williams et al found weak correlations 
between IL-6 and coronary calcification in COPD subjects. 
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Physical inactivity unsurprisingly raises the risk from cardiovascular disease, and 
inflammation could be the mechanism linking the two since lower step counts are 
associated with increased levels of circulating inflammatory cytokines, including CRP, 
IL-6 and fibrinogen, in subjects with COPD (55, 104), and regular exercise is known to 
result in a reduction in inflammation, as discussed earlier. Physical inactivity is 
strongly predictive of not only mortality, but also hospitalisation from exacerbations 
of COPD (105). Risk of cardiovascular death is known to be raised during COPD 
exacerbations (106), which could be through a pro-inflammatory state and/ or a 
change in vascular tone or wall characteristics, as demonstrated by raised arterial 
stiffness during exacerbations (107).   
 
Conversely, exercise is known to induce pro-inflammatory, as well as compensatory 
anti-inflammatory, cytokines in the acute phase (108). Many studies do not specify 
duration for subject rest, and consequently results from cross sectional studies may 
be confounded where subjects have not been adequately rested prior to 
venepuncture. Failing to account for an acute rise in inflammatory markers post 
exercise may also explain why longitudinal studies failed to observe a change in 
systemic inflammatory markers following a course of pulmonary rehabilitation (109).  
 
Evidently, there are several proposed mechanisms through which the cardiovascular 
risk increases in COPD and the development of disease is likely to be multi-factorial, 
with inflammation potentially playing a contributory role. 
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1.5 Skeletal muscle dysfunction in COPD 
1.5.1 Skeletal muscle composition 
 
Skeletal muscle performs voluntary movement under control from the somatic 
nervous system. Each muscle consists of multiple motor units, which in turn consist 
of a single motor neuron and the muscle fibres it innervates. Each motor unit has an 
“all or nothing” response so that all of the muscle fibres innervated by a nerve will 
contract in response to firing of the respective neuron.  The number and type of 
muscle fibres within each motor unit varies, and therefore the force generated by a 
whole muscle is dependent on the force generated by individual units, which in turn 
is partly determined by their fibre type composition, in addition to the number of 
motor units activated. Motor unit recruitment is dependent on the force that needs 
to be produced, and recruitment proceeds sequentially in order of size according to 
Henneman’s “size principle”, with the smallest motor units (type I) recruited first, 
and recruitment progressing to larger motor units (type IIa and then IIx). In addition 
to increasing the number of active units, the strength of muscle contraction can be 
increased by increasing the firing frequency of individual motor neurons. Speed of 
contraction also determines force of contraction, with ‘fast’ or ‘type II’ fibres having 
a faster maximum speed of muscle shortening, and therefore produce greater force 
and power for any given velocity than type I fibres.  
 
Human skeletal muscle has three pure muscle fibre types, defined by the 
predominant myosin type they contain, which in turn predict the contractile and 
metabolic properties of the fibre. Type I fibres utilise oxidative metabolism, which is 
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energy-efficient and makes type I fibres fatigue resistant although their contractions 
are slower and less powerful than type IIx fibres. In contrast, type IIx fibres use 
anaerobic glycolytic metabolism, which generates lactate, leading to lowered 
intracellular pH and early fatigue. There is an intermediate fibre type, type IIa, which 
utilises both oxidative and anaerobic and oxidative metabolism.   
 
‘Slow-twitch’ muscles that are in constant use, such as the postural muscles, are 
composed almost entirely of type I fibre units, whereas fast-witch muscles adapted 
for fast or powerful contractions such as the oculomotor muscles are composed of 
mainly type II fibre units.  Muscles such as the quadriceps and the diaphragm require 
both sustained movement and fast, powerful contractions, and have an equal 
mixture of a 50% type I and 50% of type II fibres in healthy adults. Skeletal muscle is 
highly plastic however, and this ratio can change in response to physical training as 
well as natural processes such as ageing.  Fibre proportions in the same muscle 
cannot be assumed to be the same in different species. 
 
1.5.2 Fibre Shift 
 
There is a shift towards type I fibres in the diaphragm of COPD patients (110, 111), 
likely reflecting the response to increased respiratory load. Conversely in the 
quadriceps of patients with COPD, there is loss of type I fibres, and a shift towards 
type II fibres proportionally, as illustrated in Figure 1.2. The pattern of change in 
quadriceps fibre proportion in COPD is opposite to that seen in healthy, ageing 
muscle where there is a decrease in the proportion of type II fibres (112).  
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The change in fibre type proportion in COPD change is heterogeneous however, with 
around a quarter of patients having normal muscle fibre morphology, with the 
remainder displaying isolated fibre shift, isolated atrophy or a combination of both 
(113). Gosker et al suggested that the proportion of type I fibre loss in the 
quadriceps correlates with severity of airflow obstruction (113), although 
subsequent work by Natanek et al demonstrated that TLCOc was the only 
independent predictor of type I fibre proportion (114). Vastus lateralis fibre shift has 
been shown to independently predict mortality, although not in subjects with an 
FEV1 >50% predicted, where age was the only predictor of mortality (115). 
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Figure 1.4 Fibre type composition in COPD subject and age-matched control. 
Immunofluorescent staining for fibre typing of quadriceps muscle 10 µm sections under 10 x 
magnification. Type I fibres are stained blue, type IIa fibres appear green and laminin appears red. 
The image on the left is from a patient with COPD and the image on the right is from an age-
matched control, illustrating the reduced proportion of type I fibres in COPD. (Source: D Mohan) 
 
 
All previous studies that have examined the molecular basis of muscle dysfunction in 
COPD have relied on whole muscle samples, therefore failing to account for the 
heterogeneity in fibre type composition amongst COPD subjects (116). 
 
1.5.3 Sarcopenia 
 
Sarcopenia is characterized by age-related progressive and generalised loss of 
skeletal muscle mass and strength (117).Unlike cachexia, which is defined solely as 
(unintentional) loss of mass, sarcopenia is defined via a combination of low muscle 
mass and low muscle function or performance, reflecting that muscle strength does 
not rely only on mass, and the changes in function can partially be related to changes 
in fibre size and type. Severe sarcopenia can be defined as a skeletal muscle index 
Patient Control 
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(SMI) of ≤8.50 kg/m2 for men and ≤5.75 kg/m2 for women (when mass is measured 
via bioimpedance) in combination with either a handgrip strength of <30kg for men 
and <20kg for women or a gait speed of <0.8m/s.   
 
Sarcopenia appears to be more prevalent in subjects with COPD than age-matched 
controls (118), but prevalence does not appear to differ according to gender and 
increases with age (119). Jones et al estimate a prevalence of 14.5% of sarcopenia in 
their cohort of 622 COPD patients, but since subjects were recruited from a hospital 
outpatient setting, this may represent an overestimate. Interestingly, over one third 
of sarcopenic patients in this study did not exhibit quadriceps weakness and there 
was no significant difference in prevalence of sarcopenia between subjects with 
quadriceps weakness and those without quadriceps weakness.  
 
COPD patients exhibiting sarcopenia have evidence of type I fibre atrophy as well as 
lower type I fibre proportion in comparison to COPD subjects without sarcopenia 
(118). In conjunction with ageing, COPD may cause differential rates of atrophy 
between type I  and II fibres, which may give the appearance of fibre shift. 
 
 
1.5.4 Peripheral skeletal muscle functional abnormalities in COPD 
 
A combination of reduced muscle strength (120) and reduced muscle endurance 
(121) leads to peripheral skeletal muscle dysfunction in COPD patients, with the 
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lower limbs being more affected than the upper limbs (122, 123). This has led to the 
lower limb muscle dysfunction being attributed to physical inactivity. Physical 
inactivity is undoubtedly important, being an independent predictor of mortality in 
COPD, and exercise training, especially intense training, not only improves muscle 
performance in mild-to-moderate COPD, but also partially reverses some of the 
pathological changes in terms of a reduction in type II fibre proportion, muscle 
hypertrophy and improvement in oxidative capacity (124, 125). Physical inactivity 
and muscle dysfunction both appear to precede the development of significant 
airway obstruction in COPD, which would support that mechanisms other than 
disuse atrophy also contribute to muscle dysfunction in COPD (126, 127). 
Furthermore, disuse atrophy should cause atrophy of all fibre types, whereas fibre 
atrophy is selective in COPD. The selective distribution of muscle weakness implies 
that local factors must be in play in addition to systemic ones. 
 
The quadriceps muscle is the main locomotor muscle, and therefore the most 
studied lower limb muscle in human COPD subjects. Besides disuse atrophy, a 
multitude of factors have been proposed as contributing to quadriceps weakness in 
the COPD population; oral steroid use, cachexia, recurrent exacerbations, oxidative 
stress and systemic inflammation (28, 128, 129), with age, gender and fat free mass 
being the main determinants of individual quadriceps strength (22). Airflow 
obstruction has not been shown to correlate with quadriceps strength (130-132), 
although studies examining these associations likely been underpowered, whereas 
the much larger study by Seymour et al  (133) found a weak association between 
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FEV1 and quadriceps strength, and a weak association was also found between FEV1 
and fibre type proportion by Patel et al (115).  
Depletion of fat free mass is common in COPD, affecting almost a third of patients, 
and is a powerful predictor of mortality in its own right (134, 135). Engelen et al  
(136) showed that absolute quadriceps and handgrip muscle strength, and when 
corrected for body fat free mass, is significantly lower in COPD patients versus 
controls, but not when corrected for fat-free mass at the extremities, implying that 
strength per unit of muscle bulk is not impaired in COPD but rather that there is loss 
of muscle mass at the extremities. Evidence of handgrip weakness in COPD patients 
in that study is contrary to previous work however, and this small cohort included a 
significant proportion of subjects on long-term oral steroids, which could confound 
results. Franssen et al  demonstrated that upper limb muscle mass is preserved in 
cachectic COPD patients, whereas lower muscle limb mass is reduced, as did Man 
and co-workers (137).  These observations when coupled with the finding that the 
rate of decline in quadriceps strength outpaces that of the decline in fat free mass at 
1 year lends support to the idea that the presence of weakness is not dependent 
solely on cachexia (24, 138). These studies highlight the importance of selecting the 
correct tool to define weakness; correcting for overall fat-free mass or BMI likely 
produces an overestimate of weakness since it does not correct for regional 
cachexia, however correcting for regional cachexia is limited by resources in large 
studies or clinical practice, since it requires scanning of the quadriceps muscle, 
through DEXA, CT or ultrasound scanning. 
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Quadriceps weakness is demonstrated in at least one third of the COPD population 
(22), relating to increased healthcare utilization costs independently of the degree of 
COPD severity (139). Unlike studies investigating fat free mass, the prevalence of 
quadriceps weakness has not been studied in many large cohorts, and the estimate 
of 32% is likely to be under-representative since Seymour et al derive their 
regression equation from a healthy population containing both smokers and non-
smokers.  
 
Quadriceps weakness and thigh muscle mass are independent predictors of 
mortality in COPD; in fact, quadriceps weakness is a more accurate predictor of 
morality than FEV1 of transplant-free survival in patients with severe COPD (140, 
141). Since quadriceps weakness is one of the COPD manifestations most amenable 
to treatment, through pulmonary rehabilitation and measures to promote physical 
activity, this makes skeletal muscle dysfunction an important therapeutic target in 
COPD. 
 
1.5.5 Inspiratory muscle weakness 
 
Inspiratory muscle weakness is important in COPD, with the imbalance generated by 
increased respiratory load coupled with reduced inspiratory muscle strength possibly 
contributing to the sensation dyspnoea and morbidity (139, 142). Additionally, 
hypercapnia can result from real or functional (as a consequence of hyperinflation) 
inspiratory muscle weakness (143) and maximal inspiratory pressure is a predictor of 
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mortality (144). The diaphragm is naturally the focus of most studies on inspiratory 
muscle weakness, given its role as the principal muscle of respiration. 
 
Diaphragm strength can be measured in a number of ways, either through invasive 
tests such using electrical or magnetic stimulation (137) or the non-invasive, maximal 
Sniff nasal inspiratory pressure (SnIP) (145, 146), which is a highly sensitive test for 
diaphragmatic weakness in COPD, but is not very specific. This is in part due to SnIP 
values being further reduced by hyperinflation (147), both because of impaired 
transmission pressure from the oesophagus (pleural space) to the nose and also 
because of the diaphragm fibre shortening that occurs with hyperinflation (148). 
Other factors such as cachexia, chronic steroid use and inflammation have been 
suggested as possible contributory factors for inspiratory muscle weakness (149-
151).  Undernutrition was not found to be a determinant in a small study looking at 
SnIP values in COPD patients with high versus low BMI, however the patients with 
higher BMI were almost 10 years older than the underweight patients, and fat free 
mass may have better stratification tool than BMI for cachexia (152). Patients with 
chronically elevated levels of steroids, as seen in Cushing’s syndrome, do not appear 
to have weak diaphragms even though their quadriceps were found to be weak in a 
study by Mills et al  (153). Arguably, endogenous steroid production may affect the 
diaphragm muscle differently to exogenous steroid production, however acute 
administration of oral steroids also did not appear to result in weakening of the 
diaphragm muscle (154).  
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SnIP is a better predictor for mortality in COPD than the IC/TLC ratio (155), raising 
the possibility that it may capture cachexia in addition to the effects of 
hyperinflation.  SNIP has the advantage of being quick, painless and easy to perform, 
therefore being more acceptable to patients. It can also be performed without the 
need for highly trained staff as compared to measuring lung volumes or magnetic/ 
electrical stimulation of the diaphragm.  SnIP is therefore a potentially attractive 
biomarker, especially considering that hyperinflation is the only lung function 
parameter that improved with administration of anti-inflammatory MAPK inhibitors 
in COPD (59, 60). To date, no studies have examined the responsiveness of SnIP to 
anti-inflammatory therapy nor has the relationship between SnIP and inflammation, 
as measured by fibrinogen, been examined. 
 
1.5.6 Molecular signalling 
 
The interactions of molecular signalling pathways that lead to muscle atrophy are 
complex, and still being elucidated. Muscle atrophy occurs when the net balance of 
muscle protein breakdown (atrophy or catabolism) exceeds that of new protein 
synthesis (hypertrophy or anabolism). In vitro and murine models constitute most of 
the work carried out looking at the intracellular signalling of muscle atrophy. A 
further limitation of existing work is that of the triggers used to induce atrophy; 
molecular interactions in disuse atrophy are not necessarily the same as those seen 
in cachexia. The mechanisms for muscle atrophy in human COPD muscle therefore 
still require much investigation, particularly with muscle from patients with COPD, 
where the triggers may be a combination of inflammation, disuse and cachexia. 
61 
 
 
Muscle proteolysis in governed by several networks, including the oxidative stress 
pathway, activation of caplains, non-lysosomal proteases and autophagy. The most 
predominant of all pathways however is the ubiquitin-proteosomal pathway, with 
two ubiquitin ligases being key – atrogin-1 and muscle-specific RING finger protein 
(MuRF-1), which are up regulated across multiple atrophy models, including chronic 
metabolic diseases and denervation (156-158). 
 
The IGF-1/ Akt/ PI3K hypertrophy pathways have been demonstrated to both 
increase the rate of protein synthesis, as well as act as inhibitors of proteolysis in 
order to prevent atrophy. Conversely, activation of the p38 MAPK, NF-kB, FOXO, p53 
and AP-1 pathways can result in skeletal muscle atrophy (159-161). 
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Figure 1.5 Schematic diagram of hypertrophy and atrophy signalling pathways in skeletal 
muscle. Myostatin, Forkhead box O (FOXO), nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-kB), muscle atrophy F-box (Atrogin-1), muscle-specific ring finger 1 (MuRF-1), Insulin-like 
growth factor (IGF-1), serine/threonine protein kinase AKT (AKT), glycogen synthase kinase 3β 
(GSK3β), ribosomal protein S6 kinase (P70S6K), mitogen-activated protein kinase (MAPK), 
mammalian target of rapamycin (mTOR), Phosphoinositide-3-kinase (PI3K), Phosphatidylinositol 4,5-
bisphosphate (PIP2), Phosphatidylinositol (3,4,5)-trisphosphate (PIP3) (Source: D Mohan)  
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1.5.6 NF-kB pathway 
 
Tumour necrosis factor alpha (TNF-a) is a potent inducer of cachexia, and chronic 
TNF-a activation induces the classical NF-kB pathway, as shown below (162). 
 
Fig 1.6 Schematic representation of the classical and alternative Nf-kB pathway. 
Reproduced from Bakkar et al (2010) NF-kappaB signaling: a tale of two pathways in 
skeletal myogenesis. Physiological Reviews. doi: 10.1152/physrev.00040.2009. (162) 
 
The NF-kB family of transcription factors regulates a variety of cellular functions 
through differential dimerization. TNF-a signalling results in degradation of the IkB 
molecule, causing relocation of the p50 and p65 heterodimer (also known as Rel A) 
to the nucleus, where binding to DNA results regulates expression of genes, 
including those encoding cytokines, chemokines, cell adhesion molecules, acute 
phase proteins and several enzymes including those involved in the ubiquitin-
proteosomal system.  
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An alternative Nf-kB or disuse atrophy pathway also exists, with immobilisation 
leading to activation of the BAFF receptor, which then leads to degradation of the 
IkK molecule, releasing the p100 molecule (also known as Rel B) to act via p52 which 
then translocates to the cell nucleus to act as a transcription factor. 
 
NF-kB regulates myogenesis through cyclin D binding (163). Additionally, muscle re-
modelling is affected to cause atrophy through mechanisms such as p65 causing 
destabilisation of MyoD RNA (164) and NF-kB acting through YY1 to inhibit mir29 
(165, 166). It additionally appears to have a role in protecting against oxidative 
stress. TNF-α appears to negatively regulate muscle oxidative phenotype in a NF-kB 
dependent manner. (167) 
 
Murine models suggest that NF-kB is key to the development of muscle atrophy, and 
that genetic inhibition of NF-kB leads to sparing of the muscle tissue (168, 169).   
 
Plasma levels of NF-kB repressing factor (NFRF) are reduced in patients with stable 
COPD, suggesting a link between systemic inflammation and Nf-kB (170). 
 
Despite evidence of NF kB being a key regulator of muscle mass in murine and in-
vitro models, human biopsy samples from the vastus lateralis have failed to show 
up-regulation of the NF kB pathway(171).  
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Additionally, studies of TNF-a expression within human vastus lateralis samples have 
given conflicting results, although these studies have relied on small numbers of 
patients. Barreiro et al  found reduced TNF-a expression the vastus lateralis muscle 
of COPD patients (172), whereas increased levels were reported by Rabinovich et al  
(173), and no difference being reported by three groups (174-176). 
 
The lack of consensus between groups in terms of inflammatory signaling in muscle 
biopsies from COPD patients can be due to several differences in study protocols; for 
example, timing of biopsy, fasting status of subjects, phenotypic composition of 
cohorts, quality of biopsy specimens, assay specificity and form of expression 
analyzed. Protocols vary between groups in terms of the amount of rest specified 
pre-biopsy, which can confound results since exercise induces time-dependent 
changes in housekeeping, metabolic and myogenic gene expression profiles (177, 
178). Furthermore, examination of molecular pathways can be influenced by 
whether subjects have been fasted or not prior to biopsy since feeding activates 
protein synthesis pathways (179). Given disease heterogeneity, different phenotypic 
composition of cohorts can also give rise to varying results. For example, subjects 
may have differing fibre type composition (116) or where patients with low BMI are 
examined, these patients may represent subjects with stable, low BMI or patients 
with cachexia, with differing molecular pathways activated between the two. Quality 
of biopsy specimens is also important to consider, since specimens with a greater 
degree of intramuscular fat content may have different expression profiles if muscle 
and fat are homogenized together. Assay specificity for certain markers has 
improved in recent years, for example TNF-a (37), therefore there may be 
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discrepancy between older and newer research. Finally, it is important to consider 
whether literature refers to gene expression or protein expression. Gene expression 
as determined by PCR can estimate levels of mRNA transcripts, however PCR cannot 
ascertain whether these mRNAs are translated into protein. Protein expression can 
therefore be more useful to determine whether a pathway is active or not, but it is 
important to differentiate between phosphorylated and unphosphorylated proteins 
in order to look at pathway activation. Importantly, molecular changes do not 
necessarily correlate with physiological changes in humans due to the complexity of 
molecular networks, which can make identification of molecular therapeutic targets 
challenging (180). 
 
1.6 P38 MAPK  
 
P38 MAPK inhibition has long been proposed as a promising therapy for COPD (181, 
182) as well as other disease models, including those involving inflammation and 
myocardial injury.  Increased p38 MAPK expression has been observed in alveolar 
macrophages from COPD patients (183). In COPD patients, p38 MAPK appears to 
stabilise transcription of chemokines that are key in COPD pathogenesis, such as 
TNF-a, IL-6 and IL-8.  Activation of p38 kinases is associated with TNF-a induced 
expression of ICAM-1 on pulmonary microvascular endothelial cells, MMP-9 
activation, pulmonary arterial cell stimulation in response to hypoxia, 
hyperosmolarity-induced IL-8 expression in bronchial epithelial cells, and enhanced 
eosinophil trafficking and survival, suggesting a key role for the p38 MAPK pathway 
in airway inflammation in COPD. Inhibition of p38 MAPK causes a reduction in 
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circulating cytokines related to airway inflammation (184, 185) as well as a reduction 
in cardiac-stress activated kinases(186). Furthermore, administration of p38 MAPK 
inhibitors has been shown to attenuate progression of COPD in animal models, 
whereas oral dexamethasone did have not had the same effect (183, 187) suggesting 
that p38 MAPK acts via steroid independent pathways, and could therefore be used 
in patients not responsive to steroid therapy. 
 
TNF-α additionally appears to act via p38 MAPK to stimulate the ubiquitin ligase 1/ 
MAFbx pathways in myotubes, suggesting a mechanism for muscle atrophy in COPD 
(188). The role of p38 MAPK in the quadriceps muscle remains under debate, with 
Lemire et al  finding increased p38 MAPK activation alongside increased Atrogin1 
levels in their study of 18 patients with COPD (189), whereas a much larger study of 
105 patients found that neither p38 MAPK nor its downstream targets were more 
activated in COPD than healthy controls (190).  
 
A selective, competitive inhibitor of p38 MAPK α/β, Losmapimod, has been trialled in 
COPD patients as part of two separate randomised control trials. The anti-
inflammatory drug failed to show a significant improvement in FEV1 or number of 
exacerbations, but did significantly reduce plasma fibrinogen by 11% and showed a 
reduction in lung hyperinflation (59).  In a separate population, Losmapimod again 
showed a reduction in inflammation and a trend towards an improvement in hyper-
inflation but no significant improvement in FEV1 or 6 minute walking distance (60). A 
randomised control trial of another p38 MAPK inhibitor has shown an improvement 
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in FEV1 at 6 weeks, even though the improvement was less than the clinically 
meaningful difference in bronchodilator trials. Furthermore, the study had different 
inclusion criteria (36) and importantly included subjects who were not optimised on 
bronchodilator therapy prior to the start of the trial, which could explain the 
improvement in FEV1.  Additionally, it may be that p38 MAPK inhibitors benefit a 
subset of patients with COPD, and may improve symptoms or cardiovascular risk 
without significantly improving FEV1.  Certainly, early trials of p38 MAPK inhibitors 
appear to improve vascular inflammation in patients with hypercholesterolaemia 
(191), and it is possible that similar effects are observed in subjects with COPD. 
 
Therefore, it is feasible that p38 MAPK inhibition may benefit patients with COPD in 
the future but further data from randomised control trials is needed. The effect of 
Losmapimod or p38 MAPK inhibition on cardiovascular outcomes or muscular 
outcomes has not yet been examined in patients with COPD. 
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1.7 Aims of Thesis  
 
This thesis aims to explore the relationship between markers of systemic inflammation and 
the cardiovascular and skeletal muscle manifestations in COPD. Fibrinogen, a marker of 
inflammation, has recently been qualified as a biomarker for use in trials of COPD and forms 
the key biomarker of interest. Whilst fibrinogen is known to relate to exacerbations, its 
relationship with cardiovascular and muscle parameters in COPD is yet to be explored and 
the overarching theme of the thesis is to assess whether it is a useful biomarker for trials of 
cardiovascular and muscle manifestations of COPD. Firstly, I want to assess whether markers 
of inflammation are associated with markers of muscle weakness and cardiovascular 
parameters in COPD subjects. Secondly, I want to assess whether the muscular and 
cardiovascular parameters improve by inhibiting inflammatory pathways in COPD subjects 
with evidence of elevated fibrinogen. Lastly, I aim to assess whether inflammatory pathways 
form a future therapeutic target in muscle. Specifically, I aimed to test the following 
hypotheses: 
 
1. That there is a combined phenotype of systemic inflammation, muscle weakness and 
elevated cardiovascular risk. I examine whether elevated levels of fibrinogen relate 
to reduced quadriceps strength and increased arterial stiffness, and the prevalence 
of these manifestations in chapter 3. 
 
2. That systemic inflammation relates to inspiratory muscle weakness, as measured by 
elevated fibrinogen levels and sniff nasal inspiratory pressure (SNIP) respectively. I 
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will additionally explore other associations with SNIP in order to comment on its 
potential use as a biomarker in COPD trials in Chapter 4. 
 
3. That inhibition of the p38 MAPK pathway through a novel anti-inflammatory agent 
improves muscular and cardiovascular parameters in patients with COPD who have 
evidence of inflammation as measured via elevated fibrinogen. The results from this 
randomized control trial are presented in chapter 5. 
 
4. That inflammatory signalling in the quadriceps muscle is fibre specific and forms a 
potential target for future therapy. It is unclear whether NFkB signalling is 
upregulated in human COPD subjects, and the discordance in existing literature may 
arise due to signalling being fibre specific. I hypothesize that up-regulation of NF-kB 
signalling in Type 1 fibres causes fibre atrophy but this change in signalling is not 
seen on analysis of whole muscle due to the lesser portion of Type 1 fibres present 
within the sample. I will test this hypothesis by developing and using a novel laser 
capture micro-dissection method to separate skeletal muscle fibres according to 
subtype before extracting RNA to reveal differential signalling between muscle 
fibres. Such a method may have utlity in detecting future therapeutic targets in 
skeletal muscle in COPD. 
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Chapter 2 
2. Methods 
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2.1 Study Design 
Study 1 is a cross-sectional observational study of 61 subjects known as the “Fibre specific 
signalling study” conducted only at the Royal Brompton Hospital, London. . Select data from 
the 61 subjects in study 1 additionally contributed to the ERICA (Evaluating the Role of 
Inflammation in Chronic Airways disease) study, a prospective cross-sectional observational 
study of 800 subjects with COPD, aspects of which I analysed for this thesis. Finally, study 2 
is also known as the EVOLUTION study, which is a randomized control, double blind trial. 
 
2.2 Ethical Approval 
The Research Ethics Committees of Harrow and Cambridge approved the studies described 
here ((NCT01471587)and NCT01541852for Studies 1 and 2 respectively). Both studies were 
carried out in accordance with the Declarations of Helsinki. Written consent was obtained 
from all participants. Select data from study 1 also contributed towards the ERICA study (UK 
CRN ID 11101), a prospective, longitudinal, observational study of 800 subjects with COPD 
conducted across five UK academic centres. I was responsible for data harmonisation and 
quality control of the muscle measurements in the ERICA study, and supervised training 
across the 5 UK centres for ERICA (192) hence I have permission to use this data as part of 
this thesis. 
 
2.3 Power calculation 
 
The primary aims of the ERICA study were to identify new biomarkers that might be of 
potential value for the stratification for entry into future trials, especially those addressing 
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non-pulmonary manifestations of COPD, with fibrinogen, QMVC and aPWV forming the key 
biomarkers of interest. Specifically, the main objectives were to determine how effectively 
plasma fibrinogen predicts cardiovascular and/or skeletal muscle manifestations of COPD, to 
determine the predictive power of these biomarkers for hospitalisation and death, to 
investigate the extent of overlap between cardiovascular and muscle manifestations in 
COPD and to investigate the extent of inter-relationships between clinical biomarkers. The 
ERICA study was powered on the basis of a tertile analysis of aPWV and QMVC. Assuming an 
average aPWV of 10 (standard deviation (SD) 1.0m/s) and a minimal clinically relevant 
difference of 0.4m/s, 230 patients per tertile provide 90% power at p<0.01 to detect this 
difference between the top and bottom quartiles. For aortic pulse wave velocity, a 
difference of 0.4m/s per decade in the healthy population has been reported (193), and was 
taken as a clinically relevant difference. Assuming an average QMVC of 32 (SD 8kg) (133), 
220 patients per tertile will provide 90% power at a significance of p <0.01 in order to detect 
the minimum clinical difference of 3kg between the top and bottom tertiles. The minimum 
clinical difference for QMVC was based on a 10% limit of reproducibility of QMVC 
measurements, and given an average of 32kg for QMVC, this corresponds to a 3kg 
difference. Additionally, a difference of 38 Nm (3.87 kg) has been shown to be associated 
with greater risk of mortality in the general, older population (194). Allowing for a 10% 
dropout rate and incomplete datasets, approximately 800 patients were required.   
 
For study 2, a formal power calculation was considered inappropriate as this was an 
exploratory trial, but based on previous data (195), 30 subjects per treatment arm was 
deemed a feasible sample size to provide a 90% chance of achieving a reasonable 
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assumption of the effect size of losmapimod (where the null hypothesis is the effect size is 
zero) versus placebo on arterial inflammation, as measured by tissue-to-blood ration (TBR), 
assuming a standard deviation of 0.3 of TBR.  
 
 
2.4 Subject selection for cross-sectional study (Study 1) 
2.4.1 COPD patients 
Male and female patients aged between 40 and 90 years, with clinically diagnosed GOLD II – 
IV stage disease confirmed by post-bronchodilator spirometry, in clinically stable condition 
for the preceding 4 weeks and a minimum of 10 pack year smoking history were included. 
Exclusion criteria were exercise limiting neuromuscular problems, or concurrent other 
respiratory disease (e.g. asthma, bronchiectasis, sarcoidosis) or inflammatory diseases. 
 
2.4.2 Healthy age-matched controls 
 
Age-matched male and female volunteers without respiratory disease were included.  
 
2.5 Subject selection for interventional study (Study 2) 
 
Detailed inclusion and exclusion criteria are provided in Chapter 5. Briefly, male and female 
patients with confirmed GOLD stage I – IV COPD, aged between 50 and 85 years, a minimum 
10 pack year smoking history and ability to provide informed consent were included.  
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The following were exclusion criteria: 
 a cardiovascular event in the last 6 months (e.g. myocardial infarction, 
stroke) 
 known significant lung disease other than COPD 
 concurrent use of danurubicin, doxorubicin, topotecan, mitoxantrone 
 previous lung volume reduction surgery 
 prior exposure to Losmapimod 
 known clinically significant diagnosis in which inflammation is known or 
thought to play a role (e.g. inflammatory bowel disease, lung fibrosis, 
bronchiectasis) 
 current or chronic history of liver disease 
 insulin controlled or poorly-controlled Type 1 or Type 2 diabetes 
 significant exposure to radiation through research participation in the last 3 
years 
 women of childbearing age 
 drug or alcohol dependency in the past 6 months 
 use of systemic corticosteroids in the 4 weeks prior to administration of the 
drug 
 
Patients were invited to an initial screening visit, and had to meet the following criteria in 
order to be enrolled into the trial; post-bronchodilator spirometry with a FEV1/FVC ratio 
<0.7, a baseline of fibrinogen of >2.9 g/L, ALT of < 2x upper limit of normal (ULN), ALP and 
bilirubin <1.5 ULN and an ECG demonstrating a QTc interval <450msec.  
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2.6 Assessments 
The following table illustrates the assessments used in each study, as marked by a cross. 
Study 1 carried out these assessments spread out over 2 visits, which were a minimum of 1 
week apart. The second of these visits was a fasting visit, during which no exercise tests 
were done and subjects had phlebotomy, muscle biopsy and assessment of fat free mass. 
 
For study 2, the study schedule required 10 visits over a 4 month period, and further detail 
is given in Chapter 5. Following an initial screening visit (V 1), subjects returned for CT-PET 
scans on V2 and V8. Study assessments were carried out on V3, during which they were 
randomized onto the trial medication/ placebo, and then repeated after three months of 
taking the medication at V9. Visits 4, 5, 6, 7 and V10 required phlebotomy, urine sampling 
and routine observations only. 
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  Assessment Cross-sectional study (1) Interventional Study (2) 
Spirometry X X 
SNIP X X 
Anthropometric measurements X X 
Fat-free mass X X 
Rectus femoris cross-sectional area X  
Measurements of quadriceps strength 
(QMVC) 
X  
Physical activity monitor X  
6 minute walk test X X 
Short physical performance battery X  
Blood Pressure X X 
12-lead ECG X X 
Pulse wave velocity X X 
Health related quality of life 
questionnaires 
X X 
Venous blood sampling X X 
Quadriceps muscle biopsy X  
 
Table 2.1 Summary of study assessments in studies 1 and 2. ‘X’ denotes assessment inclusion. 
 
2.6.1 Measurements of Lung function 
2.6.1.1 Spirometry, lung volume and diffusing capacity for carbon monoxide 
 
Staff from the RBH lung function department performed the following assessments. Post-
bronchodilator spirometry was performed, with values expressed as percentages of 
predicted values according to European Coal and Steel Community (ECSC) reference values 
(196). Lung volumes were measured using plethysmography and diffusing capacity for 
carbon monoxide was measured using the single breath technique (CompactLab system, 
Jaeger, Germany) and were determined in accordance with European Respiratory Society 
(ERS)/ American Thoracic Society (ATS) recommendations  (197-199). Arterialised capillary 
earlobe blood samples were used to give resting oxygen and carbon dioxide tensions. 
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2.6.1.2 Sniff nasal inspiratory pressure (SNIP) 
 
Subjects had one nostril occluded by a suitably sized bung, which was connected to a hand-
held SNIP-meter (MicroRPM, Carefusion, UK) via a platstic catheter.  Subjects were asked to 
remain seated upright in a chair (approximately 90o of knee and hip flexion) whilst taking in 
a maximal and fast inspiratory sniff following a normal expiration to functional residual 
capcity. The highest  measurement was recorded, with both nostrils tested at least ten 
times (200).  
 
2.6.2 Anthropometric measurements 
 
Height was measured using a stadiometer, with the subject standing against a wall without 
their shoes. Weight was using the Tanita body composition analyser as described below. 
 
2.5.3 Measurements of muscle mass 
2.6.3.1 Fat-free mass 
 
Fat-free mass was estimated using single-frequency (50kHz) bioelectrical impedance 
analysis via TANITA BC 418MA (Tanita Corporation, Tokyo, Japan) (201). Subjects were first 
asked to void their bladder, and to remove shoes, socks and outer clothing before stepping 
onto the body composition analyser.  
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In subjects with COPD, a sex specific disease regression equation was used to determine fat 
free mass (FFM) (202): 
FFM = 8.383 + 0.465*ht2/R + 0.213wt (males) 
FFM = 7.610 + 0.474*ht2/R + 0.184wt (females) 
In the above equations, ‘ht’ denotes height (cm), R is resistance or impedance (ohms) and 
‘wt’ is mass or body weight (kg). 
 
2.6.3.2 Measurement of rectus femoris cross-sectional area (RF-CSA) 
 
A mid-thigh ultrasound scan of the rectus femoris quadriceps muscle was performed using a 
TOSHIBA machine and a 8Mhz linear array probe (PLM805, Toshiba Medical Systems, 
Crawley, UK),  as described by Seymour et al  (203). Subjects were rested in a supine 
position with the knee in passive extension. The skin was marked at three-fifths of the 
distance between the anterior superior iliac spine and the superior patellar border. Cross 
sectional area was measured using the planioteric method to outline the inner echogenic 
line of the rectus femoris. Three consecutive readings were obtained within 10% of each 
other; the results from these were averaged to give the RF-CSA.  
 
2.6.3.3 Measurement of quadriceps strength  
 
Strength was assessed as Quadriceps maximal volitional contraction (QMVC) force (204). An 
inextensible strap was placed around the right ankle and connected to a strain gauge (unless 
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there was a contra-indication to test that side, in which case all measurements were carried 
out on the left side). Subjects were placed in a seated position, with their knee flexed at an 
angle of 90 degrees over the edge of the quadriceps chair. 
 
Signals from the strain gauge were processed as a digital output by a Powerlab recording 
unit (ADInstruments, Oxford, UK) connected to a PC running LabChart software 
(ADInstruments) sampling at 10 kHz. A known 29kg weight was used for calibration prior to 
QMVC measurement. 
 
Subjects were asked to extend their knee with maximal effort against the strap for 5 
seconds. Encouragement was provided until no further increase in QMVC could be 
visualised. QMVC is recorded as the highest force sustained for 1 second (recorded in kg) as 
achieved in six efforts, with a minimum of 20 seconds between each effort. The % predicted 
MVC was determined as according to regression equations based on age, gender and FFM.  
 
Predicted QMVC force in kg =  
56.2 - (0.30 x Age (years)) + (0.68 x FFM (kg)) - (0.15 x Height (cm)) - (3.42 if Female) 
 
The residual standard deviation from the analysis of Seymour et al  was 8.58 kg; therefore, 
patients with an ((observed-predicted QMVC)/ 8.58) <-1.645, were considered weak (133). 
 
Intra-observer and inter-observer reliability of QMVC measurements was excellent, with 
intra-class correlation coefficients of 0.96 and 0.98 respectively in measurements carried 
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out on 10 volunteers prior to the commencement of the study. Measurements were carried 
out on the same day with a minimum of 30 minutes rest between each set of observations. 
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Figure 2.1: Photograph of study subject undergoing measure of quadriceps maximal 
volitional contraction 
 
2.5.4 Measurement of physical activity 
 
Subjects were asked to wear a multisensor biaxial accelerometer armband (Sensewear, 
Bodymedia, Pittburgh, USA) for one week as described previously (205). Subjects were 
asked to wear the armband continuously unless bathing, and to place it on the upper arm 
above the right elbow. Data were downloaded and processed using the Sensewear 
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professional software (version 6.1), and a valid physical activity level (PAL) or step count 
measurement was defined as >22 hours (92%) wearing time a day for at least 5 consecutive 
days that included a weekend. The PAL was calculated using the equation below: 
 
Physical Activity Level = Total energy expenditure/ Resting energy expenditure  
 
2.6.5 Measurements of exercise performance 
2.6.5.1  6-minute walk test (6MWT) 
 
A 6MWT was performed in accordance with the ATS 2002 guidelines (206) (without a 
practice walk) on a standard 30 metre corridor. Subjects were given standardized 
instructions during the test, and no other encouragement. Where necessary, subjects were 
permitted to use portable oxygen and a researcher carried the oxygen for the subject.  The 
distance walked was recorded in meters.  
 
2.6.5.2  Short Physical Performance battery 
 
The short physical performance battery (SPPB) was comprises three components – standing 
balance, 4m gait speed and timed 5 repeat sit to stand manoeuvres, with each component 
scoring a potential 4 points. All assessments are timed using a stopwatch, and times are 
recorded in seconds to 2 decimal places.  
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Standing balance is assessed as the ability to stand with feet positioned side-by-side, in 
semi-tandem and in full tandem for 10 seconds each. Subjects are asked to stand with their 
eyes open and hands resting on their sides.  
 
4m gait speed is measured using a pre-defined, level 4m track and subjects are asked to 
walk at their normal pace, as if they were walking to the shops, with the time taken to cross 
the 4m mark recorded. The assessment is carried out twice, and the best of two 
measurements is recorded.   
 
The sit-to-stand test requires a suitable, firm, non-fixed chair (seat height of 18 inches), and 
subjects are asked to fold their arms across their chest and stand up fully from a seated 
position five times, and to do this manoeuvre as quickly as possible.     
 
The final score out of a maximum 12 was recorded (207, 208), and the scoring is illustrated 
below in figure 2.2 (209): 
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Figure 2.2 Scoring for Short performance physical battery (SPPB)  
Reproduced from “Phenotypic Characterisitics Associated with Reduced Short Physical 
Performance Battery Score” by Patel et al, May 2014. Chest 145(5): 1016-1024. 
doi:10.1378/chest.13-1398 (209) 
  
86 
 
2.6.6 Measurements of cardiovascular status 
2.6.6.1  Blood pressure measurements 
 
Systolic and diastolic blood pressure measurements (mm Hg) were recorded in triplicate 
following an initial five minutes of seated rest (or ten minutes of supine rest for supine 
blood pressure) using the Omron M6 sphygmomanometer (Omron Healthcare Europe, 
Hoofddorp, Netherlands). A minimum of one minute was given between each recording. An 
average of the final two readings was recorded. The non-dominant arm was used for 
measurements. 
 
2.6.6.2  Electrocardiogram 
 
A standard 12-lead electrocardiogram (ECG) was carried out on all subjects. Subjects were in 
supine position. Values for heart rate, PR interval, and QRS duration and QT interval were 
recorded. For study 2, the Friedrich’s corrected QT (QTcF) interval was calculated: 
 
 
2.6.6.3  Pulse Wave Velocity and aortic augmentation index 
 
Carotid-femoral pulse wave velocity (PWV), central blood pressure and aortic augmentation 
(AIx) were measured in fasting subjects using application tonometry via the Sphygmocor 
system (PWV medical, Sydney, Australia) (93, 210, 211). Subjects had to fast for a minimum 
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of 4 hours and refrain from medications (if possible) for 6 hours prior to measurements. 
PWV measurements were ECG- gated and undertaken 10 minutes after the subjects had 
been resting in a supine position and following measurement of supine blood pressure. 
Physical distance between the sternoclavicular notch and the carotid and the femoral pulses 
was measured using a tape measure. AIx measurements were carried out following a 
minimum of 5 minutes seated rest and measurement of seated blood pressure. Only 
readings that had an acceptable quality index of >80% were included for AIx; for PWV, 
acceptable readings had to have a standard deviation of <1.0 and fall within 0.5 m/s of each 
other. Readings were repeated until two good quality readings for both PWV and AIx were 
obtained and the average of two measurements for each was recorded. The non-dominant 
hand/ side was used for blood pressure, AIx and PWV readings. 
 
Intra-observer reliability of PWV measurements was excellent, with intra-class correlation 
coefficients of 0.96 in measurements carried out on 10 volunteers on the same occasion 
prior to the commencement of the study. Obtained sphygmocor traces were additionally 
visually inspected by experts on the study team for quality assurance.  
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Figure 2.3 Photograph of study participant having measurement of carotid pulse wave 
velocity 
 
 
2.6.7 Health-related quality of life assessment 
 
Subjects were asked to fill out the St. George’s respiratory questionnaire (SGRQ) (212), the 
MRC dyspnoea score (213)  and the COPD assessment test (CAT). (214) They were also 
asked to fill out a questionnaire detailing smoking history, past medical history, family history 
and medications. 
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2.6.8 Collection of venous blood and extraction of plasma and serum 
 
Phlebotomy was performed to collect approximately 50mls of venous blood following at 
least a 4 hour fast. Samples were sent to the RBH haematology and biochemistry 
laboratories for analysis of fibrinogen, full blood count, urea and electrolytes, full lipid 
profile and hsCRP. Additionally, 2 serum and 2 EDTA bottles were spun at 15000 rpm at 4oC 
for 15 minutes in the Eppendorf 5804R centrifuge. The clear supernatant from serum 
samples was then pipetted into 2ml cryovials for storage at -80oC. EDTA samples also had 
supernatant pipette; additionally, the greyish buffy coat layer at towards the bottom of the 
supernatant was removed and stored in separate cryovials. 
 
2.6.9 Collection of quadriceps muscle samples 
 
Subjects underwent a percutaneous needle biopsy of the vastus lateralis of the quadriceps 
(of the leg on which strength and mass assessments were performed) as described by 
Bergstrom (215). The patient was rested for a minimum of 20 minutes in a supine position, 
fasted for at least 4 hours and the biopsy done on a different day to measurements of 
exercise performance to minimise the effects of recent activity on biopsy findings. The 
biopsy was carried out using sterile technique, using sterile equipment and gloves. The skin 
was cleaned using Chlorhexadine solution, following which 2% Lignocaine was used to 
infiltrate the skin, subcutaneous tissue, and the muscle of the vastus lateralis. After allowing 
sufficient time for the local anaesthetic to work, a scalpel was used to make a 1cm incision 
into the skin, through which the Bergstrom needle was inserted into the muscle layer. A 
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50ml syringe was connected onto the Bergstrom needle via a 3-way tap, and was used to 
apply suction and aspirate muscle. The wound was closed with steristrips and covered with 
a water-proof dressing. 
 
Samples were either flash frozen in liquid nitrogen or mounted on cork and OCT before 
being more gradually cooled in liquid isopentane. Both sets of samples were stored at -80oC. 
 
Fig 2.4 Photograph of quadriceps biopsy using Bergstrom method 
 
2.7 Statistical Analysis 
 
Statistical analysis was performed using GraphPad Prism v5.0 software and Statview v5.0.1 
(SAS Institute Inc, Cary, USA). Further detail on relevant statistical methods is provided in 
the methods section of individual results chapters. 
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Chapter 3 
3.  Cardiovascular and muscle manifestations: phenotypes in COPD 
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3.1 Background 
 
Chronic Obstructive Pulmonary Disease (COPD) is recognised to be complex and 
heterogeneous, with a variety of pulmonary and extra-pulmonary manifestations (10), the 
latter being not only common in chronic obstructive pulmonary disease (COPD) (1, 18) but 
contributing significantly to morbidity and mortality (16, 18, 25, 27). Parenchymal damage 
to the lungs in COPD is currently irreversible, and consequently therapies targeting organs 
other than the lungs are increasingly prioritised as a way of reducing morbidity and 
mortality in COPD. Whilst spirometry has traditionally been used to define the presence of 
COPD, disease heterogeneity means that this single variable cannot reliably predict the 
burden of comorbidities or individual disease progression (216), necessitating a search for 
other biomarkers for use in clinical trials targeting extra-pulmonary disease manifestations. 
Identification of clusters of disease attributes is important for determining prognosis and 
targeting therapy, the latter requiring better understanding of underlying pathogenesis and 
developing biomarkers that relate to treatment and presence of comorbidities, thus 
validation and characterization of phenotypes in COPD is currently a research priority.  
 
Elevated cardiovascular risk and peripheral skeletal muscle dysfunction form two of the 
most important, established co-morbidities in COPD in terms of prevalence and risk of 
mortality (18, 22, 23, 27). Cardiovascular disease forms the second commonest mode of 
death in COPD (217), and conversely COPD appears to be an independent risk factor for 
developing cardiovascular disease (13). Quadriceps weakness is evident in one third of 
COPD patients (22), relating to increased healthcare utilisation (139) and mortality (141). 
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The degree of overlap between these two important co-morbidities remains unclear, 
although it is likely that the cardiovascular and skeletal muscle manifestations in COPD are 
intimately interlinked, since skeletal muscle dysfunction or the presence of angina can limit 
physical activity in COPD patients, with inactivity causing further muscle weakness in 
addition to increasing cardiovascular risk. Targeting skeletal muscle weakness, 
cardiovascular disease and/or physical inactivity in COPD patients can therefore prevent the 
“downward disease spiral” in COPD. Pulmonary rehabilitation as a therapy is effective in 
improving muscle strength, although it does not appear to improve arterial stiffness (92, 
218) and the presence of several barriers to rehabilitation, such as access, transport and 
patient motivation, make an alternative, pharmaceutical approach attractive. 
 
Systemic inflammation has been proposed as a mechanistic link between these 
comorbidities (28, 81) (36), as well as other comorbidities in COPD, and consequently there 
is considerable interest in novel anti-inflammatory therapies under for targeting these 
manifestations (181, 219). Although recent data from Van Fleteren and colleagues suggests 
low grade systemic inflammation does not vary significantly amongst phenotypes (23), the 
results require validation in larger, multicentre cohorts with a wider panel of inflammatory 
markers. Most studies of comorbidities have examined one or two conditions in isolation, 
and it remains unclear as to what degree the cardiovascular and peripheral skeletal muscle 
manifestations in COPD overlap, and whether inflammation is indeed the missing link.  
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Establishing the role of inflammation in COPD is limited by the use of differing panels of 
inflammatory markers across studies; of these, ECLIPSE has been the most comprehensive, 
finding that fibrinogen is the most stable and repeatable systemic inflammatory biomarker 
in COPD, although importantly the repeatability of white cell count was not assessed as part 
of this study (42). Interest in fibrinogen as a biomarker for COPD trials has grown with 
evidence that elevated levels  of fibrinogen relate to worse lung function, reduced physical 
activity, frequent exacerbations and all-cause mortality (40, 55, 61, 220). Fibrinogen has the 
added advantage of being easy to measure, with clinical assays widely in use (42), and is 
under consideration by regulatory authorities for use as a biomarker in clinical trials in COPD 
(63). Since fibrinogen is known to predict cardiovascular disease in the general population 
and cardiovascular causes form a significant portion of deaths in COPD, it is feasible that 
fibrinogen relates to cardiovascular disease in COPD (44). In COPD, skeletal muscle 
weakness relates to physical inactivity (55), frequent exacerbations (139) and mortality 
(141), all of which are independently associated with elevated fibrinogen.  Hitherto, the 
value of fibrinogen in predicting cardiovascular and/or skeletal muscle phenotypes has not 
been examined. 
 
The “Evaluating the Role of Inflammation in Chronic Airways disease” (ERICA)study was 
designed with the intention of studying fibrinogen in relation to the cardiovascular and 
skeletal muscle manifestations in COPD, and is unique among large collaborations in 
focussing on extra-pulmonary, rather than pulmonary, manifestations of COPD. Both 
cardiovascular disease and peripheral muscle dysfunction can have varied clinical 
manifestations, however in order to analyse data objectively, a single variable measure was 
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required for each. Aortic pulse wave velocity (PWV) is considered the gold-standard 
measure of arterial stiffness and is a powerful, non-invasive, independent risk factor for 
cardiovascular events and mortality in the general population (87) and was, therefore, 
chosen as a surrogate measure of cardiovascular disease. Quadriceps maximal volitional 
contraction (QMVC) is widely accepted as a measure of peripheral muscle dysfunction and 
predictor of mortality in COPD (141). 
 
Here, we address two objectives: firstly, whether cardiovascular and skeletal muscle 
manifestations exist as distinct entities in COPD or whether there is an overlap syndrome. 
Secondly, we wished to evaluate whether inflammation, as measured by readily available 
clinical markers plasma fibrinogen, high sensitivity C-reactive protein (hsCRP) and white cell 
count (WCC) are associated with either cardiovascular disease or peripheral muscle 
weakness. 
 
3.2 Methods 
 
Subjects with a clinical diagnosis of COPD were recruited as part of study 1 and the ERICA 
study. All subjects provided written informed consent. Subjects had to be aged between 40 
and 90 years, with a clinical diagnosis of COPD (confirmed via smoking history of at least 10 
pack years and post-bronchodilator spirometry (FEV1 of <80% predicted and FEV1/FVC of 
<0.7)), and assessments were carried out on subjects who had been clinically stable for at 
least 4 weeks. Exclusion criteria were significant respiratory disease other than COPD, 
exercise limiting neuromuscular disease or an inability to provide written consent. 
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Assessments were carried out over two visits, with a minimum interval of 1 week between 
visits, following which subjects were followed up via 6-monthly questionnaires for 2 years. 
Post-bronchodilator spirometry, 6 minute walk, SPPB, QMVC, health related quality of life 
questionnaires and carotid intima media thickness measurements were carried out during 
the first visit, with the second, fasting visit being used to carry out pulse wave velocity 
measurements and venepuncture. 
 
For the purposes of determining manifestations, the presence of cardiovascular risk was 
defined by an elevated arterial stiffness of >10 m/s (94, 217). Skeletal muscle weakness was 
defined according to the gender-specific regressive Seymour equation ((Observed – 
Predicted QMVC)/ 8.58) <-1.645) (22).  Subjects were labelled according to the presence or 
absence of manifestations:  ‘CV’ for subjects with cardiovascular manifestations only, ‘SM’ 
for subjects with skeletal muscle weakness only, ‘B’ for subjects with both manifestations 
and ‘N’ for subjects with neither manifestation. 
 
The full study population was included in the main analysis. A sensitivity analysis was carried 
out that excluded subjects with simultaneously elevated hsCRP (>20 mg/L) and WCC (>11.0 
x 109/L), to exclude the possibility that data were skewed by participants with subclinical 
exacerbations. 
 
Data were tested for normality by plotting histograms. Continuous data is expressed as 
mean (standard deviation), with categorical data and/or non-normally distributed data 
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expressed as median (interquartile range). Univariable regression was carried out before 
determining variables to input for multiple linear regression; variables demonstrating co-
linearity or with a significance level >0.05 on univariable analysis were excluded from the 
multiple regression model. Linear regression analyses were conducted to estimate the 
dependence of two functional outcomes (QMVC and PWV) on each inflammatory biomarker 
(fibrinogen, hsCRP, WCC), with adjustment for known or expected confounders. Non-
normally distributed variables were log transformed prior to analysis.  The validity of the 
model was checked by examining goodness of fit and the distribution of residuals. A p value 
of <0.05 was accepted as significant. Statistical analysis was carried out using Statview 
v5.0.1 for Windows (SAS Institute, Cary, USA) and R (221) version 3.0.0 for Microsoft 
Windows with RStudio version 0.98.953. 
 
3.3 Results 
 
746 subjects with COPD were recruited into the ERICA study, of which 729 met trial 
inclusion criteria. The number of subjects with missing data per variable is detailed in Table 
3.1. 664 subjects had valid PWV measurements, 697 subjects had valid QMVC 
measurements and 618 subjects had data on both PWV and QMVC measurements.  Table 
3.2 describes baseline demographics for the overall cohort and individual phenotypic 
groups. The population had a mean age of 65 years, 60% were males, with a substantial 
smoking history, moderate to severe COPD (mean FEV1 of 52.2 % predicted), mean PWV of 
10.3 m/s and mean QMVC of 30.6 kg (68.2% predicted). 
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Variable Number of subjects with missing data 
Smoking history 11 
Height 6 
Weight 12 
Body mass index 12 
Fat free mass 35 
Forced expiratory volumes in 1 second 4 
Forced vital capacity 4 
Quadriceps maximal volitional contraction 32 
Short physical performance battery 12 
6 minute walk distance 36 
Supine heart rate 56 
Supine mean arterial pressure 15 
Pulse wave velocity 65 
Fibrinogen 13 
High sensitivity-C-Reactive Protein 20 
White cell count 15 
Medical Research Council dyspnoea score 10 
COPD Assessment Test score 10 
SGRQ total score 24 
Exacerbation history 104 
Diabetes history 8 
Antihypertensive therapy 11 
Cholesterol lowering therapy 15 
Previous history of myocardial infarction 10 
 
Table 3.1 Variables with missing data; Number of subjects with missing data per variable in total ERICA cohort 
(n = 729) 
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Variable Overall 
(n =729) 
 Neither co-
morbidity (N) 
(n=195) 
Skeletal muscle 
weakness 
alone (SM) 
(n=137) 
Cardiovascular 
manifestation 
alone (CV) 
(n=154) 
Both skeletal 
muscle and 
cardiovascular 
manifestation 
(B)  
(n=132) 
Demographics 
Age (years) 67 (8)  66 (7) ** 63 (8) *** 70 (7) *** 70 (7) *** 
Gender (%male) 60.7  58.5  54.8 67.5 62.9 
Smoking history (total 
pack years) 
47 (27)  44 (27) 47 (27) 51 (31) 45 (25) 
% current smokers 30.5  34.9 34.3 29.9 27.5  
Anthropometrics 
Height (cm) 167(9)  166 (9) 166 (10) 167 (9) 166 (10) 
Weight (kg) 76.3 (18.3)  73.2 (16.5) * 74.5 (17.9) 76.4 (16.5) 79.1 (20.4) 
BMI (kg / m
2
) 27.3 (5.8)  26.3 (4.9) ** 26.8 (5.6) 27.1 (4.9) 28.3 (6.5) * 
Fat free mass (kg) 50.9 (11.0)  49.6 (10.5) 50.1 (11.2) 51.9 (10.5) 52.2 (11.9) 
Spirometry 
FEV1 (L) 1.34 (0.53)  1.50 
(0.52)*** 
1.30 (0.53)  1.32 (0.50) 1.26 (0.50) 
FEV1 (% predicted) 52.2 (16.1)  57.5 
(14.2)*** 
49.3 (16.4)* 51.9 (16.4) 50.6 (15.9) 
FVC (L) 2.80 (0.87)  3.05 
(0.84)*** 
2.74 (0.94) 2.79 (0.83) 2.59 (0.80) ** 
FEV1/FVC 0.48 (0.13)  0.49 (0.12) 0.48 (0.13) 0.47 (0.12) 0.49 (0.13) 
Muscle Indices 
QMVC (kg) 30.6 (11.5)  36.0 (10.1) 23.4 (7.9) 36.7 (10.7) 22.7 (8.2) 
QMVC (% predicted) 68.2 (20.7)  81.3 (15.3) 51.5 (12.0) 82.2 (14.9) 50.2 (12.9) 
SPPB  total score 10 (1,12)  11 (3,12) *** 10 (3,12) 11 (4,12) * 9 (2,12) *** 
6 MW distance (m) 345 (130)  403 (103)*** 340 (131) 361 (125) 282 (132)*** 
Cardiovascular Indices 
Supine HR (beats/ 70 (12)  67 (12)*** 68 (11) 71 (10) 74 (12) ** 
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minute) 
Supine MAP (mm Hg) 98 (12)  96 (11) 94 (11)** 100 (10) 100 (12)* 
APWV (m/s) 10.3 (2.6)  8.3 (1.1) 8.3 (1.1) 12.2 (2.0) 12.7 (1.9) 
Inflammatory markers 
Fibrinogen (g/dL)  3.50 (0.89)  3.44 (0.94) 3.47 (0.93) 3.49 (0.78) 3.52 (0.90) 
hsCRP (mg/L) 6.55 (12.1)  7.43 (19.5) 6.09 (8.13) 5.50 (6.75) 6.45 (6.96) 
WCC (x10
9
/L) 7.49 (2.16)  7.36 (2.14) 7.14 (2.19) 7.42 (1.95) 7.69 (2.38) 
Health related quality of life questionnaires 
MRC dyspnoea score 
(1-5) 
3 (1, 5)  2 (1,5)  3 (1,5) 3 (1,5) 4 (1,5) 
CAT score (0-40) 20 (1,40)  17.5 (1,38) 
*** 
22 (1,39)*** 19 (3,40) 22 (6,40) 
SGRQ total score 52.2 (21.8)  45.3 
(21.0)*** 
58.0 (21.1)** 48.4 (21.7)* 56.9 (19.8)* 
Comorbidities 
Exacerbations per year 2.2 (2.2)  2.0 (1.7) 2.4 (1.9) 2.0 (2.3) 2.1 (2.3) 
Diabetes (%) 11.2  6.2 7.2 10.4 18.3** 
Anti-hypertensive 
therapy (%) 
35.9  31.4 28.9 39.0 43.9 * 
Anti-
hypercholesterolaemi
a therapy (%) 
32.6  22.8 28.5 37.9 ** 43.8 *** 
Previous myocardial 
infarction (%) 
7.8  6.2 6.6 9.0 9.2 
Table 3.2 Baseline characteristics of COPD subjects from the ERICA study (n= 729) and according to 
manifesations  (n =618).  
Baseline demographics for overall cohort (n = 729) and phenotypic groups. Values expressed as mean 
(standard deviation) for continuous variables and median (range) for discrete variables. Group ‘N’ (n=195) 
represents subjects with neither elevated aortic pulse wave velocity nor skeletal muscle weakness. Group ‘SM’ 
(n=137) represents subjects with skeletal muscle weakness alone. Group ‘CV’ (n=154) represents subjects with 
cardiovascular manifestation, defined as elevated aortic pulse wave velocity, alone, and group ‘B’ (n=132) 
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contains subjects demonstrating both skeletal muscle weakness and elevated aortic pulse wave velocity. 
Skeletal muscle weakness according to predicted quadriceps maximal volitional contraction, based on 
equations developed by Seymour et al (22) and elevated  aortic pulse wave velocity defined as >10 m/s. 
List of abbreviations: BMI = body mass index, FEV1 = forced expiratory volume in 1 second, FVC = forced vital 
capacity, QMVC = quadriceps maximal volitional contraction, SPPB = short physical performance battery, 6MW 
= 6 minute walk, HR = heart rate, MAP = mean arterial pressure, aPWV = aortic pulse wave velocity, CRP = C-
reactive protein, WCC = white cell count, MRC = medical research council, CAT = COPD assessment test, SGRQ 
= St George’s respiratory questionnaire, * = p<0.05, **= p<0.01, *** p=<0.001 
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Group composition 
Subjects were categorised into the four groups: ‘SM’ (skeletal muscle weakness alone), ‘CV’ 
(cardiovascular manifestation alone), ‘B’ (combination of muscle and cardiovascular 
manifestation) and ‘N’ (neither cardiovascular nor skeletal muscle manifestation). Of the 
618 subjects, 195 (31.5%) were classified as ‘N’, 137 (22.2%) as “SM”, 154 (24.9%) as “CV” 
and 132 (21.4%) as “B” (Figure 3.1). In total, 269 out of 618 (43.5%) subjects had evidence 
of muscle weakness and 286 of 618 (46.3%) had an elevated PWV.  
 
Figure 3.1 Distribution of cardiovascular and skeletal muscle manifestations amongst 
COPD subjects in the ERICA study. Distribution of cardiovascular and muscular comorbidities in 
COPD (total n=618). Group ‘N’ (n=195) represents subjects with neither elevated aortic pulse wave 
velocity nor skeletal muscle weakness. Group ‘SM’ (n=137) represents subjects with skeletal muscle 
weakness alone. Group ‘CV’ (n=154) represents subjects with cardiovascular manifestation, defined as 
elevated aortic stiffness, alone, and group ‘B’ (n=132) contains subjects demonstrating both skeletal 
muscle weakness and elevated aortic stiffness. Skeletal muscle weakness according to predicted 
quadriceps maximal volitional contraction, based on equations developed by Seymour et al (22) and 
elevated arterial stiffness was defined as an aortic pulse wave velocity of >10 m/s. 
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Differences in characteristics amongst groups 
Smoking history, body composition and spirometry indices were similar across all four 
groups (Table 3.2). Subjects with elevated PWV were older and more likely to be male. 
Subjects with skeletal muscle weakness alone were younger, had worse health status  
scores and reported more frequent exacerbations despite having fewer comorbidities than 
groups “CV” or “B”.  Where elevated PWV was present in combination with muscle 
weakness, functional outcomes judged by 6MWD and SPPB were worse, whereas subjects 
with neither manifestation had the best health status and functional outcomes. Subjects 
with  skeletal muscle weakness had shorter 6MWD, mean 340m (SD 131m) and 280m (SD 
132m) in groups SM and B (respectively), compared with 406m (SD 103m) in groups ‘N’ or 
361m (SD 125m) in ‘CV’. Groups ‘N’ and ‘SM’ had fewer subjects with diabetes, 
hypertension and hypercholesterolaemia than groups ‘CV’ or ‘B’. The incidence of previous 
myocardial infarction in groups ‘N’ and ‘SM’ was lower (6.2% and 6.6% respectively) than 
groups ‘CV’ and ‘B’ (9% and 9.2% respectively). 
 
Systemic Inflammatory Markers 
Inflammatory markers did not differ between groups (Table 3.2). Using linear regression 
analysis, fibrinogen was not associated with either PWV (p = 0.62) or QMVC (p = 0.68), as 
shown in tables 3.3 and 3.4 respectively. Furthermore, hsCRP and WCC were unrelated to 
PWV (p = 0.51 and p = 0.25 respectively) or to QMVC (p = 0.13 and p = 0.51 respectively), as 
can be seen in the appendices (Tables A1- A4). 
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These results did not change significantly when 9 individuals with simultaneously raised 
WCC and hsCRP were excluded in a post hoc sensitivity analysis (Tables A5 – A10 in the 
appendices).   
 
Associations with quadriceps weakness 
 
Data for QMVC had a left-skewed distribution, as illustrated in figure 3.2. With QMVC as the 
dependent variable, a number of independent variables were first subjected to univariate 
analysis. Age, gender, FEV1, mean arterial pressure, hsCRP, alcohol use, fat free mass and 
height all correlated significantly with QMVC as demonstrated in Figure 3.3a. Fibrinogen, 
white cell count and pulse wave velocity were not significantly correlated with QMVC, as 
demonstrated in Figure 3.3b, however correlations between QMVC versus PWV and 
fibrinogen were approaching significance (p = 0.07 and p =0.08 respectively) on univariate 
analysis. 
 
Figure 3.2 Histogram demonstrating left-skewed distribution of quadriceps maximal 
volitional contraction (kg) in subjects (n = 618) 
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Figure 3.3 Univariable regression for COPD subjects (n=618) with quadriceps maximal volitional contraction 
(QMVC) as the dependent variable on the y-axis. Figure 3.3a shows independent variables that correlate 
significantly with QMVC: age (p=0.008), height (p<0.0001), FEV1 (p<0.001), mean arterial pressure (MAP) 
(p=0.02), high sensitivity C-reactive protein (hsCRP) (p = 0.03), alcohol (p<0.001), fat free mass (FFM) 
(p<0.0001). Gender (not shown) was also had a significant association (p <0.001). Figure 3.3b shows 
independent variables that do not correlate significantly: fibrinogen (p=0.08), white cell count (WCC) (p=0.84), 
pulse wave velocity (PWV) (p=0.07)). Univariable regression performed using Statview v5.0.1. 
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Multiple regression analysis was then used to build a model to examine associations with 
QMVC; significant associations with QMVC were found in terms of age, gender, fat-free 
mass and FEV1 (Table 3.3). Fibrinogen, smoking history and height did not emerge as 
significant associations. 
 
Variable Estimate Standard error P value 
Log fibrinogen -0.59 1.44 0.68 
Age (years) -0.17 0.05 <0.001 
Gender 6.25 1.04 <0.0001 
Current smoker -0.21 0.78 0.79 
Fat free mass 0.37 0.05 <0.0001 
Height -0.12 0.06 0.064 
FEV1 4.7 0.82 <0.0001 
Site 2 -1.03 1.4 0.46 
Site 3 -2.63 1.17 0.025 
Site 4 0.08 1.39 0.95 
Site 5 -0.29 1.61 0.86 
   
Table 3.3 Linear regression analysis for associations with quadriceps maximal volitional 
contraction in subjects with COPD (n=658). Age, gender, fat-free mass and FEV1 emerge as the only 
significant associations with quadriceps weakness (p <0.001, p <0.0001, p <0.0001 and p<0.0001 
respectively), with fibrinogen not emerging as being significantly associated (p=0.68). Site 1 is set as 
the index, comparator site for remaining sites. 
 
FEV1 has not been found to be a determinant of QMVC in past (smaller) cohorts, yet after 
adjusting for age, gender, height and weight and comparing FEV1 %predicted and 
QMVC%predicted, a statistically significant although weak correlation (R=0.187, p<0.0001) 
emerges, as illustrated in Figure 3.4.  
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Figure 3.4 Correlation between FEV1% predicted and QMVC%predicted (R=0.187, p<0.0001) 
 
 
Associations with Aortic Stiffness 
 
Data for PWV were skewed to the left, as illustrated in figure 3.5 below: 
 
Figure 3.5 Histogram showing left-skewed distribution of pulse wave velocity (m/s) in overall 
ERICA cohort (n = 618)  
 
Simple regression was first carried out for a number of independent variables, as illustrated 
in Figure 3.6. A multiple regression model was then constructed (Table 3.4); age, gender, 
supine heart rate, supine mean arterial pressure and diabetes were significantly associated 
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with PWV (Table 3.3). Smoking history, FEV1, previous myocardial infarction, anti-
hypertensive therapy and cholesterol lowering therapy were not significantly associated. 
 
Figure 3.6 Univariable regression for COPD subjects (n=618) with pulse wave velocity (PWV) as the 
dependent variable on the y-axis. Figure 3.6a shows independent variables that correlate significantly with 
PWV: age (p<0.0001), BMI (p=0.01), alcohol use (p=0.02), mean arterial pressure (MAP) (p<0.0001), FEV1 
(p=0.001), high sensitivity CRP (hsCRP) (p=0.0043), white cell count (WCC) (p=0.01). Age and smoking status 
were also significantly correlated (p= 0.02 and 0.004 respectively) but are not shown. Figure 3.6b shows 
independent variables that do not correlate significantly: cholesterol (p=0.33), fibrinogen (0.32), pack year 
history (p=0.08) and QMVC (p=0.07). Univariate regression performed using Statview v5.0.1. 
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Variable Estimate Standard error P value 
Log fibrinogen 0.18 0.37 0.62 
Age (years) 0.13 0.01 <0.0001 
Gender 0.46 0.20 0.023 
Supine heart rate 0.05 0.01 <0.0001 
Supine mean arterial pressure 0.06 0.01 <0.0001 
Current smoker -0.18 0.20 0.36 
Smoking pack year history 0.001 0.003 0.77 
FEV1 (L) -0.12 0.20 0.54 
Diabetes 0.95 0.29 <0.01 
Previous heart attack 0.07 0.35 0.84 
Anti-hypertensive therapy -0.01 0.20 0.97 
Cholesterol lowering therapy 0.25 0.21 0.23 
Site 2 0.86 0.35 0.02 
Site 3 0.43 0.29 0.14 
Site 4 -0.92 0.36 0.01 
Site 5 0.77 0.41 0.06 
 
Table 3.4  Linear regression analysis for associations with cardiovascular co-morbidity, as measured by aortic 
pulse wave velocity, in subjects with COPD (n=640). Age, gender, supine heart rate, supine mean arterial 
pressure and the presence of diabetes are significantly associated with aortic pulse wave velocity (p < 0.0001, 
p = 0.023, p<0.0001, p<0.0001 and p<0.01 respectively), but fibrinogen is not associated with aortic pulse wave 
velocity (p = 0.62). Site 1 is set as the index, comparator site for remaining sites. 
 
3.4 Discussion 
 
Increased cardiovascular risk and/or skeletal muscle weakness was present in almost half of 
the COPD subjects in our cohort, and contrary to expectations these extrapulmonary 
manifestations are present distinctly, without evidence of a distinct phenotype combining 
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the two comorbidities.  Since these manifestations do not coexist more frequently than 
expected by chance they likely require different therapeutic approaches. The presence of 
skeletal muscle weakness appears to be more deleterious to health than the presence of 
cardiovascular disease, evidenced by lower performance indices and greater exacerbation 
frequency in subjects with quadriceps weakness. Furthermore, in spite of its association 
with poor outcomes in COPD, plasma fibrinogen does not appear to be a suitable biomarker 
for predicting the presence of these manifestations and is likely to be of limited use in 
clinical trials addressing these comorbidities. Our findings do not support the concept that 
anti-inflammatory therapy aiming to reduce fibrinogen is likely to reduce aortic stiffness or 
improve quadriceps strength in COPD, however randomized control trials would clearly 
better address this question (222).   
 
 
Multimorbidity 
 
Our study is one of the few to have examined the co-existence of cardiac and muscle 
manifestations. Van Fleteren and colleagues (23) reported a lower prevalence of 
cardiovascular and muscular co-morbidity in their smaller cohort of patients referred to a 
rehabilitation centre. Although they do not comment on the overlap between the cachectic 
and cardiovascular clusters, 10% of patients in the cardiovascular cluster had muscle 
wasting and 7% of cachectic patients had a history of myocardial infarction.  Siebeling et al 
(223) report much lower co-existence of cardiovascular and muscular comorbidities at 2-
3%,but define these comorbidities by patient recall. In contrast, we found that 21.4% of our 
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cohort exhibited both elevated PWV and quadriceps weakness, although this proportion is 
not greater than expected given the overall prevalence of these features. Since 43.6% of our 
cohort has muscle weakness and 46.3% have elevated PWV, the probability of having both is 
20.2%, which is almost identical to the observed figure of 21.4%, suggesting that there is not 
an independent, overlap syndrome. 
 
The presence of skeletal muscle weakness appears to be more deleterious than the 
presence of cardiovascular co-morbidity alone, since muscle weakness was associated with 
worse health status, functional outcomes and more frequent exacerbations despite 
affecting younger subjects. The reduction in 6MWD in the presence of muscle weakness 
alone is clinically significant, and in the presence of both comorbidities, the reduction is 
twice that of the clinically meaningful important difference of 30m (224).  
 
Prior studies have reported that CRP, WCC and fibrinogen are associated with more 
comorbidities (44), but our study suggests that circulating levels of these markers do not 
predict the presence of cardiovascular or muscle comorbidities in COPD, lending support to 
recent data that refutes the link between low grade systemic inflammation and these 
manifestations in COPD (23, 92).  Persistent systemic inflammation is only present in 16% of 
patients with COPD (26); given that we report prevalence of both aortic stiffness and 
quadriceps weakness is much higher than 16%, it seems improbable that inflammation 
could be a key aetiological factor. Elevated levels of fibrinogen in CODP may instead 
originate from the lung or represent frequent exacerbations in COPD (225), although it is 
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accepted that this mechanism would also be associated with episodic systemic 
inflammation.  Our findings suggest that anti-inflammatory therapies are likely to be of 
limited use in treating these manifestations, at least while patients are stable. Furthermore, 
these distinct comorbidities require independent management. 
 
Muscle Weakness 
 
Few studies have examined the prevalence of muscle weakness in literature with large 
cohort studies; other studies measuring muscle co-morbidity in COPD can often include 
different diagnostic methods, such as muscle mass measurements (23), handgrip strength, 
self-reported history of musculoskeletal disease such as osteoarthritis (223) or QMVC, with 
only the latter providing a true measure of quadriceps strength. Measurement of 
quadriceps force is objective, although the volitional nature of the test is a limitation in 
comparison to measures of body composition. Additionally QMVC requires specialised 
equipment and personnel; consequently few studies report prevalence of quadriceps 
weakness. Studies looking at fat-free mass indices report between 10% (226) and 50% (134) 
of COPD subjects having depleted fat free mass, however the higher values are only 
reported for subjects with severe airflow obstruction rather than a mixed COPD population, 
but the importance of a universal definition for muscle weakness is highlighted here. 
Seymour et al  studied quadriceps weakness, reporting an overall prevalence of muscle 
weakness of between 32% and 33% in UK and Dutch COPD populations when using a gender 
specific regression equation to predict QMVC (22)  but the Seymour equation possibly 
underestimates the prevalence of weakness, as the reference population for the regression 
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equation contained ex-smokers, and quadriceps strength is known to be lower in ex-
smokers compared to non-smokers. In our cohort, the prevalence of quadriceps weakness is 
higher at 43.6% than in the Seymour cohort, however ERICA recruited a more diverse 
population as a multicentre study. In COPD, muscle weakness precedes the development of 
cachexia (24), and is distributed regionally, with relative upper limb sparing (123), therefore 
measures other than QMVC are likely to underestimate prevalence of quadriceps muscle 
weakness, a measure known to significantly impact physical activity levels (55).  
 
Subjects exhibiting skeletal muscle weakness appeared to be particularly at risk when 
examining integrative exercise parameters such as 6MWT that reflect a combination of 
muscle performance as well as cardiovascular status and lung function impairment. Subjects 
with muscle weakness not only had a lower 6MWD than subjects with cardiovascular 
disease alone, but this difference was greater than the minimal clinically important 
difference of 30m (224). Subjects with muscle weakness alone had a mean 6MW distance of 
340m, whereas subjects in group ‘B’ walked 282m on average, the former value 
representing increased risk of hospitalisation and the latter representing increased mortality 
risk (227).  
 
Interestingly, annual exacerbation frequency was significantly higher in groups that had 
muscle weakness, whereas cardiovascular disease is traditionally thought to relate to 
exacerbations. Patel et al  demonstrated in their cohort that stable-state PWV related to a 
statistically significant increased frequency of exacerbations, even though the magnitude of 
the correlation was low at 0.2 (107). Our findings would suggest that measures to preserve 
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physical activity and/or fat free mass may benefit in preventing exacerbations. Indeed, 
pulmonary rehabilitation is one such measure of improving muscle strength that is known to 
reduce hospital readmission following exacerbation of COPD (218, 228). 
 
Age, gender, and FFM were significantly associated with QMVC, which is in agreement with 
previous findings (22, 205, 229), with addition of FEV1 as being independently associated 
being a novel finding.  
 
It is interesting to note that FFM was not lowest in group ‘SM’, but in group ‘N’ although 
these differences do not reach statistical significance. This supports earlier work suggesting 
that the quality of muscle, and not just quantity, gives rise to muscle weakness in COPD, 
either through fibre shift or increased muscle adiposity (230).  Muscle capillirization is 
known to be different in COPD quadriceps, further explaining functional differences in the 
absence of loss of muscle mass, therefore measuring muscle performance or strength is 
arguably more important than measuring fat free mass alone.  FFM depletion was only 
measured via bioelectrical impedance in this study, which is known to underestimate 
muscle mass  as compared to dual-energy X-ray absorptiometry (DEXA) scans and are the 
gold standard for measuring body composition. An important underlying assumption when 
measuring FFM via BIA is that FFM loss is evenly distributed, whereas this is not the case in 
COPD, where the locomotor muscles are more affected than shoulder girdle muscles (123). 
Furthermore, loss of FFM at the extremities appears is greater in patients with COPD than in 
controls, but does not appear to differ between patients with emphysema and chronic 
bronchitis, whereas truncal FFM depletion in mainly observed in the emphysematous 
phenotype (231).  Therefore, BIA is a crude measure in our large population of diverse 
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patients, however the mean FFM in all groups is lower than cut-offs associated with 
increased mortality risk in several cohorts (232). An alternative explanation for the lower 
FFM and higher QMVC measure in group ‘N’ could also be the volitional nature of QMVC, 
which could give rise to measurement variation across different subject groups however 
subjects were asked to perform QMVC six times in order to try and capture their maximal 
effort. 
 
Whilst several studies report low grade systemic inflammation and the presence of muscle 
weakness in COPD, very few examine the relationship between systemic inflammatory 
markers and quadriceps strength directly in stable subjects. To our knowledge, no study has 
examined the association between quadriceps strength and fibrinogen or WCC in COPD 
subjects, with a few reporting associations between quadriceps strength and TNF-α or IL-6, 
but not CRP (229, 233). Hence we are the first to report that systemic inflammation whether 
measured as CRP, WCC or fibrinogen has no association with quadriceps strength. 
Publication bias may mean that previous studies have had similar, negative results and are 
therefore not in the literature. Furthermore, quadriceps strength is not consistently used as 
a measure across studies to evaluate peripheral muscle function, with quadriceps CT or 
ultrasound cross sectional area, or fat free mass frequently preferred for ease of measure or 
equipment availability.  
 
 
Cardiovascular disease  
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Cardiovascular co-morbidity affects between 28% to 70% of COPD patients (14, 18, 223), 
agreeing with our measured 46.3% prevalence judged as elevated PWV. Reasons for the 
wide variation in prevalence include definition of cardiovascular co-morbidity, diagnostic 
method, populations studied and study inclusion criteria. A significant limitation of several 
studies is the use of patient recall to define co-morbidity (14, 18, 223). Whilst in agreement 
with other estimates, our definition of cardiovascular co-morbidity is not without limitation, 
notably as we use unadjusted PWV values, which are known to be affected by age and blood 
pressure (94). Defining this characteristic based on one criterion may explain the proportion 
of subjects with a history of myocardial infarction in categories ‘N’ and ‘SM’, suggesting that 
elevated PWV cannot reliably predict cardiovascular disease alone.  
 
Raised inflammatory markers such as hsCRP, fibrinogen and WCC appear to predict 
cardiovascular risk in the general population (68), with some evidence for this in COPD (27, 
38, 44, 81), although several studies do not find differences in inflammatory markers 
between COPD subjects with and without cardiovascular disease (65, 234), the latter 
possibly being underpowered to detect differences . The relationship between inflammatory 
markers and arterial stiffness is less clear in COPD: Van Fleteren et al  (92) and Sabit et al  
(64) both report an association between sTNFR1 and PWV in COPD subjects but differ on 
whether and IL-6 and PWV are related, with the latter including control subjects in their 
multivariate regression and finding a positive correlation. WCC did not relate to arterial 
stiffness in COPD subjects according to Van Fleteren et al, Maclay et al (88) and McAllister et 
al (90), the latter two, from the same group, also finding no association between CRP and 
PWV.  Mills et al  (65) report a correlation between arterial stiffness and serum CRP in their 
117 
 
COPD subjects but not controls, however their method uses only univariate regression and 
aortic augmentation index as the marker for arterial stiffness, which is not the gold standard 
and relates to gender.  In contrast, Bhatt et al (235) found no association between PWV and 
hsCRP or fibrinogen on univariate analysis, but did not go on to examine these in a 
multivariate analysis; furthermore, they failed to find an association between systolic BP 
and PWV in their cohort, an association which has been widely reported in both COPD and 
healthy subjects, suggesting that their cohort is unusual. 
 
Associations with PWV in our patients were similar to those in healthy subjects in other 
cohorts (94). We did not find an association between PWV and inflammatory markers 
(fibrinogen, hsCRP and WCC). Differences in results could be due to sample size, selection of 
inflammatory markers as well as differences in baseline subject characteristics between 
other studies. Furthermore, if the primary source of inflammation is the lung rather than 
cardiovascular, then a direct relationship between PWV and inflammatory markers may not 
be observed.  
 
Furthermore, we did not find an association between FEV1 and PWV in multivariate analysis, 
in contrast to earlier work (236), suggesting that PWV is not linked to the severity of airflow 
limitation at least in people diagnosed with COPD.  Our results suggest that pathways other 
than systemic inflammation may be important in the development of cardiovascular disease 
in COPD, although our conclusions are limited to the panel of biomarkers we used. 
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Modalities other than PWV, such as flow mediated dilatation or positron emission 
tomography, may better link inflammation and cardiovascular disease in COPD (102).  
 
Our findings can be interpreted in two ways; inflammation may play a less pivotal role in 
cardiovascular disease progression in COPD than previously thought, and other mechanisms 
may be more important, including common genetic lung and cardiovascular determinants 
(237). Alternatively, it could be that inflammation relates more closely to endothelial 
dysfunction (100) or atherogenesis rather than arterial stiffness, the latter of which 
represents both sympathetic tone as well as arterial wall composition. Arguably, pulse wave 
velocity is a measure of risk of future cardiovascular events, and does not alone confirm the 
existence of cardiovascular disease, therefore measuring its association with inflammatory 
markers is not definitive in terms of linking inflammation and cardiovascular disease in 
COPD. 
 
 
Fibrinogen and Inflammation 
 
Fibrinogen was not significantly different across the different groups but was numerically 
lowest in group ‘N’, and hsCRP and WCC also did not significantly differ between the four 
groups. Valvi et al  have reported a lower mean fibrinogen of 3.07 g/L in their study 
population with a fibrinogen of >3.93 g/L conferring increased risk of mortality(220), values 
that were similar to those reported by Mannino et al  in a separate US cohort (238), 
whereas the ECLIPSE study reported a value of 4.62g/L associated with the presence of 
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heart disease versus 4.45g/L  in the absence of heart disease (27) in COPD subjects. The 
differences in fibrinogen values may be due to differing methods or assays when measuring 
fibrinogen, as well as different study demographics; for example, studies by Valvi and 
Mannino et al have presumed a COPD diagnosis with available pre-bronchodilator 
spirometry, therefore COPD subjects in these studies could potentially have asthma.  A 
mean level of 2.9g/L in healthy non-smokers (61) would suggest that our cohort does indeed 
have elevated fibrinogen at a mean 3.5g/L, with groups containing co-morbidities exhibiting 
very similar mean values. 
 
Lower physical activity resulting from the presence of one or more co-morbidity could 
possibly be driving the slightly higher fibrinogen values in the co-morbid groups SM, CV and 
B, since physical activity is known to inversely relate to fibrinogen (55), and physical 
performance measures such as 6MW distance and SPPB score are significantly lower in the 
comorbid groups. Reference ranges for fibrinogen in COPD therefore need further 
evaluation across different populations to determine what constitutes elevated risk, and 
associations with phenotypes and/or mechanistic causes of mortality require further 
characterisation.   
 
 
Critique 
 
The cross sectional nature of the data is a particular limitation; it is not possible to examine 
the temporal effects of inflammation on the development of these manifestations. 
Furthermore, the development of clinically apparent comorbidities cannot be assessed at 
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this stage, however follow-up data from our subjects will help in addressing this question in 
future as longitudinal data collection for self-reported outcomes and mortality is ongoing at 
the time of writing this thesis. The lack of healthy control subjects is a further limitation of 
our study. Since COPD is considered by many to be a disease of accelerated ageing (239, 
240), comparison with a healthy cohort may show similar features albeit with the healthy 
controls being older on average than COPD subjects.  No current large cohort studies have 
been designed specifically to primarily investigate the cardiovascular and skeletal muscle 
manifestations in COPD, nor has fibrinogen been examined prospectively in relation to these 
extra pulmonary manifestations previously. Although we failed to recruit our planned total 
of 800 subjects, we had fewer dropouts or incomplete data sets than expected and thus did 
meet our planned sample size requirement. 
 
Non-homogeneity of sites in terms of subject characteristics is a further limitation, therefore 
we corrected for study site in the regression analysis. We also harmonised data collection 
prior to subject recruitment to avoid variation in the conduction of assessments across 
multiple sites (241).  Our cohort may better represent the general population of individuals 
with COPD, as unlike most published studies, the inclusion criteria for ERICA permitted 
participation of subjects with known comorbidities, was multicentre and not limited to a 
particular demographic (e.g. those referred for rehabilitation).  Nevertheless given the 
participating institutions, our findings are likely to be most generalizable to secondary care. 
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The composition of different groups is very different in terms of gender therefore results 
have to be interpreted with a degree of caution; the differences in height, weight and BMI 
at least appear to be in part related to the gender composition of the different groups. We 
attempt to overcome this by using gender-specific equations to determine skeletal muscle 
weakness, however gender is not known to be a determinant for arterial stiffness. It is 
encouraging to note that the overall demographics of the group in terms of age, gender and 
FEV1 are very similar to other observational cohorts, and we have studied a range of COPD 
patients, from moderate to very severe COPD.  
 
PWV and QMVC are respectively objective measures of cardiovascular risk and the risk of 
sarcopaenia or physical frailty (22, 87, 141).  As such these measures constitute both a 
strength and weakness of the current study.  Their strength is that they provide a 
continuous variable as an output, are not subject to recall bias and detect disease which 
may yet be clinically undeclared.  Their weakness follows from this property; specifically a 
patient may never experience a clinical event despite being at risk of it.  For the assessment 
of inflammation we used only use readily available clinical measures of systemic 
inflammation, but these may fail to reflect other inflammatory pathways or what is 
occurring at the tissue level. Using arbitrary cut-offs to determine co-morbidity is a further 
methodological limitation, especially when there are no healthy groups for comparison, 
however this was necessary to examine overlap of co-morbidities. For this reason, a cox 
regression model was not attempted when examining associations with QMVC and PWV, in 
order to treat them as continuous variables. A cluster analysis could be a useful alternative 
to examine distribution of phenotypes. The cut-off values for both QMVC and PWV have 
been established elsewhere in literature (22, 94), but only the reference value for QMVC has 
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been examined in COPD. PWV is a powerful, independent predictor of cardiovascular risk in 
the healthy population but there is no longitudinal data in COPD populations to assess 
whether PWV predicts cardiovascular events in COPD subjects. Cardiovascular manifestation 
is determined by a raw value of PWV, which is known to be affected by age and therefore a 
value of 10 m/s for a younger individual is more likely to represent a pathological process 
than for an older subject, and could explain the older demographic of subjects with the 
cardiovascular manifestation.  
 
Examining other cardiovascular parameters such as carotid intima media thickness (CIMT) 
will be important to see whether the outcomes are the same as when PWV is used. 
Similarly, muscle dysfunction is more than weakness alone, and represents reduced 
endurance too, which QMVC does not capture.   
 
Although we have the benefit of a well characterised cohort, the presence of comorbidities 
such as diabetes and pre-existing cardio- or cerebrovascular disease is mainly confirmed via 
patient recall and questionnaires as well as medication history; there may therefore be 
omissions and severity or control of these comorbidities is harder to account for. 
Additionally, the presence of concurrent inflammatory conditions is mainly determined via 
medication history, and patient recall could impact the accuracy of excluding subjects with 
active inflammatory conditions. 
 
 
Implications and future work 
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This body of work would suggest that firstly, cardiovascular and muscular manifestations are 
both important in COPD yet need to be managed individually and that secondly, benefits 
from anti-inflammatory therapy for skeletal muscle and cardiovascular manifestations are 
doubtful. Fibrinogen should not be used as an enrichment biomarker in trials addressing 
skeletal muscle or cardiovascular manifestations. 
 
Future work will focus on the predictive power of PWV, QMVC and fibrinogen on mortality 
and readmission in this cohort, as well as examination of other cardiovascular measures, 
and assessing which of these measures is most relevant to COPD. 
 
 
Conclusions 
 
We prospectively examined fibrinogen as a predictor of cardiovascular and skeletal muscle 
manifestations in COPD, and the findings suggest that fibrinogen is not a suitable biomarker 
for predicting the presence of these comorbidities.  
 
Our data support the existence of distinct cardiovascular and muscle manifestations in 
COPD, but not the existence of a separate phenotype that combines these, consequently 
these manifestations need to be addressed individually, and inflammation cannot be 
thought of as a shared risk factor. A greater prevalence of skeletal muscle weakness was 
found in this cohort than that previously found amongst COPD patients, and this coupled 
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with the significantly worse exercise parameters in patients exhibiting weakness than those 
exhibiting cardiovascular risk alone would suggest that skeletal muscle weakness should be 
a key focus for future design of therapeutics. 
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Chapter 4 
4.  SnIP and fibrinogen in COPD 
 
  
126 
 
4.1 Background 
 
As shown in the previous chapter COPD patients have evidence of an increased 
fibrinogen suggesting the presence of inflammation.  In principle an anti-
inflammatory agent might, by reducing airway inflammation improve expiratory flow 
and thus reduce hyperinflation (59, 60).  Static hyperinflation is conventionally 
assessed by whole body plethysmography. However this approach has 
disadvantages, partly because the equipment is expensive and therefore scarce but, 
in addition, can be poorly tolerated due to its claustrophobic nature.  Perhaps for 
these reasons, experience in multicentre studies suggests that quality control may be 
hard to achieve outside specialist centres.  
 
The ‘gold standard’ for measurement of respiratory muscle strength has been 
considered the oesophageal or transdiaphragmatic  pressure elicited by a maximal 
voluntary manoeuvre or in response to bilateral stimulation of the phrenic nerves 
(242).  However the passage of oesophageal and gastric balloon catheters is not 
appealing to some patients and may be impossible in those with swallowing 
difficulties.  Inspiratory muscle strength can also be measured non-invasively as 
maximal inspiratory pressure (MIP) but this manoeuvre may be technically difficult 
and can often underestimate respiratory muscle strength through poor subject 
motivation and cooperation with technique (243, 244). In this context, the maximal 
sniff nasal inspiratory pressure (SnIP) is potentially a valuable alternative measure of 
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inspiratory muscle strength (245), since the sniff is a measure which patients are 
intuitively familiar with. 
 
Whilst SnIP is a measure of global inspiratory muscle strength in healthy subjects and 
in patients with neurological disease, in whom it is closely associated with 
hypercapnia (246), in COPD, it has been considered to principally reflect 
hyperinflation, which is the principal cause of reduced diaphragm strength in COPD; 
specifically hyperinflation changes the orientation of the diaphragm so that a smaller 
proportion of the overall contraction is translated to reducing intrathoracic pressure 
(247, 248). Treatments such as lung volume reduction (249, 250)  that reduce 
hyperinflation or methods that reduce ventilatory load (251) can improve both 
twitch transdiaphragmatic pressure, through changing the oesophageal component, 
and SnIP (248).  
 
Thus, in COPD, SNIP values likely reflect both hyperinflation and overall cachexia.  
Intriguingly recent work by our group in a single centre demonstrated that SnIP is a 
better predictor of mortality in COPD than the traditional measures of hyperinflation 
such as the IC/TLC ratio (155), and SnIP additionally relates to the BODE index, with 
values less than 63 cmH2O predictive of a higher BODE index score (252). BODE index 
is additionally known to relate to IC/TLC ratio (253), further supporting the concept 
that SnIP may relate to BODE.  
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SnIP is therefore a potentially attractive biomarker, being non-invasive, predictive of 
mortality and robust in its measurements which might capture in an integrative 
fashion both hyperinflation and possibly cachexia. When considering that 
hyperinflation is the only lung function parameter that improved with administration 
of an anti-inflammatory MAPK inhibitor, Losmapimod, in COPD (59, 60), the 
evaluation of SnIP as a biomarker becomes more important. Losmapimod was shown 
to lower plasma fibrinogen by 11% in trial subjects with COPD, but, to date, no 
studies have examined the relationship between SnIP and inflammation, as 
measured by fibrinogen.  
 
The primary objective is therefore to examine whether fibrinogen is associated with 
SnIP in COPD and the secondary objective is to explore whether there are other 
important clinical associations, such as fat free mass, FEV1 or exacerbation 
frequency, to inform the utility of SnIP as a potential biomarker in trials of COPD. 
 
4.2 Methods 
 
Subjects with a clinical diagnosis of COPD were recruited as part of study 1 (Fibre 
specific signalling study) at the Royal Brompton Hospital, London. Select data from 
COPD subjects participating in study 1 contributed data to the overall ERICA cohort. 
All subjects provided written informed consent. Subjects had to be aged 40 – 90 
years, with a clinical diagnosis of COPD (confirmed via smoking history of at least 10 
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pack years and post-bronchodilator spirometry (FEV1 of <80% predicted and 
FEV1/FVC of <0.7)), and assessments were carried out on subjects who had been 
clinically stable for at least 4 weeks. Exclusion criteria were significant respiratory 
disease other than COPD, exercise limiting neuromuscular disease or an inability to 
provide written consent. 20 healthy age matched subjects without respiratory, 
inflammatory or significant neuromuscular disease were recruited into study 1 as 
controls. 
 
Assessments were carried out over two visits, with a minimum interval of 1 week 
between visits, following which subjects were followed up via 6-monthly 
questionnaires for 2 years. Post-bronchodilator spirometry, 6 minute walk, SPPB, 
QMVC, health related quality of life questionnaires  were carried out during the first 
visit, with the second, fasting visit being used to carry out venepuncture and SnIP. 
The subset of COPD and healthy subjects recruited into study 1 additionally 
underwent full lung function tests and arterial blood gas measurements. 
 
Data was assessed for normality using histograms and Shapiro-Wilks test. 
Differences between COPD and control subjects were tested using unpaired t-test 
and Mann-Whitney test for normally and non-normally distributed data respectively. 
Simple, univariable regression was carried out to assess correlation between 
independent variables and SnIP. Variables of interest or ones that showed a 
significant relationship were included subsequently in a multiple regression model. 
Where there was evidence of co-linearity between independent variables, only the 
variable with the strongest association was included in the model at one time. 
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Validity of the model was examined by looking at goodness of fit and distribution of 
residuals. Significance was accepted as a p-value of <0.05. Statistical analyses were 
carried out using Statview v.5.0.1 and GraphPad Prism v5.0. 
 
4.3 Results 
 
Overall 729 COPD and 20 healthy subjects were recruited. Of the COPD subjects, 32 
did not have SnIP values, and 10 subjects had evidence of active infection 
(simultaneously raised WCC, CRP and fibrinogen) leaving 687 COPD subjects in the 
final analysis. Of the 729 COPD subjects, 61 were from study 1, with 4 subjects 
having simultaneously raised inflammatory markers, leaving 57 subjects with COPD 
to be examined from study 1.  
 
Data for SnIP values had a right-skewed distribution, as shown in Figure 4.1. 
 
 
Figure 4.1 Histogram demonstrating right-skewed distribution of SnIP values in overall 
ERICA cohort (n=687) 
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Baseline demographics for control and COPD subjects (from the overall cohort and 
the study 1 subset) are described in Table 4.1.  Control and COPD groups did not 
differ significantly in terms of age, gender of BMI but the COPD group naturally 
contained a greater proportion of current and ex-smokers than control subjects. 
BODE score was as expected higher in COPD subjects than controls, and FFM, SnIP, 
spirometry and muscle performance indicators such as 6MW distance, SPPB score 
and QMVC were lower in COPD subjects as expected. COPD subjects also showed 
significantly more inflammation than the controls in terms of hsCRP, WCC and 
fibrinogen. Health related quality of life scores were correspondingly worse in the 
COPD subjects as compared to controls, with significantly higher CAT scores and 
MRC dyspnoea scores from COPD subjects.  
 
Despite subjects from study 1 appearing frailer than the overall cohort in terms of 
having a higher BODE index, lower FFMI, lower BMI and lower mean FEV1 (43.2% 
predicted vs. 52.3 % in the overall cohort), the two groups had identical mean SnIP 
values of 54.9 cmH2O, and surprisingly subjects from study 1 had better muscle 
performance indicators, demonstrating QMVC expressed as % predicted (73.0% vs. 
69.3%; p=0.05) and SPPB score (11 vs. 10; p=0.0006 ) and better exercise 
performance with a higher mean 6MW distance (404m vs. 349m; p=0.002).  
 
Univariable regression analysis revealed a trend to association with fibrinogen 
(p=0.09).   The following independent variables had a significant correlation with 
SnIP: age, gender, height, FFM, FFMI, BMI, FEV1, FVC, FEV1/FVC, QMVC, SPPB, BODE 
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score, CAT score, MRC dyspnoea. However smoking status, logCRP, WCC, 
exacerbation frequency and self-reported alcohol consumption had no relationship 
with SnIP. Independent variables without co-linearity and with the strongest 
associations with SnIP were tested in multiple regression models with SnIP as the 
dependent variable, and these variables are highlighted in bold in Figure 4.2.  
133 
 
 Control (n=20)  Overall COPD 
(n=687) 
P-value Study 1 COPD 
subjects (n=55) 
P-value 
Demographics    
Age (years) 65 (9)  67 (8) 0.16 66 (8) 0.58 
Gender (%male) 65  61 0.69 70 0.67 
Smoking status 
-Current smokers 
-Ex-smokers 
-Never smokers 
 
20% 
25% 
55% 
  
30% 
70% 
- 
 
- 
- 
- 
 
14% 
86% 
- 
 
- 
- 
- 
Smoking pack years 12 (15)  47 (27) <0.0001 46 (33) <0.0001 
BODE score 0 (0,0)  3 (1,5) <0.0001 4 (1,6) <0.0001 
Exacerbations/ year NA  2.22 (2.2) - 1.95 (2.2) - 
Anthropometrics    
Height (cm)  169 (9.0)  167(9.4) 0.32 169 (7.6) 0.99 
Weight (kg) 74.3 (67.7)  76.3 (18.2) 0.98 70.4 (15.6) 0.14 
Fat free mass (kg) 54.8 (47.6)  45.8 (9.1) <0.0001 45.4 (7.2) <0.0001 
BMI (kg/m
2
) 26.0 (5.0)  27.2 (5.7) 0.44 24.7 (5.3) 0.29 
FFMI (kg/m
2
) 18.5 (18.0)  16.3 (2.3) <0.0001 15.5 (2.9) <0.0001 
Lung function measures    
FEV1 (L) 2.98 (0.71)  1.34 (0.53) <0.0001 1.16 (0.54) <0.0001 
FEV1 %predicted 109 (13.0)  52.3 (16.1) <0.0001 43.2 (19.5) <0.0001 
FVC (L) 4.07 (0.85)  2.80 (0.88) <0.0001 3.23 (0.71) <0.0001 
FEV1/FVC 0.73 (0.04)  0.48 (0.12) <0.0001 0.36 (0.15) <0.0001 
TLC (L) 6.25 (1.50)  - - 7.56 (1.53) <0.0001 
TLC (%) 107 (13.5)  - - 124 (20.7) <0.0001 
RV (%) 101 (17.3)  - - 185 (60.4) <0.0001 
RV/TLC (%) 37.1 (6.27)  - - 55.3 (10.2) <0.0001 
FRC 3.56 (0.77)  - - 5.22 (1.55) <0.0001 
FRC (%) 108 (17.5)  - - 164 (43.8) <0.0001 
TLCO (%) 89.7 (20.6)  - - 48.2 (22.1) <0.0001 
Inflammatory markers    
Fibrinogen (g/L) 3.2 (0.65)  3.47 (0.85) 0.06 3.51 (0.73) 0.05 
WCC (x10
9
/L) 6.3 (1.4)  7.4 (2.0) 0.001 7.4 (2.2) 0.05 
hsCRP (g/L) 4.5 (6.3)  5.7 (7.0) 0.02 6.0 (5.4) 0.02 
Muscle markers    
SnIP (cm H20) 68.3 (22.0)  54.9 (22.7) 0.01 54.9 (21.6) 0.01 
QMVC (kg) 38.3 (11.7)  30.5 (11.5) 0.005 31.4 (8.6) 0.03 
QMVC %pred 79.8 (17.3)  69.1 (30.6) 0.01 73.0 (17.4) 0.14 
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6 MWD (m) 585 (92)  346 (130) <0.0001 404 (126) <0.0001 
SPPB (of 12) 12 (12,12)  10 (8,12) <0.0001 11 (10,12) 0.003 
Health related quality of life    
MRC score (1-5) 1 (1,1)  3 (2,4) <0.0001 3 (2,4) <0.0001 
CAT score  5.1 (4.9)  19.8 (8.3) <0.0001 18.3 (7.5) <0.0001 
Table 4.1 Baseline demographics of control and COPD subjects from ERICA and Study 1. 
Comparison was made between age-matched control subjects (n=20) and COPD subjects in 
the overall ERICA cohort (n=684) and in study 1 (n=55). 
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 Std. coefficient Std. error P value 
Age -0.12 0.10 0.002 
Gender -0.27 1.71 <0.0001 
Height 0.36 0.09 <0.0001 
FFM 0.31 0.09 <0.0001 
FFMI 0.15 0.38 <0.0001 
Weight 0.18 0.05 <0.0001 
QMVC 0.40 0.07 <0.0001 
QMVC %pred 0.26 0.03 <0.0001 
SPPB 0.32 0.35 <0.0001 
logCRP -0.03 0.65 0.52 
WCC -0.02 0.44 0.69 
Fibrinogen -0.07 1.00 0.09 
FEV1 0.39 1.53 <0.0001 
FVC 0.41 0.91 <0.0001 
FEV1 % 0.19 0.05 <0.0001 
FEV1/FVC 0.06 6.94 0.17 
Oxygen sats -0.01 0.41 0.72 
Smoking status -0.06 1.88 0.14 
Alcohol 0.06 0.07 0.13 
BODE -0.24 0.37 <0.0001 
Exacerbations -0.04 0.43 0.38 
CAT score -0.19 0.10 <0.0001 
MRC -0.23 0.76 <0.0001 
 
Figure 4.2 Univariable regression of independent variables versus SnIP in COPD subjects 
(n=687) 
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FVC, FFM and age had the strongest associaions with SnIP respectively, with a model R2 
value of 0.198 (Table 4.2). Neither height nor gender were associated with SnIP, nor were 
they when FVC was substituted with FEV1 (Table 4.3), which had a weaker association with 
SnIP than FVC, with a model  R2 value of 0.179. Fibrinogen was not independently associated 
with SnIP in multiple regression analysis (Table 4.4), whereas QMVC is associated with SnIP 
independently of gender and FFM (Table 4.5).  
 
 
Table 4.2 Strongest associations with SnIP (model R2 = 0.198) 
 
 
Table 4.3 FEV1 and SnIP (R
2 = 0.179) 
 
 
Table 4.4 Fibrinogen and SnIP 
 
 
Table 4.5 QMVC and SnIP 
25.026 9.731 25.026 2.572 .0103
1.470 2.294 .032 .641 .5218
-.224 .103 -.080 -2.174 .0301
.437 .112 .179 3.900 .0001
8.614 1.157 .340 7.445 <.0001
Coefficient Std. Error Std. Coeff. t-Value P-Value
Intercept
Sex
Age
Steiner FFM
FVC
Regression Coefficients
SnIP vs. 4 Independents
43.576 9.036 43.576 4.823 <.0001
-3.678 2.116 -.081 -1.739 .0826
-.270 .104 -.096 -2.601 .0095
.333 .119 .136 2.805 .0052
11.402 1.818 .269 6.272 <.0001
Coefficient Std. Error Std. Coeff. t-Value P-Value
Intercept
Sex
Age
Steiner FFM
FEV1
Regression Coefficients
SnIP vs. 4 Independents
46.221 9.886 46.221 4.675 <.0001
-3.841 2.127 -.084 -1.806 .0714
-.268 .104 -.096 -2.568 .0104
.329 .119 .134 2.754 .0061
11.254 1.828 .266 6.157 <.0001
-.670 .942 -.026 -.711 .4773
Coefficient Std. Error Std. Coeff. t-Value P-Value
Intercept
Sex
Age
Steiner FFM
FEV1
Fibrinogen
Regression Coefficients
SnIP vs. 5 Independents
35.182 9.302 35.182 3.782 .0002
-.937 2.211 -.021 -.424 .6717
-.190 .106 -.068 -1.795 .0731
.146 .126 .059 1.161 .2460
9.794 1.874 .231 5.226 <.0001
.418 .093 .215 4.495 <.0001
Coefficient Std. Error Std. Coeff. t-Value P-Value
Intercept
Sex
Age
Steiner FFM
FEV1
QMVC
Regression Coefficients
SnIP vs. 5 Independents
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In sub-analysis of subjects from study 1, univariable regression was used to 
determine which lung function indices correlated best with SnIP in COPD and control 
subjects (Table 4.6).  RV/TLC ratio was the best predictor of SnIP in COPD but not in 
controls, followed closely by FEV1 in COPD subjects as well as healthy subjects. Age 
and FFM remain correlated with SnIP in COPD subjects from this smaller cohort, but 
not gender, CAT score and MRC dyspnoea score. In the healthy controls, age was not 
a significant predictor but gender and FFM were. Both COPD and control subjects 
show a significant relationship between QMVC and SnIP. Age and FEV1 or age and 
RV/TLC ratio, but not FFM, remain significant predictors of SnIP in multiple 
regression models as seen in tables 4.7 and 4.8. 
 COPD (n=55)  Control (n = 20) 
 Coefficient Std. error P  Coefficient Std. error p 
        
Age -0.29 0.34 0.03  -0.37 0.55 0.10 
Gender 0.03 6.61 0.82  -0.44 9.60 0.05 
FFM 0.26 0.41 0.05  0.53 0.40 0.02 
BMI 0.38 0.52 0.004  0.28 1.00 0.23 
FFMI 0.27 1.43 0.05  0.47 1.83 0.04 
FEV1 0.51 4.71 <0.0001  0.46 6.43 0.04 
FVC 0.31 4.12 0.02  0.46 5.5 0.04 
FEV1/FVC 0.40 18.32 0.002  0.21 101 0.39 
TLC -0.24 1.91 0.07  0.36 3.20 0.12 
RV -0.33 0.05 0.02  0.14 0.30 0.57 
RV/TLC -0.56 0.24 <0.0001  0.02 0.83 0.92 
TLCO (%) 0.38 0.13 0.005  0.28 0.24 0.24 
FRC  -0.23 1.88 0.10  -0.21 -0.29 0.38 
PaO2 0.29 2.04 0.03  0.41 5.0 0.07 
VO2/kg 0.27 0.67 0.06  -0.18 0.84 0.47 
Fibrinogen 0.002 4.0 0.99  0.27 7.60 0.25 
CAT -0.11 0.41 0.41  0.15 1.10 0.54 
MRC -0.24 2.39 0.08  0.12 14.0 0.62 
QMVC 0.34 0.34 0.01  0.45 0.39 0.04 
 
Table 4.6 Correlation between lung function indices and demographics versus SnIP in COPD 
and control subjects from study 1 
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Table 4.7. Multiple regression in COPD subjects from study 1 (n=55); FEV1 as an independent 
predictor, r-squared 0.629 
 
  
Table 4.8. Multiple regression in COPD subjects from study 1(n=55); RV/TLC as an 
independent predictor, r-squared 0.622 
 
Correlation of SnIP with FEV1, RV/TLC and FRC is demonstrated below in Figure 4.3:   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Correlation between SnIP and FEV1, FRC and RV/TLV in COPD subjects from study 1 (n=55) 
79.052 23.108 79.052 3.421 .0013
-.855 .291 -.330 -2.940 .0050
.181 .383 .060 .472 .6388
21.446 4.985 .540 4.302 <.0001
Coefficient Std. Error Std. Coeff. t-Value P-Value
Intercept
Age (years)
Steiner FFM
FEV1 (L)
Regression Coefficients
SNIP vs. 3 Independents
136.167 29.110 136.167 4.678 <.0001
-.639 .300 -.246 -2.128 .0385
.422 .378 .137 1.116 .2701
-1.051 .257 -.498 -4.089 .0002
Coefficient Std. Error Std. Coeff. t-Value P-Value
Intercept
Age (years)
Steiner FFM
RV/ TLC
Regression Coefficients
SNIP vs. 3 Independents
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Given that FEV1 is a predictor of SnIP, the distribution of SnIP values across GOLD stage was 
examined in Figure 4.4. As expected, the both the range as well as median and mean SnIP 
values fell with increasing airflow obstruction. 
 
 
Figure 4.4 Distribution of SnIP values across GOLD stages in overall ERICA cohort (n=687) 
  
 GOLD II 
(n=392) 
GOLD III 
(n= 231) 
GOLD IV 
(n=64) 
Minimum 8.0 9.0 8.0 
25% Percentile 39.0 38.0 33.0 
Median 55.0 51.0 42.0 
75% Percentile 76.0 67.0 59.0 
Maximum 157.0 118.0 84.0 
Mean 57.8 53.0 45.3 
Std. Deviation 24.3 20.4 17.4 
Std. Error 1.2 1.3 2.2 
Lower 95% CI of mean 55.4 50.3 40.9 
Upper 95% CI of mean 60.2 55.6 49.6 
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4.4 Discussion 
 
Our primary hypothesis, that inflammation, whether measured as fibrinogen, WCC 
or CRP, is associated with SNIP was rejected since these parameters were not 
associated with SnIP in multivariate analysis.  However SnIP did correlate with 
parameters that one might predict to be relevant, such as FEV1.  Novel associations 
confirmed by this study were those with indices of whole body cachexia such as 
reduced fat free mass and QMVC.  Consistent with the known prognostic 
implications of those measures, we also observed associations between SNIP and 
other important prognostic measures such as BODE score, CAT score and MRC 
dyspnoea score, suggesting SNIP could be a potentially useful future biomarker 
particularly for interventions aimed at cachexia, sarcopenia or hyperinflation.  
 
That inflammatory markers do not appear to relate to SnIP is perhaps surprising 
given that an anti-inflammatory agent (Losmapimod) reduced both fibrinogen and 
hyperinflation (59, 60). Hyperinflation does appear to relate to inflammation, with 
systemic inflammation being dampened following lung volume reduction surgery 
(254), however since SnIP reflects both diaphragm weakness and hyperinflation, the 
most likely explanation, which is also consistent with the data, is that any 
relationship SnIP has with inflammatory markers is dwarfed by the relationship with 
hyperinflation. 
 
The main previously reported determinants of SnIP have been age, gender and the 
RV/TLC ratio in COPD subjects; other measures of lung function such as FEV1 
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surprisingly do not appear to be determinants from previous studies (146, 255).  
Uldry et al argued that this was because SnIP reflected inspiratory muscle strength as 
opposed to FEV1 or FVC, which are measure airflow obstruction.  Our findings show 
that FEV1 and FVC are in fact the strongest predictors of SnIP in COPD, followed by 
FFM and age, making it more likely (consistent with the data obtained in normal 
subjects by Wanke et al) that hyperinflation has a curvilinear rather than linear 
relationship with inspiratory muscle strength (256). Measurement of SnIP does have 
drawbacks, since it moderately underestimates oesophageal pressure, and therefore 
moderately underestimates respiratory muscle strength in COPD subjects (146), 
particularly if there is severe airway disease which prevents rapid equilibration of 
pressure within the airways.  
 
Surprisingly, gender is not independently associated with SnIP when these factors 
are accounted for, in contrast to previous studies that have examined healthy 
individuals, suggesting that, in COPD, measures that relate to muscle mass or 
integrity in an individual override traditionally important predictors such as gender. 
It is therefore unsurprising that measures of muscle performance such as QMVC, 
6MWT and SPPB relate well to SnIP.  
 
The correlation between QMVC and SnIP would lend support to skeletal muscle 
wasting in COPD being a generalised process at least in some patients with COPD, 
and furthermore that FFM is an important determinant of muscle strength, 
contradicting earlier very small scale work by Hamnegard et al  which suggested that 
142 
 
undernutrition does not impact diaphragm weakness (152). This study compared 10 
subjects with low BMI (<17) to subjects with high BMI (27) and found no difference 
in either voluntary SnIP or twitch Pdi between groups; however subjects in the 
higher BMI group were almost 10 years older on average and hampering the 
acquisition of accurate magnetic stimulation and twitch values. The study also used 
BMI as a stratifying tool; analysis of subjects from study 1 shows that whilst BMI is 
not different between COPD subjects and controls, FFM is significantly depleted in 
COPD patients and would therefore have been a better tool to use. 
 
Exacerbation frequency did not appear to impact SnIP. Since we calculated 
exacerbation frequency through use of steroids, this also would support earlier 
findings that oral steroid use does not impact inspiratory muscle strength (154). 
 
The large numbers in the ERICA cohort allow for observation of correlations that may 
not be apparent in smaller studies; for example, CAT score and MRC dyspnoea score 
are significantly albeit weakly correlated with SnIP in the larger cohort but not in the 
subset of COPD patients from study 1. This could in part explain why previous studies 
have failed to observe a correlation between FEV1 and SnIP, since most of them have 
been carried out in much smaller numbers. Conversely, there is the possibility of a 
type I error in that the ERICA study is overpowered to detect differences.  A further 
reason for the failure to observe these correlations in smaller studies could be due to 
multiple lung function testing in the same visit, whereas these tests were carried out 
on different days in study 1. Since FEV1 and SnIP are both volitional measures, poor 
subject motivation could be a confounding factor, although inspiratory muscles 
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appear surprisingly resistant to fatigue in COPD, and even in measurement of SnIP is 
patients with acute asthma (247).  
 
 
Mean SnIP values in our study are lower at 55 cmH2O amongst COPD patients than 
prior studies, which typically report values of >60 cmH2O in COPD, and are lower 
than the threshold of 60 or 70 cmH2O used to determine diaphragm weakness in 
healthy female or male individuals respectively. Given the influence of 
hyperinflation, new reference ranges in COPD need to be determined for what 
constitutes diaphragm weakness. The main ERICA cohort is limited by lack of 
plethysmographically determined lung volume data, but there appears to be a 
different spread of data according to GOLD stages, with even GOLD II stage subjects 
showing a mean SnIP of 57 cm H2O. 
  
Critique 
 
SnIP has been demonstrated to be repeatable within a 3 week period, although 
Nikoletou et al  did not test repeatability beyond that period (257). In order to 
eliminate learning effect, they recommended a minimum of 10 manoeuvres 
performed on at least 2 separate occasions, however subjects performed a number 
of respiratory tests at each study session however, raising the question of 
motivational failure prior to SnIP measurements. Inspiratory muscles have been 
shown to be surprisingly resistant to fatigue following exercise in both moderate 
(258) and severe COPD (259) however, these studies did not measure whether SnIP 
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is affected by fatigue. Repetitive measurement of SnIP in patients presenting with 
acute asthma demonstrates non-fatiguability however, with intraclass correlation of 
0.88 in 15 subsequent SnIP measurements in asthmatics, compared with 0.86 for 
control subjects (260).   In our study, the best SnIP measurement out of 10 efforts 
was recorded, as per previous guidance, however since 2 sessions are required to 
eliminate the learning effect, perhaps the maximal SnIP may not have been always 
recorded in this study. Additionally, the cross-sectional nature of the study means 
that the evolution of SnIP over time has not been recorded.  
 
The cross-sectional nature of the study additionally means that causality cannot be 
inferred. 
 
Multiple regression was not carried out in the study 1 control subjects since the 
number of control subjects was too small. Furthermore, unbiased tests such as 
factor or hierarchical cluster analysis could have been an alternative way of 
examining associations with SnIP, but since this was a highly exploratory analysis, 
modelling through multiple regression was deemed the best method as this does not 
predefine numbers of clusters or nature of clustering. 
 
When comparing demographics for study 1 COPD subjects with the overall ERICA 
cohort, it is interesting to note that subjects recruited into study 1 at the Brompton 
have similar SnIP values and better muscle performance indicators on average, 
despite having lower FFMI and worse spirometry. Such differences could highlight 
recruitment centre bias, since the Brompton is a tertiary centre, and recruits are 
145 
 
from relatively more educated, affluent backgrounds with better access to 
pulmonary rehabilitation than centres such as Cardiff, where half of the ERICA 
patients were recruited. This bias may partially explain the lower mean SnIP value of 
5 5cmH2O in the ERICA cohort, compared with previous studies on SnIP which have 
mostly been conducted in tertiary centres, with average SnIP values of >60 cmH2O 
for COPD subjects. 
 
Finally, the fact that the ERICA cohort is large allows us to observe associations that 
may not be apparent in smaller studies, but at the same time introduces the risk of a 
type I error. This could be a possible explanation for the weak associations found 
between variables such as FEV1 and SnIP. Even in the absence of a type I error, the 
weak associations between SnIP and markers of disease severity may limit its use as 
biomarker. The multi-centre nature of the trial also potentially introduces variability 
in measurement techniques, although training at each centre was undertaken to 
harmonize data collection before subject recruitment began. The multi-centre 
nature of the trial may give a better representation of the COPD population as a 
whole, however since we have mostly recruited subjects from secondary or tertiary 
care centres, mild COPD subjects are not represented here.  
 
Implications and Future work 
 
This is the largest study of SnIP to date in COPD, and shows that SnIP does not relate 
to inflammation, at least through cross-sectional work, but that it does relate to 
measures of muscle mass and strength, as well as FEV1 and FVC. Whilst it is perhaps 
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unsurprising that SnIP relates to indices of disease severity and body composition, 
the ERICA study is the first large study to confirm these observations. 
 
Future work on SnIP needs to focus on its use as a biomarker, and further work is 
required on three counts; firstly, repeatability of SnIP measurements over a period 
of at least 3 to 4 months, equivalent to the length of most interventional trials, is 
required. Secondly, it would be useful to see whether SnIP predicts other outcome 
measures in COPD such as exacerbations and hospital admission. Additionally, the 
responsiveness of SnIP to interventions needs further characterization in terms of 
values that change consistently and significantly. 
 
 
Conclusions 
 
SnIP is potentially a useful, quick, non-invasive integrative measure of respiratory 
muscle strength and hyper-inflation. Its correlation with measures such as BODE 
index, FEV1 and CAT score suggests that it could be a useful future biomarker in 
interventional studies, but further work is required to qualify it as a biomarker. 
Markers of inflammation, specifically fibrinogen, WCC and hsCRP, do not appear to 
relate to SnIP, however a causal relationship cannot be conclusively ruled out on the 
basis of this cross-sectional study. 
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Chapter 5 
5. Effects of p38 MAPK inhibition on skeletal muscle and cardiovascular 
function 
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5.1  Background 
 
The mitogen-activated protein kinase (MAPK) family consists of three stress-
activated protein kinase pathways: p38, c-Jun N-terminal kinase (JNK) and 
extracellular regulating kinase (ERK); these pathways are activated in response to a 
range of stressors, including inflammation, oxidative stress and pathogens. The p38 
MAPK family has been of particular interest in COPD, being implicated in the 
inflammatory response to cigarette smoking and oxidative stress. Four isoforms of 
p38 MAPK exist, and in inflammatory cells, p38α is the most abundant of these 
isoforms and therefore the most studied. 
 
In animal models, inhibition of p38 α in mice exposed to tobacco smoke resulted in a 
significant reduction in small airway macrophages (187). Inhibition of p38 MAPK 
signalling appeared to attenuate the progression of COPD in animal models (184). 
Animal models in COPD are far from satisfactory however, since they focus 
predominantly on emphysema, and not the small airways disease in COPD. Patients 
with COPD can additionally have multiple comorbidities, especially cardiovascular or 
muscle disease. Given the heterogeneity seen amongst COPD patients, animal 
models may be unable to reliably predict the effects of broad anti-inflammatory 
therapy such as p38 MAPK inhibitors.   
 
Human trials of p38 MAPK inhibitors were first carried out in patients with 
rheumatoid arthritis, where high doses resulted in side effects such hepatotoxicity, 
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which were unacceptable. Furthermore, p38 MAPK inhibition resulted in an initial 
improvement in inflammatory biomarkers, but this effect appeared to be transient, 
disappearing after a period of six weeks (261). This could be due to the complex 
nature of inflammation, where blocking of one pathway can cause diversion to 
another pathway, so that “redundant” MAP kinases such ERK and c-Jun instead 
become active. Since the nature of inflammation in rheumatoid arthritis and COPD is 
different, it is hoped that p38 MAPK inhibition does not cause similar activation of 
redundant pathways in COPD, and this is borne out in human phase II trials in COPD, 
which have shown a consistent reduction in inflammatory markers at 3 months, with 
a mean reduction in fibrinogen of 11% (59). 
 
Losmapimod is a selective, competitive inhibitor of p38 MAPK α/β under 
development by GlaxoSmithKline. Despite demonstrating an improvement in 
inflammatory biomarkers, phase II trials of the oral MAPK inhibitor Losmapimod 
have not resulted in an improvement in FEV1 in COPD patients but nevertheless did 
reduce hyperinflation in subjects receiving MAPK inhibitor therapy (59, 60). SnIP is a 
surrogate marker for hyperinflation in COPD as well as being a measure of 
inspiratory muscle strength and has the advantage of being quick, painless and easy 
to perform when compared to plethysmographic measurement of lung volumes.  
SNIP therefore should be more acceptable to patients and can be performed without 
the need for highly trained lung function technicians.  SnIP is therefore potentially an 
attractive biomarker, but no studies have examined the responsiveness of SnIP to 
anti-inflammatory therapy, therefore we also wished to evaluate the effect of MAPK 
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inhibition on hyperinflation via SnIP measurements in COPD subjects. Furthermore, 
an increase in p38 MAPK signalling in the quadriceps of COPD patients was 
demonstrated by Lemire et al (262), thereby suggesting that MAPK inhibition could 
improve peripheral skeletal muscle function, although we were unable to reproduce 
this finding in our group (190). Therefore, we wished to evaluate the effect of MAPK 
inhibition on fat free mass and 6 minute walk distance in COPD subjects as measures 
of quadriceps function.  
 
P38 MAPK inhibition is also reported to improve cardiovascular inflammation in 
subjects with hypercholesterolaemia (191), as well as in the immediate aftermath of 
acute coronary events (263). Therefore, we also wanted to assess the effects of 
losmapimod on cardiovascular inflammation and function. 
 
Heterogeneity in COPD is likely to mean that one therapy is unlikely to benefit all 
patients with COPD, as is the case with existing anti-inflammatory therapies. For 
example, inhaled corticosteroids benefit COPD subjects with a history of frequent 
exacerbations or those with raised eosinophils (264, 265). Similarly, Roflumilast, a 
PDE-4 inhibitor, benefits patients with chronic bronchitis or frequent exacerbations 
(266). Therefore, it is likely that Losmapimod will only benefit a subset of COPD 
patients, and accordingly we designed stratified entry into the study to include 
subjects with a greater degree of inflammation, as measured by a high baseline level 
of fibrinogen (>2.8 g/L).  
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Study 2 (also known as the EVOLUTION trial) is a randomised, double-blinded, 
placebo control trial of losmapimod in COPD subjects with evidence of elevated 
fibrinogen. The primary endpoints for the EVOLUTION trial are changes in vascular 
inflammation as measured via arterial FDG-PET and endothelial function as 
measured by brachial flow mediated dilatation. For the purposes of this thesis, I will 
focus on whether MAPK inhibition improved cardiovascular and muscular 
parameters by examining select trial secondary endpoints, namely changes in aortic 
pulse wave velocity, SNIP and 6MWD, as well as safety endpoints in terms of 
spirometry, ECG changes, blood markers and adverse events. 
 
5.2  Methods 
 
Subjects with GOLD stage I to IV COPD were assessed for enrolment into study 2 at 
two UK centres (Royal Brompton Hospital, London and Addenbrookes Hospital, 
Cambridge). I was involved in writing the study protocol, as well as instructing sites 
on performing muscle and respiratory measures at the site initiation visits. 
Furthermore, I screened and recruited all subjects at the London site as well as 
performing screening, baseline and end of treatment assessments on all subjects at 
the London site. I oversaw the running of the trial at the London site, with research 
nurses and physiotherapists assisting in routine follow up visits for these subjects.  
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Subjects attended screening visit 1 to confirm eligibility, provide consent and to 
undergo post-bronchodilator spirometry, ECG, blood pressure measurement, 
physical examination, medical history, urine dipstick and fasting blood tests. Study 
entry and exclusion criteria are listed in the methods chapter, but for convenience 
are also described under table 5.1. The cut-off for fibrinogen was based on a 
population study by Dahl et al (61), where 2.7 – 3.3 g/L and >3.3 g/L formed the 
middle and upper tertiles of fibrinogen in a Danish population, and corresponded to 
increased risk of worse FEV1 and increased hospitalisation in smokers in comparison 
to a fibrinogen level of <2.7 g/L in non-smokers. 
Inclusion Criteria Exclusion criteria 
 Male/female aged 50-85 years of age 
inclusive at screening, weighing ≥ 45 kg 
& BMI ≤35 kg/m
2
. 
 A clinical diagnosis of COPD with GOLD 
Stages 1, 2, 3, or 4, or GOLD-U. 
 FEV1/FVC <0.7 post bronchodilator 
 Participant is a smoker or an ex-smoker 
with a smoking history of at least 10 
pack years (1 pack year = 20 cigarettes 
smoked per day for 1 year or 
equivalent). 
 Baseline plasma fibrinogen value of >2.8 
g/L (Klauss method). 
 ALT < 2xULN at screening; alkaline 
phosphatase and bilirubin  1.5xULN at 
screening (isolated bilirubin >1.5xULN is 
acceptable if bilirubin is fractionated and 
direct bilirubin <35%). 
 Subjects must have a QTc<450 msec on 
screening (V1) ECG (using average value 
of triplicate ECGs).  For patients with 
complete Right bundle branch block, the 
QTc must be <480msec on Screening V1 
ECG.  Patients with other ECG findings 
will be excluded if warranted at the 
discretion of the CI/PI.  QTc readings will 
be QTcF. 
 If participants consent to optional MRI, 
they must fulfil local imaging centre 
requirements. 
 Inability to provide Informed Consent. 
 A cardiovascular event in the last 6 
months  
 Patients on daunorubicin, doxorubicin, 
topotecan, mitoxantrone. 
 Previous lung reduction surgery. 
 Known clinically significant pulmonary 
diagnoses in which inflammation is 
thought to play a role including 
diagnosis of bronchiectasis, sarcoidosis, 
lung fibrosis, interstitial lung disease, or 
α1-antitrypsin deficiency. 
 Known hepatitis B or C 
 Active or chronic liver disease, or known 
hepatic or biliary abnormalities 
 Known chronic infections such as HIV or 
known active tuberculosis 
 Diagnosis of rheumatoid arthritis, 
connective tissue disorders and other 
conditions known to be associated with 
active chronic inflammation (e.g. 
Inflammatory Bowel Disease). 
 Insulin controlled Type 1 or Type 2 
diabetics 
 Diabetics on oral hypoglycaemics/diet 
with HbA1c (DCCT) > 8% (OR HbA1c 
(IFCC) > 64 mmol/mol), at screening. 
[note: fasting glucose to be checked 
again at first FDG-PET/CT scan, and if 
glucose > 11mmol/L at that visit, 
patients will be excluded from trial] 
 Participation in research trial in the last 
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3 years which involved exposure to 
significant ionising radiation (i.e. 
cumulative research radiation dose >5 
mSv) 
 History of malignancy within the past 5 
years (with the exception of localized 
carcinoma of the skin that has been 
resected for cure). 
 Previous exposure to Losmapimod. 
 Subjects who have donated more than 
500 mL of blood within 2 months prior 
to the trial medication administration, 
Visit 3 
 Participation in a clinical trial where the 
patient has received a drug or new 
chemical entity within 30 days or 5 half-
lives, or twice the duration of the 
biological effect of the drug (whichever 
is longer) prior to the first dose of trial 
medication. 
 History of alcohol/drug abuse or 
dependence within the past 6 months 
 Women of childbearing potential 
 An unwillingness of male patients to 
abstain from sexual intercourse with 
pregnant or lactating women; or an 
unwillingness of the patient to use 
appropriate contraception 
 Any medical history or clinically relevant 
abnormality that is deemed by the 
principal investigator and/or medical 
monitor to make the patient ineligible 
for inclusion because of a safety concern 
 Use of systemic corticosteroids (oral or 
IV) prior to visit 2 
Table 5.1 Inclusion and exclusion criteria for subject enrolment into study 2 
(EVOLUTION study) 
 
 A summary schedule of study visits is illustrated in figure 5.1. Eligible subjects underwent 
baseline high resolution CT chest and FDG-PET scans at visit 2, as well as an optional MRI, of 
the thorax. Baseline measurements were carried out at visit 3 (V3) and included physical 
examination, anthropometrics, ECG, blood pressure, spirometry, 6 minute walk test, SnIP, 
flow mediated dilatation (FMD), pulse wave velocity and collection of fasting blood and 
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urine samples as described in Chapter 2. Subjects were randomised (1:1) at visit 3 into 
either the placebo or the interventional arm that received 7.5mg of Losmapimod twice 
daily, and continued treatment for 120 days, after which they returned for scans at visit 8 
and then visit 9 (V9) to undergo a repeat of all baseline V3 assessments at the end of 
treatment. Interim visits 4 (day 14), 5 (4 weeks), 6 (8 weeks) and 7 (12 weeks) and post-
treatment visit 10 (week 18) constituted routine observations, checking compliance with 
medication, fasting blood measurements and urine dipstick. 
 
Figure 5.1 Trial flow chart 
 
Data from V3 and V9 for randomised subjects who completed the trial and did not have 
exacerbations of COPD in the 4 weeks preceding visits 8 and 9 was used to assess the effect 
of Losmapimod on 6 minute walk distance and SnIP measurements.  
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Based on previous data (195), 30 subjects per treatment arm was deemed a feasible sample size to 
provide a 90% chance of achieving a reasonable assumption of the effect size of losmapimod (where 
the null hypothesis is the effect size is zero) versus placebo on arterial inflammation, as measured by 
tissue-to-blood ration (TBR), assuming a standard deviation of 0.3 of TBR.  
 
Change from baseline for outcomes was analysed using linear regression models, with the change 
from baseline as the dependent variable, treatment as the independent variable, and baseline value 
and treatment site as covariates. For PWV, systolic blood pressure was included as a covariate. The 
analysis included all participants who received treatment with losmapimod or placebo, except those 
who had an exacerbation (defined as requiring systemic corticosteroids) within four weeks of the 
follow-up scan. Blood biomarker data were log transformed prior to analysis.  A p-value <0.05 was 
deemed significant for all statistical analyses. Analyses were performed using R (221) version 3.0.0 
for Microsoft Windows with R-Studio version 0.98.953. 
 
5.3 Results 
 
160 subjects were assessed for eligibility at the initial screening visit, with 73 subjects being 
randomized and 63 subjects eventually completing the study, as shown in the CONSORT 
diagram in Figure 5.2. Due to exacerbations occurring within 4 weeks of the end of 
treatment visit, 4 subjects in the control arm and 3 subjects in the treatment arm were 
excluded from the primary endpoint analysis, giving 30 subjects in the control arm and 26 in 
the treatment arm. A fibrinogen level of <2.9 g/L was the commonest reason for subjects 
being ineligible for the study. For randomized subjects, the commonest reason for not 
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completing the trial was exacerbation of COPD preventing attendance of the follow up 
visits. 
 
 
Figure 5.2 CONSORT diagram for Study 2 
 
Baseline demographics for study participants are described in table 5.2. There were no 
significant differences at baseline between treatment and control groups in terms of age, 
gender, smoking history or body mass index. The two groups differed slightly in terms of 
ethnicity, however white British and Irish ethnicities are arguably quite similar in origin, and 
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these constituted over 97% of patients in both groups. The groups were fairly well matched 
in terms of COPD severity. Treatment compliance was excellent in both groups (Table 5.3) 
with mean compliance of >95% at each visit. 
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Variable Control (n = 30) Treatment (n = 26) 
Age (years) 69.0 (7.14) 67.3 (7.82) 
Ethnicity 
White: British 
White: Irish 
Black: Carribbean 
 
88.6% 
8.6% 
2.9% 
 
96.9% 
3.1% 
0% 
Gender (M:F) 25:10 22:10 
Smoking status 
Current smoker 
Ex-smoker 
 
8.6% 
91.4% 
 
12.5% 
87.5% 
Smoking history (pack years) 43 (25) 48 (24) 
Height (cm) 172 (8.8) 168 (8.4) 
Weight (kg) 76.9 (14.5) 73.9 (15.3) 
BMI (kg/m
2
) 25.8 (3.7) 25.9 (4.3) 
GOLD stage 
I 
II 
III 
IV 
 
14.3% (5/35) 
34.3% (12/35) 
37.1% (13/35) 
14.3% (5/35) 
 
6.2% (2/32) 
46.9% (15/32) 
28.1% (9/32) 
18.8% (6/32) 
Table 5.2 Baseline demographics for study 2.  
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 Control (n=30) Treatment (n = 26) 
Week 4 97.7 (3.76) 97.7 (3.93) 
Week 8 97.4 (5.14) 96.2 (8.34) 
Week 12 97.0 (6.73) 98.8 (2.67) 
Week 16 97.8 (7.29) 98.9 (3.57) 
Table 5.3 Treatment compliance at each visit. Values expressed as percentages (standard deviation). The 
number of tablets in each bottle was manually counted by study staff before being dispensed to subjects at 
dispensing visits. Compliance was measured by counting tablets at each follow up visit and calculating the 
difference between actual and expected number of remaining tablets and expressing the difference as a 
percentage of the original number of tablets in each bottle. 
  
 
In terms of inflammatory markers, treatment with Losmapimod did have a significant effect 
on fibrinogen, with significantly lowered fibrinogen levels in the treatment group at day 14 
although levels slowly returned to baseline through the remaining 120 day treatment period 
(table 5.4). HsCRP and WCC were not significantly lowered in the treatment group (table 5.5 
and 5.6).  
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 Fibrinogen Treatment 
effect 
p-value Placebo (n = 30) Losmapimod (n = 26) 
Baseline  3.42 (0.49) 3.56 (0.74) - 
Day 14 3.41 (0.65) 3.24 (0.67) 0.003 
Day 28 3.44 (0.54) 3.28 (0.61) 0.09 
8 weeks 3.39 (0.55) 3.52 (0.86) 0.65 
12 weeks 3.41 (0.60) 3.40 (0.77) 0.47 
16 weeks (end of treatment) 3.40 (0.52) 3.31 (0.54) 0.71 
Off treatment  3.38 (0.66) 3.76 (0.75) - 
Table 5.4 Treatment effect on fibrinogen values. Mean fibrinogen values expressed (standard 
deviation) at baseline, day 14, day 28, week 8, week 12, week 16 and and end of treatment. Baseline 
represents commencement of treatments with placebo or Losmapimod and week 16 constitutes end 
of treatment. p-values represent differences in treatment effect between groups. Treatment effect 
is determined via linear regression, with change from baseline as the dependent variable, treatment 
as the independent variable, and baseline and site as covariates as specified in the methods  
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  hsCRP  
Control (n=30) 
hsCRP 
Treatment (n=26) 
p-value 
Baseline  5.27 (8.03) 6.03 (7.33) - 
Day 14 6.59 (13.6) 6.40 (10.8) 0.34 
Day 28 6.51 (13.6) 6.62 (10.4) 0.90 
8 weeks 7.94 (17.1) 8.74 (14.3) 0.96 
12 weeks 6.77 (9.67) 6.36 (9.89) 0.35 
16 weeks (end of treatment) 4.98 (6.28) 3.54 (3.70) 0.44 
Off treatment  6.33 (8.62) 4.89 (3.87) - 
Table 5.5 Treatment effect on hsCRP values. Mean hsCRP values expressed (standard deviation) at 
baseline, day 14, day 28, week 8, week 12, week 16 and at end of treatment. Baseline represents 
commencement of treatments with placebo or Losmapimod and week 16 constitutes end of 
treatment. p-values represent differences in treatment effect between groups. Treatment effect is 
determined via linear regression, with change from baseline as the dependent variable, treatment as 
the independent variable, and baseline and site as covariates as specified in the methods 
 WCC 
Control (n= 30) 
WCC 
Treatment (n=26) 
p-value 
Baseline  6.81 (1.67) 7.14 (1.87) - 
Day 14 6.80 (1.52) 7.36 (2.23) 0.29 
Day 28 6.86 (1.68) 7.80 (2.41) 0.21 
8 weeks 7.13 (1.82) 7.99 (2.87) 0.49 
12 weeks 7.09 (1.69) 8.13 (2.41) 0.17 
16 weeks (end of treatment) 7.11 (1.47) 7.56 (2.17) 0.53 
Off treatment  6.97 (1.53) 7.56 (2.02) - 
Table 5.6 Treatment effect on WCC values. Mean WCC values expressed (standard deviation) at 
baseline, day 14, day 28, week 8, week 12, week 16 and at end of treatment. Baseline represents 
commencement of treatments with placebo or Losmapimod and week 16 constitutes end of 
treatment. p-values represent differences in treatment effect between groups. Treatment effect is 
determined via linear regression, with change from baseline as the dependent variable, treatment as 
the independent variable, and baseline and site as covariates as specified in the methods 
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Figure 5.3 Box and whisker plots for fibrinogen and hsCRP in COPD subjects on losmapimod (n=26) 
and placebo (n=30) treatment during study 2 (EVOLUTION study). Median values represented by 
circles or squares, with interquartile range represented by bars 
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 Placebo (n = 30) Losmapimod (n = 26) P-
value 
Baseline 
(day 0) 
End of 
treatment 
(16 
weeks) 
Net 
change 
Baseline 
(day 0) 
End of 
treatment 
(16 
weeks) 
Net 
change 
FEV1 (L) 1.40 (0.54) 1.45 (0.59) 0.07 (0.22) 1.32 (0.60) 1.33 (0.53) -0.02 (0.14) 0.09 
FEV1% pred 51.8 (21.6) 53.6 (22.9) 2.3 (9.9) 49.5 (19.3) 52.4 (17.3) 0.00 (7.15) 0.31 
FVC (L) 3.12 (0.80) 3.09 (0.87) 0.01 (0.38) 2.93 (0.90) 2.80 (0.82) -0.03 (0.35) 0.59 
FVC %pred 87.9 (19.7) 87.6 (18.5) 0.3 (13.9) 86.0 (16.3) 86.8 (19.2) -0.04 (11.0) 0.96 
FEV1/FVC 0.47 (0.17) 0.48 (0.17) 0.009 
(0.06) 
0.45 (0.15) 0.48 (0.14) -0.002 
(0.06) 
0.50 
SnIP(cmH2O) 60.3 (21.3) 64.6 (22.9) 4.2 (12.3) 64.1 (18.9) 66.3 (21.9) 2.38 (11.7) 0.46 
6MWT (m) 410 (114) 434 (88) 11 (51) 356 (109) 371 (106) 8 (45) 0.13 
BMI (kg/m
2
) 26.3 (3.4) 25.5 (3.6) -0.6 (2.5) 26.2 (4.5) 26.1 (4.5) -0.25 (0.9) 0.50 
FFM (kg) 53.5 (10.9) 53.6 (10.2) 0.6 (7.1) 53.1 (11.3) 51.2 (11.6) -0.12 (1.6) 0.68 
PWV (m/s) 10.5 (2.5) 9.9 (2.4) -0.6 (1.5) 9.5 (3.1) 9.2 (2.7) -0.5 (1.8) 0.98 
Systolic blood 
pressure (mm 
Hg) 
138 (20) 136 (17) -0.9 (16) 133 (15) 133 (17) -0.5 (17) 0.69 
Heart rate 
(beats/minute) 
74 (12) 76 (11) 3 (10) 74(12) 74 (12) 0.3 (11) 0.32 
QTc interval 
(ms) 
416 (15) 413 (24) -3.5 (23.8) 412 (19) 416 (25) 5.2 (12) 0.10 
 
Table 5.7 Treatment effect on trial endpoints.  Baseline measurements taken prior to randomization 
at day 0, with end of treatment measurements being undertaken following 16 weeks (120) days of 
treatment with either placebo or Losmapimod. No significant differences were observed between 
control and treatment groups in terms of spirometry (FEV1, FVC and FEV1/FVC), sniff nasal 
inspiratory pressure (SnIP), 6 minute walk distance (6MWT), body mass index (BMI), fat free mass 
(FFM), pulse wave velocity (PWV), flow mediated dilatation (FMD), Glyceryl Trinitrate (GTN) 
responsiveness, systolic blood pressure, heart rate, QTc interval 
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Treatment with losmapimod did not result in a significant improvement in spirometry  (FEV1, 
FEV1%pred, FVC, FVC %, FEV1/FVC), SnIP, 6 minute walk distance or body composition in terms 
of body mass index or fat free mass (table 5.7). There was no significant improvement in 
cardiovascular measures in terms of pulse wave velocity systolic blood pressure or heart 
rate in the treatment group compared to the control group. 
 
In terms of safety endpoints (QTc interval, spirometry, heart rate and blood pressure) and 
adverse events, there were no significant differences reported between the control and 
treatment groups. There were 34 and 30 subjects with respiratory adverse events in the 
losmapimod and placebo groups, with 19 and 12 of these respectively, due to COPD 
exacerbations. A summary of adverse events is reported in table 5.8 below: 
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 Losmapimod 
n=36 
Placebo 
n=37 
Total adverse events  n=85 n=79 
Respiratory n (%) 34 (40%) 30 (38%) 
Dyspnoea 6 2 
Cough 5 6 
Cold or Flu symptoms 3 9 
Wheeze 1 1 
COPD exacerbation 19 12 
Gastrointestinal n (%) 12 (14%) 10 (13%) 
Abdominal pain 5 1 
Bloating or indigestion 2 1 
Constipation 1 1 
Diarrhoea 2 1 
Increased stool frequency 0 1 
Gastroenteritis 0 1 
Nausea or vomiting 1 3 
PR bleed 0 1 
Elective Surgical procedure 1 0 
Cardiovascular n (%) 1 (1%) 2 (3%) 
Atrial flutter 0 1 
Swollen ankles 1 1 
Musculoskeletal n (%) 4 (5%) 7 (9%) 
Musculoskeletal pain or swelling 4 5 
CNS and Ophthalmological n (%) 6 (7%) 16 (20%) 
Dry or sore eye 1 2 
Elective eye surgical procedure 0 1 
Dizziness or light headed 1 3 
Headache 4 9 
Skin and soft tissue n (%) 3 (4%) 3 (4%) 
Cellulitis 0 1 
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Table 5.8: Summary of adverse events during treatment with losmapimod (n=36) and placebo (n = 
37).  
 
Basal cell carcinoma 0 1 
Dry skin 2 0 
Rash 1 1 
Renal and Urological n (%) 7 (8%) 1 (1%) 
Proteinuria 1 0 
Micturition difficultly 1 1 
Urinary tract infection 5 0 
Dental and ENT n (%) 14 (16%) 5 (5%) 
Dry mouth 2 0 
Mouth ulcers, or gingivitis or toothache 3 1 
Jaw pain 0 1 
Nasal congestion, or polyps, or nose bleed 4 1 
Sinusitis 1 1 
Sore throat 4 0 
Hayfever 0 1 
Systemic n (%) 3 (4%) 2 (3%) 
Fever 1 0 
Loss of appetite or thirst 2 0 
Tiredness 0 2 
Abnormal laboratory result n (%) 1 (1%) 3 (4%) 
Hyponatraemia 0 1 
Elevated CRP 0 1 
Liver function test abnormality 1 1 
Serious adverse events n  10 1 
Admission to hospital with COPD exacerbation or pneumonia n (%)  6 (60%) 1 (100%) 
167 
 
5.4 Discussion   
 
Inhibition of p38 MAPK with Losmapimod does not appear to result in an improvement in 
muscle or cardiovascular parameters in patients with COPD. Losmapimod also did not 
produce an improvement in spirometry measures despite an initial 9% reduction in plasma 
fibrinogen, the magnitude of which is consistent with the 11% mean reduction reported in 
earlier trials of this drug (59, 60), although fibrinogen did not remain low in the treatment 
group throughout the 120 day treatment period unlike previous studies. 
 
Treatment and control groups were fairly similar at baseline in terms of mean age, gender 
composition, ethnicity, FFM, BMI, blood pressure and SnIP. Interestingly, the treatment 
group had a lower mean baseline pulse wave velocity of 9.5m/s, which was lower than the 
10 m/s that typically denotes elevated cardiovascular risk, and therefore had perhaps less to 
gain from anti-inflammatory treatment. The two groups also differed in their baseline 6 
minute walk distance, with the control group having a mean walking distance of 410m 
compared with 356m in the treatment group, suggesting that the treatment group was 
frailer in terms of muscle performance despite a lower pulse wave velocity.  
 
In terms of muscle parameters, there was no improvement in 6 minute walk distance with 
losmapimod treatment, which is consistent with earlier, much larger trials of Losmapimod in 
COPD (59, 60). Whole body muscle mass, as measured by fat free mass, did not improve 
with Losmapimod treatment although 120 days is possibly too short a treatment time to 
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result in significant changes in physical bulk, especially without any formal exercise regime. 
In addition SnIP, which is likely to reflect a combination of inspiratory muscle strength, 
hyperinflation and cachexia in COPD, did not improve with MAPK inhibition. Since BMI and 
FFM and therefore cachexia appear unaffected with Losmapimod treatment, it is perhaps 
unsurprising that SnIP also did not exhibit a change. Previous trials did demonstrate 
reduction in hyperinflation in COPD although they recruited many more patients, so an 
alternative explanation is that the current trial is underpowered to detect changes in SnIP. 
In order to detect a 10% difference in SnIP with losmapimod treatment, where the mean 
SnIP value in COPD is 55 cm H2O and standard deviation (data from chapter 4), a sample 
size of over 300 subjects is required, whereas our study size should be able to detect a 
difference of over 10 cm H2O or almost a 20% difference, which is unlikely to be achieved. 
Therefore the likelihood for a type II error is quite high. 
 
Cardiovascular measurements also did not show an improvement with Losmapimod, in 
contrast to trials in the non-COPD population which suggest an improvement in 
inflammation following myocardial ischaemia (263, 267) and vascular inflammation (191) 
with p38 MAPK inhibition. Since losmapimod appears to reduce fibrinogen, but not hsCRP or 
WCC, in COPD, it may be that the incorrect inflammatory pathway is being suppressed, or 
there may be diversion to other inflammatory pathways, therefore the net result on 
cardiovascular inflammation is negligible. Alternatively, the 120 day treatment period may 
be insufficiently long to demonstrate treatment effect in COPD, where mechanisms 
underlying cardiovascular inflammation are multifactorial. As with SnIP, it may be that the 
present trial is underpowered to detect changes in pulse wave velocity. 
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Nine subjects who had high fibrinogen also had findings of cancer either on their baseline 
scans or discovered during subsequent follow up of symptoms reported during the trial.  
Cancer related findings included lung cancer, lung nodules, sigmoid polyps, colorectal 
carcinoma, laryngeal cancer, pancreatic cancer and bladder cancer (see Table A11 in 
appendices). 77 subjects in total underwent PET scans, but 4 of these subjects were not 
allocated to treatment on the basis of scan findings, therefore 11.7% of the scanned 
population had cancer diagnosed within one year of trial screening. The relatively high 
incidence of cancers in a small cohort of patients suggests that elevated fibrinogen levels 
may relate to cancer related mortality in COPD. The incidence of cancer in this cohort is 
higher than the lung cancer incidence of 8% in a cohort of 2500 patients with COPD over a 
period of 5 years (1), however our findings include non-lung cancer. In a general population 
being screened with CT for occult cancer following unprovoked venous thromboembolism, 
annual incidence of cancer is approximately 3% (268). Our population is at higher risk of 
cancer through smoking, but the high cancer incidence in this stratified cohort would 
suggest that either fibrinogen is elevated directly from cancer related inflammation or else 
through venous thromboembolism. Since PET scans are not routinely performed in the 
general population, a number of patients with COPD may have undiagnosed cancer and 
population level studies may attribute their deaths to COPD or non-cancerous causes. 
Therefore, the excess mortality related to elevated fibrinogen levels in COPD may relate to 
cancer, in addition to frequent exacerbations. 
 
Critique 
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Although measures of muscle function were secondary trial endpoints of study 2, the main 
trial was powered on the basis of vascular inflammatory changes measured via 38FDG-PET 
scanning. As such, it is possible that the study is underpowered to detect significant changes 
in muscle function or cardiovascular parameters other than inflammation on PET scanning. 
Furthermore, we did not include measures of muscle strength such as QMVC in the interests 
of time, and therefore isolated quadriceps function is difficult to comment on, since fat free 
mass is a whole body measure and 6 minute walk distance is a test not only of quadriceps 
endurance, but also cardiopulmonary fitness. 
 
Study 2 was stratified on the basis of elevated fibrinogen, with the aim of selecting an 
enriched population thereby reducing the number of study subjects required to observe 
treatment effect. The initial fibrinogen level required to enter the trial was set at >3.4 g/L, 
based on data from the ECLIPSE study. However it proved extremely difficult to recruit 
sufficient numbers of subjects, with the main screening failure being an insufficiently high 
fibrinogen. The entry criteria was therefore revised to a fibrinogen level of >2.9 g/L, based 
on data from Dahl et al (61). In trying to meet study recruitment criteria, it is possible that 
we failed to recruit subjects that were “sufficiently” inflamed to benefit from anti-
inflammatory therapy, and consequently it may be that we needed more inflamed or a 
larger number of subjects to show a treatment effect. 
 
A further limitation of selecting subjects with inflammation is the nature and stage of 
inflammation. Previous work from ECLIPSE has suggested that persistent inflammation is in 
171 
 
fact observed in relatively few subjects in COPD, and also that TNF-α is raised in smokers, 
but that this difference between smokers and healthy controls disappears as COPD 
develops. This suggests a switch or change in inflammatory pathways, and it may be 
important to analyse subgroups of patients with different GOLD stage of disease for their 
response to inflammatory.  TNF-α does stimulate IL-6 production, which then stimulates 
production of fibrinogen, therefore it is feasible that Losmapimod may be more useful in 
reducing cardiovascular risk in early COPD or “healthy” smokers. 
 
A significant limitation of the study was the frequent exacerbations of COPD amongst the 
trial subjects. Since elevated fibrinogen levels relate to frequent exacerbations in COPD, it is 
unsurprising that our cohort of patients suffered from exacerbations. Where these 
exacerbations occurred 4 weeks prior to end of treatment visits, subjects withdrew from the 
trial or could not undergo all of the assessments at the end of the trial and we therefore had 
to recruit more than the 60 subjects initially intended in order to have sufficient numbers of 
patients with complete datasets.  Exclusion of subjects who exacerbated within 4 weeks of 
end of treatment visits (week 16) was necessary from the primary analysis since the 
exacerbation would result in an increased PET signal. As this was an exploratory Phase IIa 
study, the exclusion of such subjects was considered justified. 
 
Frequency of exacerbations resulted in the slight imbalance in numbers of subjects in the 
treatment versus control groups. The treatment arm of the trial appeared to have a slightly 
higher number of exacerbators, which could be one explanation for the failure to see a 
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sustained reduction in fibrinogen throughout the study as well as a lack of effect of drug on 
trial endpoints. A weakness of the study is that data for previous exacerbation history was 
not collected, and therefore it is difficult to comment on whether the treatment arm 
contained more frequent exacerbators or whether this resulted from the medication. 
Previous, larger trials of losmapimod had not noted an increase in exacerbation frequency 
with treatment however, therefore it is more likely that our study results may have been 
confounded by the inadvertent inclusion of more frequent exacerbators in the treatment 
arm.  
 
 
Implications and future work 
Results from the current trial will be subject to post hoc analyses that exclude frequently 
exacerbating subjects. Although the current trial would suggest that treatment with 
losmapimod is not beneficial in COPD for muscle and cardiovascular parameters, the trial is 
likely underpowered for measuring the effect on these parameters. It may be that 
losmapimod proves useful for other measures, for example reducing the number of 
exacerbations or mortality related to acute coronary events related to exacerbations in 
COPD, rather than improving surrogate measures of cardiac function such as arterial 
stiffness. Currently, phase III trials of losmapimod are being conducted in people with 
known coronary artery disease, with incidence of mortality or heart attacks forming trial 
primary endpoints (NCT02145468), and a phase II trial is underway for COPD patients with 
frequent exacerbations where the primary endpoint is reducing exacerbation frequency 
(NCT02299375). Losmapimod is a competitive p38 α/β MAPK inhibitor, and therefore may 
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be less efficacious in treatment of cardiovascular inflammation than p38 α MAPK inhibitors, 
where this isoform of p38 MAPK predominates. Similarly, inhibition of other p38 MAPK 
isoforms may prove to be of more benefit in improving muscle parameters. Examining the 
effect of Losmapimod in early COPD or “healthy” smokers may also be helpful since TNF-α 
appears to dominate earlier in the development of COPD. Assessing muscle strength and 
endurance with a wider range of different measures such as quadriceps maximal volitional 
contraction, and examining the effect of MAPK inhibition on molecular pathways within 
human muscle may also be important in future trials.   
 
 
Conclusions 
P38 MAPK inhibition does not improve cardiovascular or muscle parameters in COPD 
subjects, as measured via pulse wave velocity, 6 minute walk test and sniff nasal inspiratory 
pressure. Since this study may have been underpowered for measuring treatment effect on 
these measures, further, larger trials of this p38 MAPK inhibitor are warranted in COPD, 
with other parameters used instead as study endpoints. Furthermore, losmapimod inhibits 
p38 α/β MAPK isoforms, and future trials of agents that selectively inhibit other isoforms 
may be required. 
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Chapter 6 
6. Fibre specific signalling in the locomotor myopathy of COPD 
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6.1 Hypothesis 
 
Up to 30% of people with COPD exhibit quadriceps weakness (22), and this is known to 
relate to increased healthcare utilisation and mortality (139, 141).  Skeletal muscle consists 
of two fibre types, the ‘fast' glycolytic type II fibres and ‘slow’ oxidative type I fibres.  In the 
quadriceps of healthy humans these fibres are present in approximately equal proportions, 
but a consistent feature of quadriceps dysfunction in COPD is a fibre shift so that there is an 
increase in type II fibres (269) which itself is associated with reduced exercise capacity (114, 
270) and a poor prognosis independent of disease severity judged spirometrically (115).  For 
these reasons, elucidating both the molecular pathways involved in whole muscle atrophy, 
as well as mechanisms of fibre shift, are currently a research priority. 
 
There is a lack of consensus regarding the underlying molecular mechanisms for quadriceps 
atrophy in COPD, whether that is inflammatory or hypertrophy/atrophy pathways. For 
example, MURF-1 and Atrogin-1 E3 ligases are known to be involved in catabolic pathways 
in murine models (Figure 1.3) yet human studies have had conflicting results. Specifically, 
increased quadriceps expression of Atrogin-1 mRNA and downstream Nedd4 protein, but 
not MURF-1 mRNA and protein, in COPD subjects was reported by Plant et al (171), whereas 
Lemire et al reported increased Atrogin-1 mRNA and protein as well as increased MURF-1 
mRNA, although MURF-1 protein was similar in both COPD and healthy quadriceps (271). 
Conversely, Doucet et al  found both increased Atrogin-1 and MURF-1 in the quadriceps of 
COPD patients (161, 272) whereas Natanek et al  found no difference in MURF-1 mRNA 
expression between patients and controls, and lower Atrogin-1 mRNA levels in COPD 
subjects (273). In terms of inflammatory signalling, studies of TNF-a expression within 
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human vastus lateralis samples have given conflicting results, although these studies have 
relied on small numbers of patients and have been cross-sectional in nature. Barreiro et al  
found reduced TNF-a protein expression the vastus lateralis muscle of COPD patients (172), 
whereas increased quadriceps mRNA levels were reported by Rabinovich et al  (173), and no 
difference in mRNA being reported by Crul et al (174) or Petersen et al (176), and no 
difference in TNF-a expression found via immunostaining by Koechlin et al (175). The NF kB 
pathway is activated in response to TNF-a stimulation, and despite evidence of NF kB being 
a key regulator of muscle mass in murine and in-vitro models, human biopsy samples from 
the vastus lateralis have failed to show up-regulation of the NF kB pathway(171). Similarly 
Lemire et al  discovered increased activation of the p38 MAPK inflammatory pathway in 
terms of both protein and mRNA expression (271) but Riddoch-Contreras et al  found no 
difference between COPD and control subjects when analyzing mRNA and protein (190). 
These conflicting findings make the progression to development of medicines addressing 
these pathways more difficult because of uncertainty as to whether they represent a valid 
target (274). 
 
A lack of consensus between studies may be related to timing of biopsy, since both exercise 
and feeding are known to alter gene and protein expression (180). Furthermore, most 
existing studies are cross sectional in nature, and given disease heterogeneity as well as lack 
of consistency in biopsy protocols regarding rest can give rise to discrepancy in findings. The 
form of expression analyzed is also critical, since gene expression does not always correlate 
with protein expression, e.g. Natanek et al found MURF-1 protein expression was different 
between patient and controls, whereas mRNA expression was similar, and  Atrogin1 protein was not 
different between patients and controls  mRNA expression was lower in patients (273).   
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We speculated that inflammatory, atrophy and hypertrophy signalling might differ between 
type I and type II fibres, and that this may be one reason for discordant findings in different 
cohorts. Specifically, since molecular analysis in COPD has hitherto relied exclusively on 
whole muscle samples, it is possible that biologically relevant findings might be overlooked 
if they are present only in one fibre type. Laser capture microdissection (LCM) has been 
utilised to isolate myofibres previously (275, 276), although only in very small numbers and 
not in patients with COPD.  Thus the aim of the present study was to develop a method for 
LCM that could be used on specimens already held by research groups in this area and to 
test whether fibre specific differences in inflammatory and atrophy/hypertrophy signalling 
could be detected. 
 
6.2 Methods 
 
Subjects  
Male and female patients aged between 40 and 90 years, with clinically diagnosed GOLD II – 
IV stage disease confirmed by post-bronchodilator spirometry, in clinically stable condition 
for the preceding 4 weeks and a minimum of 10 pack year smoking history were included in 
study 1. Exclusion criteria were exercise limiting neuromuscular problems, or concurrent 
other respiratory disease (e.g. asthma, bronchiectasis, sarcoidosis) or inflammatory 
diseases. Healthy, age-matched participants had to have normal spirometry and be free 
from respiratory disease in addition to the above criteria. 
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61 COPD ad 20 healthy age-matched subjects underwent quadriceps biopsy as part of study 
1. Only male subjects were chosen for the pilot study to eliminate gender related hormonal 
differences between subjects. To examine differences in inflammatory signalling, subjects 
with COPD were split into tertiles according to fibrinogen and 6 male subjects from the 
highest fibrinogen tertile and 6 male subjects from the lowest fibrinogen tertile were 
chosen. Biopsies from 6 male, age-matched, non-smokers participating in study 1 were also 
chosen. The three groups were matched for age and BMI; in addition the COPD groups were 
matched for spirometry and smoking history. All subjects had to be clinically stable without 
exacerbations for at least 4 weeks prior to study measurements. 
 
Study assessments 
Subjects underwent comprehensive phenotypic assessment, for which study assessments 
have been described in Chapter 2. All subjects  had percutaneous biopsy of the vastus 
lateralis muscle from the leg used for quadriceps strength measurements under local 
anaesthetic using the Bergstorm method (215). Biopsies were carried out after 20 minutes 
of rest, and after at least 4 hours of fasting. Biopsy specimens were mounted on cork, 
embedded in OCT compound (Tissuetek compound) and frozen in pre-cooled isopentane 
before being placed in liquid nitrogen. Biopsy aliquots were also placed directly in cryovials 
and frozen in liquid nitrogen. All samples were stored at -80oC until analysis. 
 
Muscle Biopsy Analyses 
Sectioning 
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Serial OCT-embedded muscle sections (10μm) with fibres predominantly in transverse 
section were cut at –20°C in sterile conditions using nitrile gloves to minimise RNAse 
contamination. Sections were mounted on standard 1mm glass slides and stored at –80°C 
until analysis. 
 
Immunostaining 
 
For laser capture microdissection, slides with 10μm muscle cryosections were immediately 
fixed with 4% paraformaldehyde (10 minutes), and washed three times (3 minutes) with 1% 
phosphate buffered saline and 0.05% tween (PBST). To determine type II fibres, samples 
were incubated with MY32; mouse (IgG1) anti-fast myosin (Life technologies, USA) diluted 
1:200 in 1% PBST in a humidified chamber overnight at 4oC. After being washed thrice with 
PBST (3 minutes), they were incubated for 1 hour at room temperature in the dark with a 
secondary antibody, A21121; AlexaFluor 488 goat anti-mouse IgG1 diluted 1:200 in PBST. 
The slides were then washed thrice with 1% PBST for 3 minutes before being air-dried for 1 
hour in the dark. 
 
For fibre typing, sections were air‐dried for thirty minutes at room temperature and the 
slides were incubated at a room temperature (20 minutes) with 5% milk in 1% PBST. The 
slides were then washed with 1% PBST three times for 5 minutes each before being 
incubated for 1 hour at room temperature with a mix of primary antibodies diluted in 1% 
PBST; (A4.480; mouse (IgM) anti human MHC I (diluted 1:25 (Developmental Studies 
Hybridoma Bank (DSHB), University of Iowa, USA), N2.26; mouse (IgG1) diluted 1:50 (DSHB, 
University of Iowa, USA), 4HB-A; rat (IgG1)anti-laminin diluted 1:500 (Abcam, USA). The 
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slides were again washed thrice with 1% PBST for 5 minutes per wash and incubated with a 
mix containing the secondary antibodies; A31552 AlexaFluor350 goat anti-mouse IgM 
diluted 1:500, A21121; AlexaFluor488 goat anti-mouse IgG1 diluted 1:200, A11077; 
AlexaFluor568 goat anti-rat (IgG)diluted 1:500. All secondary antibodies were supplied by 
Molecular Probes, Invitrogen, Netherlands. The sections were left at room temperature for 
1 hour in a dark, humidified chamber and then subject to a further three washes with 1% 
PBST for 5 minutes each. The slides were left to air dry in the dark for 1 hour and then 
mounted with a coverslip using Fluormount (SigmaAldrich, UK) before being stored at 4oC 
until further use. 
 
Laser Capture 
 
The PALM laser capture microdissection system (Carl Zeiss,  Bernried, Germany) with a 20x 
objective and an FITC filter (395 – 490mm) was used to directly visualize  fluorescent, type II 
fibres (2+), with non-fluorescing fibres (2-) identified as type I fibres. The different fibres 
were manually selected via attached PALM software, and the PALM system used a UV 
cutting system to emit short laser pulses to cut the selected tissue, which is then catapulted 
onto an adhesive silicone cap. The two fibre populations were laser-captured using Auto-
LPC mode onto separate 0.5ml silicone, opaque adhesive caps (Carl Zeiss, Germany). 9 
cryosections per subject were pooled onto one collection cap, translating into the capture of 
1000 to 3000 muscle fibre sections per subject. 
 
Image Capture for fibre typing 
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Images were recorded with a Zeiss Axiovert 200M inverted microscope (Carl Zeiss 
microimaging, Jena, Germany) equipped with a Hamamatsu ORCA-ER camera (Hamamatsu 
Photonics K.K., Japan) under a 10x objective using three filters:  DAPI (UV (395-410nm), FITC 
(490-505nm) and TRITC (540-580nm). Images were analysed using Volocity 6.0 software 
(PerkinElmer, USA). 
 
Fibre typing 
 
A minimum of 100 fibres were analysed per subject. For each individual, the numbers of 
type I, I/IIa, IIa and IIx were recorded to calculate proportions. 
 
RNA extraction 
 
RNA was extracted using the RNAeasy FFPE kit (Qiagen, UK) according to manufacturer’s 
instructions for laser captured samples and the Trizol method for whole muscle samples as 
described previously (277), before being stored at -80oC. 
 
cDNA synthesis 
 
For cDNA synthesis, Superscript II enzyme (Invitrogen, UK) was used for laser captured RNA.  
0.5μL of random primers and 2μL of DNTP were added to 12μL of the RNA solution and 
heated to 65oC for 5 minutes before being placed on ice for 2 minutes. 4μL of 5x FS buffer, 
2μL of 0.1M DT and 1 μL Riboblock (RNAsin) were added to each sample and the sample was 
incubated at 25oC for 2 minutes. 0.5 μL of Superscript II was then added to each sample and 
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the samples incubated at 42oC for 50 minutes, followed by 70oC for 15 minutes.  The final 
20μL of cDNA was diluted with 80 μL of sterile water. 
 
For RNA extracted from whole muscle, the Omniscript RT kit (Qiagen, UK) for whole muscle 
RNA.  150ng of RNA in 11μL was heated at 65oC for 5 minutes before the addition of 2μL 10x 
RT buffer, 2 μL dNTPs 5nM, 2μL RNAse free H20, 1 μL Omniscript, 1μL DTT,  0.5 μL random 
primers and 0.5 μL Riboblock RI and incubation on ice for 2 minutes. The solution was then 
incubated at 42oC for 2 hours. 180 μL of RNAse free water was then added.  All cDNA was 
stored at -20oC.  
 
qPCR 
 
The qPCR analysis was carried out on all samples in duplicate per target gene using 10 μL of 
the SyBR Green mix (Qiagen, UK), 3 μL of sterile water, 2 μL of 1μM forward/reverse primer 
mix and 3 μL of cDNA per reaction. The reaction was set up in 96 well plates with a cover, 
using the 7500 Fast Real Time (Applied Biosystems, UK) and the following program: 95oC for 
min, then 40 cycles of 95oC for 10 seconds and 60oC for 30 seconds. Integrity of PCR 
products was confirmed by single melt curves (figure 6.1), and where this was not evident, 
by gel electrophoresis to confirm expected target size.  
 
Target primers are listed below in table 6.1. Three housekeeping genes (RPLPO, 18S and 
Beta-2-microglobulin) were chosen in order to minimise effects of fibre specific expression 
of housekeepers on normalising gene expression. In order to validate the technique, genes 
that are known to be expressed in a fibre specific manner (TNNT-1 and PANK-1) were 
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chosen in addition to MHC I, MHC IIa and MHC IIx. Although the initial aim was to assess 
inflammatory pathways (Nf kB and p38 MAPK or MAPK14) and their downstream targets 
(IkBa, p50 and p65 for Nf kB and Cyr61 for p38 MAPK), these genes were too lowly 
expressed for reliable qPCR detection. Therefore, I examined genes from the atrophy/ 
hypertrophy pathways that were likely to be highly expressed in order to test the feasibility 
of the method – these genes were Atrogin 1, MURF 1, IGF 1 and myostatin.  
 
Data were normalised to the geomean of 3 housekeeping genes (RPLPO, 18S and Beta-2-
microglobulin) using the 2-ΔCt method. The Ct (threshold cycle) is the cycle number at which 
the fluorescence signal cross the threshold at which significant and specific amplification 
occurs (the linear doubling phase of amplification). The Ct is inversely proportional to the 
amount of cDNA present since there is doubling of cDNA with every cycle, therefore the 
quantity of cDNA can be estimated by 2-Ct. To measure relative gene expression, the 
difference in Ct values between the two genes (
ΔCt) is used for quantification, or 2-ΔCt. 
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Figure 6.1 Melt curve for qPCR products. Example of single melt curve at one temperature 
point for qPCR using 18S primers, indicating production of a single PCR product 
  
185 
 
18S F 5’ GTA ACC CGT TGA ACC CCA TT 3’  
R 5’ CCA TCC AAT CGG TAG TAG CG 3’  
 
Atrogin1 F 5’ GCA GCT GAA CAA CAT TCA GAT CAC 3’ 
R 5’ CAG CCT CTG CAT GAT GTT CAG T 3’ 
 
B2M F 5’ TGC TGT CTC CAT GTT TGA TGT ATC T 3’ 
R 5’ TCT CTG CTC CCC ACC TCT AAG T 3’ 
 
Cyr61 F 5’ ACT TCA TGG TCC CAG TGC TC  3’ 
R 5’ TGC TGC ATT TCT TGC CCT TTT 3’ 
 
IGF-1 F 5’ TTT CAA CAA GCC CAC AGG GT 3’ 
R 5’ CCA CGA TGC CTG TCT GAG G 3’ 
 
IkBa F 5’ CCC TGT AAT GGC CGG ACT G 3’ 
R 5’ AGG AGT GAC ACC AGG TCA GGA 3’ 
 
MAPK14  
 
  F 5’ TGA AAT GAC AGG CTA CGT GG 3’ 
  R 5’ CTA TAA GGA GGT CCC TGC TTT C 3’ 
MHC I F 5’ AGC TGA TGA CCA ACT TGC GC 3’ 
R 5’ CCC TGG AGA CTT TGT CTC ATT AGG 3’ 
 
MHC II a F 5’ CAA TCT AGC TAA ATT CCG CAA GC 3’ 
R 5’ TCA CTT ATG ACT TTT GTG TGA ACC T 3’ 
 
MHC II x F 5’ GGA GGA ACA ATC CAA CGT CAA 3’ 
R 5’ TGA CCT GGG ACT CAG CAA TG 3’ 
 
MURF-1 F 5’ CCT GAG AGC CAT TGA CTT TGG 3’ 
R 5’ CTT CCC TTC TGT GGA CTC TTC CT 3’ 
 
Myostatin F 5’ ACA TGA ACC CAG GCA CTG GT 3’ 
R 5’ GGT TGT TTG AGC CAA TTT TGC 3’ 
 
PANK-1 F 5’ TTC GAA GAG GAC TTC AGA ATG 3’ 
R 5’ TAC ACG GCT AGA ATG CTG AC 3’ 
 
P50 F 5' AAA GGT TAT CGT TCA GTT 3' 
R 5' TTG TAG ATA GGC AAG GTC 3’ 
 
P65 F 5’ CCC CAC GAG CTT GTA GGA AAG 3’ 
R 5’ CCA GGT TCT GGA AAC TGT GGA T 3’ 
 
RPLPO F 5’ TCT ACA ACC CTG AAG TGC TTG ATA TC 3’ 
R 5’ GCA GAC AGA CAC TGG CAA CAT T 3’ 
 
TNNT-1   F 5’ GGC AA GCC AGA AGA GGA AC 3’ 
  R 5’ CAG CAG GTC TTT CTC CAT GC 3’ 
 
Table 6.1 Primer sequences for target genes 
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Statistical analyses 
 
Two-tailed Mann Whitney tests were used to examine between group differences. 
Graphpad Prism v5.0 software was used for statistical analyses. All descriptive continuous 
variables are expressed as median (interquartile range). Significance was accepted as p 
<0.05.  
 
6.3 Results 
 
Baseline demographics of the chosen subjects are shown in Table 6.2.  The two groups were 
well matched for age and body mass index, and all were Caucasian males. As expected, 
subjects with COPD had lower fat free mass, quadriceps strength and exercise tolerance. 
COPD subjects had a significantly lower proportion of type I fibres than healthy subjects (p = 
0.04), with differences in fibre type illustrated in Figure 6.2.  
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Characteristic COPD subjects 
(n= 12) 
Control subjects 
(n = 6) 
Significance 
Age (years) 68 (63,74) 68 (65, 71) 0.92 
Gender (% male) 100 
 
100  
Body mass index (kg/m2) 23.9 (20.7, 26.7) 25.5 (24.5, 26.3) 0.48 
Fat free mass index (kg/m2) 16.1 (14.7, 17.0) 20.3 (20.3, 20.9) 0.007 
Smoking pack year history 39 (31, 58) 0 (0,0) <0.001 
FEV1 (% predicted) 49.0 (38.1, 69.6) 112 (98.8,122) not tested 
FEV1 * (L) 1.53 (1.13, 2.09) 3.27 (2.86, 3.45) not tested 
FEV1/FVC † 0.41 (0.26, 0.52) 0.75 (0.71, 0.76) 0.001 
6 minute walk distance (m) 456 (402, 508) 633 (609, 658) 0.002 
Average step count/ day 3750 (3050, 4220) 10900 (7150, 13000) 0.002 
QMVC ‡  (kg) 31.7 (27.8, 38.7) 46.0 (39.1, 50.6) 0.01 
QMVC/Body mass index 1.29 (1.14, 1.56) 1.70 (1.68, 1.84) 0.02 
% type I fibres in quadriceps 36.3 (28.6, 48.2) 47.9 (43.1, 54.9) 0.04 
*Forced expiratory volume in 1 second 
† Forced vital capacity 
‡ Quadriceps maximal volitional contraction 
 
Table 6.2  Baseline Demographics for participants 
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Figure 6.2: Fibre typing of quadriceps  
10 µm sections of human quadriceps were immunostained for MHC I, IIA and laminin as 
described in the online supplement, then viewed under fluorescent illumination with a 10x 
objective. Type I fibres are shown in blue, type IIa fibres are shown in green and laminin is 
shown in red. The image on the left is from a study subject with COPD and the image on the 
right is from an age-matched control. 
 
 
Immunofluorescent staining, subsequent separation and laser capture of fluorescent, type II 
fibres (2+) is demonstrated in Figure 6.3. Identification and separation of fibres was 
possible, and was validated by analysis of relative myosin heavy chain (MHC) II expression. 
Since we captured a variable number of fibres per subject, we adjusted the MHC II (MHC IIa 
and IIx) content to MHC I content to give relative MHC II in each fibre population. As MHC 
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IIa and IIx should be more highly expressed in type II (2+) fibres, and MHC I more highly 
expressed in type I (2-) fibres, a ratio of relative MHC II content in 2+:2- fibres should be  >1. 
In all subjects except one, both the relative MHC IIa ratio and MHC IIx ratio gave a value of 
>1 when the 2+ population was normalized to the 2- population, as demonstrated in Figure 
6.4. For relative MHC IIa, the 2+:2- ratio ranged between 0.7 and 12.4 (median 3.8) for COPD 
subjects and a range of 1.5 and 25.2 (median 3.7) for controls. For relative MHC IIx, the 
range was between 1.2 and 16.5 (median 2.5) for COPD subjects and between 2.6 and 6.8 
(median 3.8) for controls, denoting good separation. Samples from the subject who did not 
have a 2+:2- ratio of >1 for both MHC IIa and MHC IIx were excluded from further analysis. 
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Figure 6.3: Laser capture of type 2 fluorescent fibres  
10µm section of human quadriceps was prepared for laser capture microdissection and 
immunostained for type II MHC as described in Methods. (A) section viewed under fluorescent 
illumination.  Type II (2+) fibres are shown in green, darker areas show the presence of type I (2-) 
fibres. (B) selected 2+ fibres are outlined and shown under fluorescent (B1) and bright-field (B1) 
illumination. (C) section after laser capture microdissection of the 2+ fibres, under fluorescent (C1) 
and bright-field illumination (C2). (D) successfully captured 2+ material fluorescing on the adhesive 
silicon cap, which is then subject to RNA extraction.    
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Figure 6.4: Validation of adequate separation of fibre populations  
Validation of separation of fibres in 2+ and 2- populations in all subjects (n=18) from laser capture 
microdissection. Each dot represents an individual subject. MHC I, MHC IIa and MHC IIx gene 
expression was determined by qPCR in both 2+ and 2- fibre populations. MHC IIa and MHC IIx 
content was then normalized to MHC I content in each 2+ and 2- sample. There should be greater 
MHC II (MHC IIa  and MHC IIx) content in comparison to MHC I content in the 2+ fibre population 
(representing type II fibres) than the 2- population (representing type I fibres). Where there is 
adequate separation, the relative MHC II:MHC I content in the 2+ versus 2- population is >1 for both 
MHC IIa and MHC IIx. For one subject, the relative MHC II: MHC I ratio was <1, therefore this subject 
was excluded from further analyses. 
 
 
A panel of genes was analysed, with robust amplification of all three housekeeping genes 
(18S, Beta-2-microblobulin and RPLPO); mean cycle threshold (Ct) in the laser captured 
samples occurred approximately 5 cycles later than that for whole muscle samples 
consistent with low levels of RNA in the LCM samples.  
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As a further validation step, we examined troponin T (TNNT-1), which is known to be highly 
expressed in type I myofibres (278, 279), and therefore should be more highly expressed in 
our 2- samples. In samples from both COPD and healthy subjects, TNNT-1 expression was 
indeed greater in the 2- fibres than the 2+ fibres (p <0.01). When TNNT-1 content in the 2- 
fibres versus 2+ fibres is expressed as a ratio, the ratio should be above 1, which is 
confirmed in all the COPD and control subjects (Figure 6.4), with a median ratio of 5.77 
(range 1.1 to 27.2), signifying 5 times higher TNNT-1 expression in the 2- versus the 2+ fibre 
population on average, as demonstrated in figure 6.5. 
 
Figure 6.5: TNNT-1 gene expression in 2- and 2+ laser captured fibres 
TNNT-1 gene expression was determined by qPCR and normalised to a geomean of 18S, beta 2 
microglobulin and RPLPO expression in laser captured 2+ and 2- fibres from 11 COPD subjects and 6 
healthy controls (total n = 17). TNNT-1 is known to be more highly expressed in type 1 fibres, 
corresponding to 2- fibres, therefore a TNNT-1 ratio for 2- : 2+ fibres should be > 1, which is 
demonstrated in all 17 subjects. The median TNNT-1 ratio in 2- : 2+ fibres was 5.77, which is 
illustrated by the horizontal bar. 
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To assess hypertrophy/ atrophy signalling, we studied IGF-1, myostatin, MURF-1 and 
Atrogin-1 in whole muscle and laser captured samples. Whole muscle sample analyses did 
not reveal significant differences between COPD and control subjects for any of the target 
genes analysed (Figure 6.6). For laser captured samples, we analysed expression for 2+ 
fibres, 2- fibres and 2+:2- ratio, the latter representing relative fibre expression. Analysis of 
the 2- fibres did not reveal significant differences between COPD and control subjects for 
any of these target genes (Figure 6.5). There was reduced MURF-1 and Atrogin-1 expression 
in the 2+ population of COPD subjects as compared to controls (p = 0.02 and p = 0.03 
respectively), with a trend towards reduced myostatin expression (p = 0.08), but no 
difference in IGF-1 expression. There were no significant differences between COPD and 
control subjects for any target gene in the 2- population. When comparing the 2+:2- ratio, 
there was a significant reduction in relative 2+ MURF-1 expression in the COPD subjects in 
comparison to the healthy subjects (p = 0.03). Atrogin-1 expression was similarly reduced 
relatively in the 2+ population of COPD subjects in comparison to controls although this 
failed to reach significance (p = 0.07). No difference was observed for IGF-1 and myostatin 
mRNA. 
 
MAPK14, PANK-1 and Cyr61 were analysed in both the laser captured samples and whole 
muscle samples, but these genes failed to amplify in the laser captured samples, 
furthermore, there was no observed difference in the expression of these genes in whole 
muscle samples obtained from COPD and control subjects. 
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Components of the Nf-kB signalling pathway (p50, p65 and IkBa) were too lowly expressed 
in the laser captured samples for reliable qPCR quantification, and therefore not subject to 
further testing. 
 
No difference in signalling was observed when groups were split by fibrinogen levels, and 
since inflammatory pathways were not subject to further analysis, all COPD subjects formed 
one group for analyses. 
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Figure 6.6: Gene expression in whole muscle and laser captured samples  
Comparison of IGF-1, Myostatin, MURF-1 and Atrogin-1 gene expression via qPCR between COPD (n 
= 11) and healthy control subjects (n = 6). *Relative fold gene expression denotes gene expression 
that has been normalized to a geomean of three housekeeping genes (18S, Beta-2-microglobulin and 
RPLPO) per sample. Gene expression has been analysed in whole muscle samples, 2+ (type II fibres) 
population, 2 – (type I fibres) population and relative fibre expression of gene in terms of 2+:2- ratio. 
There is significantly lower MURF-1 and Atrogin-1 expression in type II fibres in the COPD group (p = 
0.02 and 0.03) than in the controls. MURF-1 is also expressed relatively less in 2+ versus 2- fibres of 
196 
 
COPD patients in comparison to healthy controls (p = 0.03), with Atrogin-1 expression also being 
relatively lower in 2+ fibres than 2- of COPD patients in comparison to healthy controls, although this 
is only approaching significance (p =0.07). No difference in gene expression was detected in whole 
muscle samples or 2- fibres for any target gene.   
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6.4 Discussion 
 
Our method allows successful laser capture microdissection of human locomotor muscle 
specimens obtained by standard percutaneous needle biopsies, as opposed to prior efforts 
which have required larger specimens. The primary objective of this study was to develop 
an immunostaining technique which allows for fibre specific analysis of OCT-embedded 
samples, and this technique has been successfully validated in the present study. Using laser 
capture microdissection, the present study successfully separated type I and type II fibres, 
as demonstrated by respective MHC I and II content of the two fibre populations, as well as 
TNNT-1 expression (known to be preferentially expressed in type I fibres). Additionally, 
robust amplification of housekeeping genes demonstrated integrity of laser captured tissue, 
although this is subject to limitation as discussed later on. 
 
Using this technique in a pilot study we were able to show in exemplar atrophic signalling 
pathways that significant differences could be detected at a fibre specific level, which were 
not apparent in whole muscle.  Our study is the first to report fibre specific changes in 
atrophy signalling in human skeletal muscle, and the first study to date that has used laser 
capture micro-dissection in order to more precisely study the quadriceps of COPD patients.  
 
Critique of the Method 
 
While our method for identification and subsequent laser capture of individual muscle fibre 
populations is novel and offers several benefits, technical aspects require discussion. Firstly, 
fixing tissue in formalin allows time for immunostaining, which confers advantages over 
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histochemical staining for fibre typing, the latter being critically dependent on pH, 
temperature and duration of staining, as well as being time consuming and requiring serial 
sections to be stained at a different pH, therefore necessitating use of more tissue. 
Immunostaining relies on MHC isoforms and not on metabolic activity of the muscle cell, as 
with SDH staining used by Picard et al  (280) or ATPase staining used by Santoro et al  (275), 
thus being more reliable for identifying fibre type. Indeed our method can potentially be 
modified to further subcategorise fibres into IIa and IIx fibres, or to differentiate satellite 
cells. Our method is also much simpler than metachromatic staining, a modified 
histochemical technique used by Vanderburg et al  requiring at least 30 changes of solutions 
per slide as opposed to 12 changes of solution in our protocol (276). Our technique is 
potentially automatable with recognition of relevant fluorescent targets via computer 
programming.  
 
Secondly, formalin fixation also allows for time with laser capture without significant 
ongoing degradation of RNA at room temperature, in turn allowing the capture of 
significantly more fibres. For instance, Santoro et al  captured only 100 fibres per subject 
and Vanderburg captured 500 fibres per subject and both groups minimised the time that 
samples spent at room temperature, whereas we were able to capture up to 3000 fibres 
with samples exposed to room temperature for up to 2 days albeit with a lower RNA yield 
per fibre. We note that previous studies have set a predetermined number of fibres to be 
captured per subject thus making between subject comparisons easier; we chose instead to 
capture as much material as possible from 9 cryosections after finding that 3 cryosections 
failed to give adequate yields for MURF-1 and Atrogin-1 determination. Thirdly, frozen OCT-
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embedded samples can be analysed, therefore allowing retrospective analysis of existing 
biobanks. 
 
Whilst laser capture microdissection technology has progressed significantly since its 
inception in 1995, limitations remain in terms of duration of tissue preparation and 
processing, as well as selection of fixative materials. Our technique uses formalin, which 
allows for rapid tissue penetration but does result in extensive cross-linking of nucleic acids, 
giving low yields for RNA. Furthermore, formalin fixation can cause fragmentation of RNA, 
and therefore PCR analysis of cDNA requires careful primer selection to target short gene 
sequences.  However, it has been recognised previously that it is feasible to analyse gene 
expression from formalin-fixed samples using laser capture microdissection in tissues other 
than skeletal muscle (281, 282).  
 
Additionally, robust amplification of all three housekeeping genes in each laser captured 
sample lends support to the integrity of the RNA captured. Although immunostaining can 
allow individual fibre identification, separation of tissue via laser capture is not completely 
clean – there can be contamination from surrounding tissue as well as incomplete lifting of a 
target fibre from the slide, resulting in an enriched population of fibres, rather than a single 
fibre type. In this regard we caution that it is more appropriate to regard this technique as a 
method for enriching specimens by fibre type rather than achieving a complete separation. 
The lack of clean separation of fibres may explain why the both MHC II:I ratios were not 
higher. Alternatively, since this study examines gene expression only, it could be that there 
is silent expression of MHC II in type I fibres and vice versa, and examination of protein 
expression could have delineated this difference better. 
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Further development of the technique could explore the use of fixatives such as dithiobis 
(succinimidyl) propionate, a reversible cross-linker, for greater RNA yield than with formalin 
fixation (283). Additionally, ethanol fixed tissue could be used to examine fibre specific 
protein expression, which we were unable to perform in our samples. 
 
Compared to studies which have examined whole muscle specimens this study may be 
considered relatively small, although it is the largest study to date that examines fibre 
specific gene expression in human muscle.  Moreover since we confined our population to 
men, the data regarding signalling pathways cannot be uncritically generalized to women 
with COPD.  However the primary aim of this study was to develop the methodology and to 
show in principle that this method could identify differences which were not apparent from 
analysis of whole muscles. 
 
The cross sectional nature of this study is a further limitation. Moreover, since subjects were 
only rested for a minimum of 20 minutes prior to biopsy, it is possible that recent activity 
confounded gene expression, e.g. IGF-1 (180, 284). Similarly, different patterns of muscle 
recruitment may also affect results – since type I fibres are the first to be recruited, they are 
most active and likely to express more IGF-1 in the acute post exercise period , which may 
further confound fibre specific differences where subjects are not adequately rested. COPD 
muscle appears to respond differently to exercise than healthy muscle however, with a non-
significant change in catabolic proteins such as MURF-1 and Atrogin-1 post-exercise (180), 
suggesting that 20 minutes of rest should not impact these results, even though results from 
hypertrophy pathways may be affected.   
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Significance of the findings 
 
That fibre specific signalling should exist in skeletal muscle is supported by three other 
studies in literature. Morissette et al  demonstrated fibre specific SERCA-2 changes following 
exercise in murine models (285), and Santoro et al  (275) showed that there is differential 
expression of the human insulin receptor gene in their comparative study of six patients 
with myotonic dystrophy and two control subjects. Vanderburg et al  demonstrated lower 
MURF-1 and Atrogin-1 gene expression levels in type IIB fibres, but higher Atrogin-1 levels in 
the type I fibres of atrophied gastrocnemius muscle from rats undergoing hind limb 
suspension versus controls (276).  Whilst the application of the latter model has its 
limitation in humans, it is interesting to note that the findings in type II fibres in human 
COPD muscle mirror those of Vanderburg et al, suggesting that the ubiquitin-proteasome 
system is not as active in the type II fibres in COPD and that different pathways are activated 
in individual fibre types mediating differential atrophy of myofibres in COPD.  
 
Although it was not the primary aim of this study to make definitive observations regarding 
atrophic signalling pathways in COPD, our data do permit some observations.  MURF-1 and 
Atrogin-1 were expressed at lower levels in type II fibres of COPD subjects than in those 
from healthy controls, but not in type I fibres.  This would tend to favour survival of type II 
rather than type I fibres in keeping with the known fibre shift in COPD.  Alternatively, the 
lower Atrogin-1 and MURF-1 levels could represent a compensatory mechanism for lower 
protein synthesis in type II fibres. 
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Similarly myostatin, a negative regulator of muscle mass has previously been reported 
elevated in weak (286) patients with COPD while Plant et al  showed increased MURF-1 and 
Atrogin-1 levels in the presence of increased myostatin (171). Although we did not detect a 
significant difference in myostatin levels between COPD and healthy subjects in our whole 
muscle or type I fibres, myostatin expression was numerically lower in type II fibres (p = 
0.08).  While this finding just failed to achieve statistical significance a higher myostatin level 
in type I fibres would tend to promote relative type I fibre atrophy.  
 
Differential activation of pathways between fibres is important to consider for stratification 
of patients when designing future therapeutic agents. In addition, this technique provides 
more sensitive analyses, showing differences in gene expression in specimens enriched by 
fibre type where no significant differences could be detected in whole muscle, therefore 
potentially reducing the minimum sample size required and allowing identification of new 
targets that were previously overlooked after whole muscle analysis. Molecular studies 
using whole muscle from small numbers of COPD patients are at particular risk of failing to 
account for fibre specific changes due to the heterogeneity in fibre type composition 
amongst COPD patients (116), a problem that our method circumvents. 
 
 
Implications and future work 
 
This pilot study indicates that laser capture microdissection could be a useful addition to the 
array of techniques used in molecular analysis of muscle biopsies. Our method for 
examining OCT-embedded biopsies is novel and can be used on hundreds of frozen samples 
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stored in existing biobanks. Furthermore, it appears that laser capture of individual fibre 
types allows for more sensitive detection of differences between COPD and healthy muscle 
than analysis of whole, homogenized muscle.  
 
The current methods for laser capture are very time consuming however, and future work 
needs to focus on improving RNA yield from samples whilst simultaneously reducing the 
time taken to process each muscle sample so that greater numbers of samples can be 
analysed. In addition to improving RNA yield, using different DNA polymerases in the qPCR 
reaction may allow analysis of multiple, instead of a single, target gene per cDNA sample. 
Finally, development of techniques that additionally allow analysis of protein expression 
from such OCT-embedded samples would allow comprehensive analysis of target genes. 
 
 
Conclusion 
 
In summary, this is the first report of a fibre-specific pattern of atrophy signalling in human 
skeletal muscle, which could have important implications for development of future 
anabolic agents in COPD, as well as other conditions where there is peripheral muscle 
atrophy, such as chronic heart failure. Although the technique when undertaken manually 
remains labour intensive compared with analysis of whole muscle we suggest the use of 
laser capture microdissection be considered as part of the portfolio of techniques available 
for analysis of future molecular signalling in human muscle, given that analysis of whole 
muscle samples may not fully accommodate the heterogeneity in fibre type composition 
between COPD subjects.  
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Chapter 7 
7. General Discussions 
  
205 
 
7.1 Summary of findings 
 
 
Work from this thesis does not support a role for systemic inflammation in the pathogenesis 
of cardiovascular and muscle comorbidities in COPD, in contrast to hypotheses existing at 
the inception of the thesis. Whilst subjects from study 1 and the ERICA study demonstrated 
low-grade systemic inflammation in terms of fibrinogen, hsCRP and WCC, these 
inflammatory markers were not independently associated with either arterial stiffness or 
quadriceps strength. Using elevated arterial stiffness and reduced quadriceps weakness as 
surrogate markers of cardiovascular and skeletal muscle comorbidities, we further 
demonstrated that the degree of overlap between these two comorbidities is not greater 
than expected, and that they exist as independent manifestations in subjects with COPD. 
Sniff nasal inspiratory pressure is known to reflect a combination of inspiratory muscle 
strength and hyperinflation in COPD, but we additionally found it relates to cachexia and 
skeletal muscle strength, although not to circulating markers of systemic inflammation. 
Correspondingly, a randomized control trial of an anti-inflammatory, selective p38 MAPK 
α/β inhibitor, Losmapimod, reduced inflammation in CODP subjects as measured by 
fibrinogen but did not improve cardiovascular or muscle parameters.  
 
Molecular analysis of muscle in COPD has hitherto relied exclusively on homogenized whole 
muscle samples, and we have developed a new technique to analyse specific fibre types 
from OCT-embedded muscle specimens using laser capture microdissection. Using this 
technique, we were able to detect lower MURF-1 and Atrogin-1 gene expression in type II 
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fibres of COPD subjects as compared to controls, whereas no such differences could be 
discerned on examination of homogenized muscle.  
 
7.2 Significance of these findings 
 
 
Findings from study 1/ the ERICA cohort suggest that cardiovascular and muscle 
manifestations require independent management, and that anti-inflammatory therapies 
may not benefit patients with these manifestations. Furthermore, fibrinogen, which is 
currently under regulatory consideration for qualification as a biomarker for COPD, does not 
appear to be useful in predicting the presence of quadriceps weakness or arterial stiffness. 
This ERICA study is the largest study to date specifically designed to prospectively examine 
associations between fibrinogen and extrapulmonary manifestations of COPD. 
 
Sniff nasal inspiratory pressure also did not relate to inflammation however it was found to 
reflect cachexia in addition to muscle strength and hyperinflation in what is the largest 
cohort of COPD patients to undergo SnIP testing. SnIP also correlated with indices such as 
the BODE index, which are predictive of mortality in COPD and SnIP may have value as part of a 
composite measure or in trials that improve hyperinflation or inspiratory muscle strength, where it 
may be more acceptable to patients than body plethmysography. Longitudinal data from ERICA and 
its use in randomised interventional trials is required to assess its utility in clinical trials as 
acknowledged in the discussion for chapters 4 and 7 already. 
 
Fibre type distribution is heterogeneous amongst patients with COPD, as demonstrated by 
Natanek et al, and therefore homogenized muscle samples can fail to account for these 
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differences when examining molecular targets that may be more highly expressed in a 
particular fibre type. Existing molecular studies in COPD muscle have mostly been carried 
out in small numbers of COPD patients, which can explain the conflicting findings of such 
studies. Although labour intensive, laser capture microdissection could potentially provide a 
more sensitive technique to detect novel molecular targets for future therapy by taking 
fibre type heterogeneity into account. The immunostaining and laser capture technique we 
have developed is novel and can be used in OCT-embedded muscle samples stored in 
existing biobanks, thereby potentially allowing research groups in this field of study to 
examine hundreds of samples in this manner. The technique does not require large 
specimens of muscles, and therefore is potentially very useful in patients with cachexia or 
reduced muscle mass, in whom biopsy specimens can be harder or more painful to obtain. 
 
7.3 Limitations and Future Work 
 
The current cross-sectional nature of the data from ERICA/ study 1 is a major limitation. 
Without longitudinal data, it is difficult to comment on a temporal relationship between 
inflammation and the development of comorbidities, as well as establishing whether the 
subjects in this cohort have evidence of persistent inflammation, which appears to be an 
independent phenotype affecting 16% of COPD patients according to Agusti et al. Collection 
of longitudinal data relating to development of comorbidities, hospitalisation and mortality 
is ongoing at the time of writing this thesis. The longitudinal data from ERICA will better 
inform the predictive power of fibrinogen as a biomarker in future, not only in terms of 
mortality but also in terms of how it relates to the development of cardiovascular or muscle 
comorbidities. Similarly, the utility of SnIP as a biomarker in trials will be better assessed 
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once the longitudinal data becomes available, and the predictive power of SnIP as a marker 
of mortality can be examined against established indices such as BODE. 
 
The ERICA study was powered on the basis of a tertile analysis to detect differences in pulse 
wave velocity and quadriceps maximal volitional contraction, giving a target of 800 subjects 
once subjects withdrawals and incomplete datasets are accounted for. In the final analysis 
of the associations between fibrinogen and pulse wave velocity and quadriceps weakness, 
we decided to treat these variables continuously however since this avoids arbitrary cut-
offs.  
 
We used only a single, objective measure to define cardiovascular and muscle 
comorbidities. This not only has the advantage of using a continuous, objective variable but 
can also detect these comorbidities where subjects may not be aware of their presence. For 
example, we detected a significantly higher proportion of patients with elevated 
cardiovascular risk as opposed to patients with diagnosed cardiac disease. Similarly, many 
patients with COPD may be unaware that they have quadriceps weakness. This approach 
may fail to capture all the relevant patients however, which is evident by the small 
proportion of subjects in groups ‘N’ and ‘SM’ that recalled having had cardiovascular disease 
despite not having elevated arterial stiffness. Using a composite index of variables may 
overcome this problem in future analyses, and comparison to other relevant variables such 
as carotid intima media thickness will be essential as this data becomes available for the 
ERICA cohort. Cardiovascular risk factors cannot perfectly predict cardiovascular events, 
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even where composite scores such as the Framingham risk score are used however arterial 
stiffness has been shown to be the strongest predictor of mortality in the general 
population. Pulse wave velocity closely mirrors systolic blood pressure, and therefore has 
the dual advantage of reflecting cardiovascular function as well as predicting risk, in much 
the same way as systolic pressure is at once a measure for cardiovascular risk and function. 
Pulse wave velocity has been shown to be a superior predictor of cardiovascular risk and 
function than pulse pressure, as well as traditional risk factors, in the general population 
(86, 87, 287). 
 
Using arbitrary cut-offs to define cardiovascular and muscle comorbidities was necessary to 
categorise subjects, however a subject with a pulse wave velocity of 9.9 m/s is arguably not 
very different from a subject with a pulse wave velocity of 10.1 m/s. Future analyses could 
instead consider cluster analyses, or validating phenotypes against more established 
diagnostic criteria such as known ischaemic heart disease. It could be argued that since 
arterial stiffness is a well known prognostic marker for cardiovascular mortality in the 
general population, and that QMVC is known to be a relate to mortality in COPD, that using 
these measures to define phenotype is not wholly incorrect given Han’s definition of 
phenotype: “a single or combination of disease attributes that describes differences 
between individuals with COPD as they relate to clinically meaningful outcomes 
….symptoms, exacerbations, response to therapy, rate of disease progression, or death”. 
However both QMVC and PWV need further characterization in large COPD cohorts in terms 
of their longitudinal changes, relation to morbidity and mortality, as well as responsivess to 
interventions in COPD, and results need to be validated via different cohorts. The ERICA 
210 
 
study, as well as the ARCADE study, will contribute to a better understanding of these two 
markers once longitudinal data from these studies become available. 
 
The ERICA study had the benefit of being a multi-centre study as well as having relatively 
few entry restrictions in terms of comorbidities, which meant that results were perhaps 
more generalizable to the general population. Standard errors of certain measurements 
showed considerable inter-site variability however, despite earlier harmonisation of data 
collecting techniques, suggesting that subject characteristics were considerably different 
between sites. 
 
Study 2 may have been underpowered to detect improvements in arterial stiffness or 
muscle parameters since the study was powered on the basis of aortic inflammation on 
18FDG-PET, and future trials could not only increase sample size but may wish to look at 
inhibitors of other p38 MAPK isoforms. Future trials could also consider examining different 
parameters of muscle function such as quadriceps strength or molecular studies of muscle 
biopsies to determine changes in muscle in response to MAPK inhibition. Assessment of 
SnIP as a biomarker in clinical trials should be conducted in larger, randomized control trials 
of agents that improve muscle strength, cachexia or hyperinflation. 
 
Whilst fibrinogen did not relate to arterial stiffness or muscle strength, study 2 did find that 
screening a COPD population for high fibrinogen resulted in several new diagnosis of cancer 
in a relatively small study population. The seemingly high cancer incidence warrants further 
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scrutiny, in both study 2 data and longitudinal data from study 1, since it may be that the 
elevated mortality risk associated with high fibrinogen relates to cancer; nevertheless given 
both the cost and the ionising radiation burden inherent to PET scanning we doubt this will 
be a feasible cancer screening method. 
 
Although we developed a novel technique to examine OCT-embedded biopsy specimens, 
this technique is time consuming at present and has several limitations. Use of 
paraformaldehyde in the fixation process results in fragmentation of RNA, therefore primer 
selection has to be careful and targeted at short DNA sequences, and also means that 
protein expression in the specimens cannot be examined. Further experiments with 
alternative, non-cross linking fixative could perhaps overcome this problem. 
Paraformaldehyde also reduces RNA yield, necessitating processing of several cryosections, 
and limiting the targets examined – for example, Nf-kB signalling could not be examined due 
to low expression of the Nf-kB pathway constituents. Automating the laser capture program 
to recognise fibre staining could reduce workload, and further RNA extraction and 
amplification methods could be explored to improve yield. Finally, trialling other DNA 
polymerases may allow for analysis of expression of several genes simultaneously instead of 
just one. Existing techniques to examine fibre specific signalling in animal models and non-
COPD subjects utilise dissection of single muscle fibres, as well as laser capture 
microdissection of fresh muscle specimens. Although these techniques yield more RNA, they 
require instantaneous specimen availability, which is obviously easier in animal models.  Our 
technique has the advantage of utilising previously frozen samples, therefore allowing 
transport of specimens between centres. Therefore, despite several limitations, further 
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work should be done to improve this technique so that it becomes a useful addition to the 
portfolio of molecular methods used to examine muscle biopsy specimens in COPD. 
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Appendices 
 
 
Tables A1 to A4 contain data related to chapter 3, demonstrating linear regression analysis to 
determine whether hsCRP and WCC are associated with pulse wave velocity and quadriceps maximal 
volitional contraction. Tables A5 to A10 also contain data relating to chapter 3, with analysis of a 
sub-population where subjects with raised inflammatory markers (hsCRP >20g/L and WCC >11 x 
109/L), and therefore presumed subclinical exacerbation, were excluded from the analysis. 
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Table A1 Pulse wave velocity and hsCRP (n = 637) 
Variable Estimate Standard error P value 
Log hsCRP 0.06 0.08 0.51 
Age (years) 0.13 0.01 <0.0001 
Gender 0.46 0.20 0.02 
Supine heart rate 0.05 0.01 <0.0001 
Supine mean arterial pressure 0.06 0.01 <0.0001 
Current smoker -0.15 0.20 0.46 
Smoking pack year history 0.0004 0.003 0.90 
FEV1 (L) -0.14 0.20 0.49 
Diabetes 0.95 0.30 0.002 
Previous heart attack 0.06 0.35 0.87 
Anti-hypertensive therapy 0.01 0.2 0.98 
Cholesterol lowering therapy 0.28 0.21 0.18 
Site 2 0.77 0.36 0.03 
Site 3 0.34 0.29 0.24 
Site 4 -0.98 0.37 0.01 
Site 5 0.71 0.41 0.09 
 
Table A1: Linear regression analysis for associations with arterial stiffness, as measured by pulse wave velocity, 
with hs-CRP as the marker of systemic inflammation. Site 1 is the index, comparator site for remaining sites.
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Table A2 Pulse wave velocity and white blood count (n=638) 
Variable Estimate Standard error P value 
Log WCC 0.38 0.33 0.25 
Age (years) 0.13 0.01 <0.0001 
Gender 0.45 0.21 0.03 
Supine heart rate 0.05 0.01 <0.0001 
Supine mean arterial pressure 0.06 0.01 <0.0001 
Current smoker -0.18 0.20 0.38 
Smoking pack year history 0.001 0.003 0.87 
FEV1 (L) -0.14 0.20 0.46 
Diabetes 0.90 0.29 0.002 
Previous heart attack 0.05 0.35 0.90 
Anti-hypertensive therapy 0.01 0.20 0.97 
Cholesterol lowering therapy 0.31 0.21 0.15 
Site 2 0.75 0.35 0.03 
Site 3 0.33 0.29 0.24 
Site 4 -1.00 0.36 0.01 
Site 5 0.73 0.41 0.08 
 
Table A2: Linear regression analysis for associations with arterial stiffness, as measured by pulse wave velocity, 
with white cell count as the marker of systemic inflammation. Site 1 is the index, comparator site for remaining 
sites.  
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Table A3 Quadriceps maximal volitional contraction and hsCRP (n=651) 
Variable Estimate Standard error P value 
Log hsCRP -0.49 0.32 0.13 
Age (years) -0.18 0.05 <0.0001 
Gender 6.33 1.03 <0.0001 
Current smoker 0.03 0.76 0.97 
Fat free mass 0.40 0.05 <0.0001 
Height -0.13 0.06 0.04 
FEV1 4.26 0.81 <0.0001 
Site 2 -1.01 1.38 0.47 
Site 3 -2.57 1.15 0.03 
Site 4 0.24 1.39 0.86 
Site 5 -0.25 1.59 0.88 
 
Table A3: Linear regression analysis for associations with quadriceps weakness, as measured by quadriceps 
maximal volitional contraction, with hs-CRP as the marker of systemic inflammation. Site 1 is the index, 
comparator site for remaining sites.  
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Table A4 Quadriceps maximal volitional contraction and white blood count (n=656) 
Variable Estimate Standard error P value 
Log WCC -0.83 1.27 0.51 
Age (years) -0.18 0.05 <0.0001 
Gender 6.39 1.04 <0.0001 
Current smoker 0.02 0.78 0.98 
Fat free mass 0.39 0.06 <0.0001 
Height -0.13 0.07 0.04 
FEV1 4.57 0.82 <0.0001 
Site 2 -1.13 1.38 0.41 
Site 3 -2.65 1.15 0.02 
Site 4 0.01 1.38 0.99 
Site 5 -0.14 1.61 0.93 
 
Table A4: Linear regression analysis for associations with quadriceps weakness, as measured by quadriceps 
maximal volitional contraction, with white cell count as the marker of systemic inflammation. Site 1 is the 
index, comparator site for remaining sites. 
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Table A5 Pulse wave velocity and fibrinogen in sub-population (n=634) 
 
Variable Estimate Standard error P value 
Log fibrinogen 0.35 0.37 0.35 
Age (years) 0.13 0.01 <0.0001 
Gender 0.44 0.20 0.03 
Supine heart rate 0.05 0.01 <0.0001 
Supine mean arterial pressure 0.06 0.01 <0.0001 
Current smoker -0.17 0.20 0.40 
Smoking pack year history 0.001 0.003 0.76 
FEV1 (L) -0.07 0.20 0.71 
Diabetes 0.94 0.29 0.001 
Previous heart attack 0.09 0.35 0.80 
Anti-hypertensive therapy -0.01 0.20 0.96 
Cholesterol lowering therapy 0.21 0.21 0.31 
Site 2 0.85 0.35 0.02 
Site 3 0.40 0.29 0.17 
Site 4 -0.85 0.36 0.02 
Site 5 0.82 0.41 0.05 
 
Table A5: Linear regression analysis for associations with arterial stiffness, as measured by pulse wave velocity, 
with fibrinogen as the marker of systemic inflammation in a sub-population where subjects with 
simultaneously elevated hs-CRP of >20 mg/L and WCC of >11 x 10
9
/L were excluded from the analysis. Site 1 is 
the index, comparator site for remaining sites. 
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Table A6 Pulse wave and hsCRP in sub-population (n=632) 
 
Variable Estimate Standard error P value 
Log hsCRP 0.12 0.09 0.17 
Age (years) 0.14 0.01 <0.0001 
Gender 0.45 0.20 0.03 
Supine heart rate 0.05 0.01 <0.0001 
Supine mean arterial pressure 0.06 0.01 <0.0001 
Current smoker -0.11 0.20 0.58 
Smoking pack year history 0.001 0.003 0.87 
FEV1 (L) -0.10 0.20 0.61 
Diabetes 0.92 0.30 0.002 
Previous heart attack 0.08 0.35 0.83 
Anti-hypertensive therapy 0.01 0.20 0.97 
Cholesterol lowering therapy 0.26 0.21 0.23 
Site 2 0.75 0.36 0.04 
Site 3 0.33 0.29 0.26 
Site 4 -0.89 0.37 0.01 
Site 5 0.75 0.41 0.07 
 
Table A6: Linear regression analysis for associations with arterial stiffness, as measured by pulse wave velocity, 
with hsCRP as the marker of systemic inflammation in a sub-population where subjects with simultaneously 
elevated hs-CRP of >20 mg/L and WCC of >11 x 10
9
/L were excluded from the analysis. Site 1 is the index, 
comparator site for remaining sites. 
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Table A7 Pulse wave velocity and white cell count in sub-population (n=633) 
 
Variable Estimate Standard error P value 
Log WCC 0.54 0.34 0.11 
Age (years) 0.14 0.01 <0.0001 
Gender 0.44 0.21 0.03 
Supine heart rate 0.05 0.01 <0.0001 
Supine mean arterial pressure 0.06 0.01 <0.0001 
Current smoker -0.16 0.20 0.43 
Smoking pack year history 0.001 0.003 0.84 
FEV1 (L) -0.11 0.20 0.57 
Diabetes 0.87 0.29 0.003 
Previous heart attack 0.06 0.35 0.86 
Anti-hypertensive therapy 0.01 0.20 0.97 
Cholesterol lowering therapy 0.28 0.21 0.19 
Site 2 0.74 0.35 0.04 
Site 3 0.33 0.29 0.26 
Site 4 -0.92 0.37 0.01 
Site 5 0.78 0.42 0.06 
 
Table A7:  Linear regression analysis for associations with arterial stiffness, as measured by pulse wave 
velocity, with white cell count as the marker of systemic inflammation in a sub-population where subjects with 
simultaneously elevated hs-CRP of >20 mg/L and WCC of >11 x 10
9
/L were excluded from the analysis. Site 1 is 
the index, comparator site for remaining sites. 
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Table A8 Quadriceps maximal volitional contraction and fibrinogen (n=649) 
  
Variable Estimate Standard error P value 
Log fibrinogen -0.76 1.47 0.60 
Age (years) -0.19 0.05 <0.0001 
Gender 6.35 1.05 <0.0001 
Current smoker -0.13 0.78 0.87 
Fat free mass 0.39 0.06 <0.0001 
Height -0.13 0.06 0.04 
FEV1 4.49 0.82 <0.0001 
Site 2 -1.09 1.40 0.44 
Site 3 -2.63 1.17 0.03 
Site 4 -0.01 1.40 0.99 
Site 5 -0.30 1.63 0.85 
 
Table A8: Linear regression analysis for associations with quadriceps weakness, as measured by quadriceps 
maximal volitional contraction, with fibrinogen as the marker of systemic inflammation in a sub-population 
where subjects with simultaneously elevated hs-CRP of >20 mg/L and WCC of >11 x 10
9
/L were excluded from 
the analysis. Site 1 is the index, comparator site for remaining sites. 
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Table A9 Quadriceps maximal volitional contraction and hsCRP (n=643) 
 
Variable Estimate Standard error P value 
Log hsCRP -0.49 0.34 0.15 
Age (years) -0.19 0.05 <0.0001 
Gender 6.40 1.04 <0.0001 
Current smoker -0.04 0.77 0.96 
Fat free mass 0.40 0.06 <0.0001 
Height -0.14 0.06 0.03 
FEV1 4.17 0.82 <0.0001 
Site 2 -1.07 1.39 0.44 
Site 3 -2.63 1.17 0.02 
Site 4 0.11 1.41 0.94 
Site 5 -0.32 1.62 0.85 
 
Table A9: Linear regression analysis for associations with quadriceps weakness, as measured by quadriceps 
maximal volitional contraction, with hsCRP as the marker of systemic inflammation in a sub-population where 
subjects with simultaneously elevated hs-CRP of >20 mg/L and WCC of >11 x 10
9
/L were excluded from the 
analysis. Site 1 is the index, comparator site for remaining sites. 
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Table A10 Quadriceps maximal volitional contraction and white cell count (n=648) 
 
Variable Estimate Standard error P value 
Log WCC -0.64 1.32 0.63 
Age (years) -0.19 0.05 <0.0001 
Gender 6.45 1.05 <0.0001 
Current smoker -0.06 0.79 0.94 
Fat free mass 0.40 0.06 <0.0001 
Height -0.14 0.06 0.03 
FEV1 4.50 0.82 <0.0001 
Site 2 -1.21 1.39 0.39 
Site 3 -2.72 1.16 0.02 
Site 4 -0.10 1.40 0.95 
Site 5 -0.17 1.64 0.92 
 
Table A10: Linear regression analysis for associations with quadriceps weakness, as measured by quadriceps 
maximal volitional contraction, with white cell count as the marker of systemic inflammation in a sub-
population where subjects with simultaneously elevated hs-CRP of >20 mg/L and WCC of >11 x 10
9
/L were 
excluded from the analysis. Site 1 is the index, comparator site for remaining sites. 
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Table A11 
Subject ID Cancer Finding 
142 Adenocarcinoma of lung diagnosed on basis of V2 CT-PET 
151 Presumed bronchogenic cancer on the basis of V2 CT-PET 
134 Metastatic carcinoma of unknown primary (lung, pancreatobiliary, upper GI) on 
the basis of V2 CT-PET 
502 Pancreatic mass seen V2 CT-PET; initially diagnosed as cyst at MDT but 
eventually diagnosed with pancreatic cancer. Withdrawn from trial. 
536 Sigmoid colon polyps on V2 CT-PET (dysplastic but non-malignant on biopsy). 
Polyps excised and finished trial. 
541 Lung nodule on V2 CT-PET; MDT advised 6 monthly follow up and suitable for 
continuing in trial. Diagnosed as adenocarcinoma of lung 3 months post-trial. 
543 Colon cancer diagnosed from V2 CT-PET; withdrawn from trial prior to 
randomization. 
546 Bladder cancer diagnosed within 6 months of finishing study (not picked up on 
CT-PET but had been referred to urology on basis of microscopic haematuria 
during study).  
531 Laryngeal cancer diagnosed within 12 months of finishing study (not picked up 
on CT-PET but patient had symptoms of dysphagia prior to study which were 
under investigation and repeat endoscopy had been negative) 
 
Table A11: Cancer findings in subjects from study 2. Details of subjects with cancer-related findings during or 
within 12 months of study completion who had a high plasma fibrinogen (>2.9 g/L) at the screening visit. 
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Figure 1.1  The comorbidome by Divo et al   2012  
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Figure 1.2  Persistent systemic inflammation by Agusti et al 2012  
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Figure 1.3  The role of inflammatory mediators in different stages of atherosclerosis by Fisk et al 
2014 
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Figue 1.6  Schematic representation of the classical and alternative Nf-kB pathway. Bakkar et al 
2010 
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Figure 2.2 Scoring for Short performance physical battery by Patel et al 2014* 
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